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ABSTRACT
CHARACTERIZATION OF THE EFFECT OF PHOTOBIOMODULATION ON
PERIPHERAL BLOOD MONONUCLEAR CELLS AND CD4+ T CELLS FROM
HEALTHY DONORS AND MULTIPLE SCLEROSIS SUBJECTS
by
Miguel Tolentino
The University of Wisconsin-Milwaukee, 2020
Under the Supervision of Professor Jeri-Annette Lyons, PhD
Multiple Sclerosis (MS) is a CD4+ T cell-mediated autoimmune demyelinating
disease. The pathogenesis of MS is a combination of a pro-inflammatory autoimmune
response coupled with nitrosative and oxidative stress. Mitochondrial dysfunction within
the central nervous system (CNS) leads to a reduction of ATP and high concentrations
of nitric oxide leads to the production of reactive oxygen and nitrogen species (ROS and
RNS), resulting in oxidative and nitrosative stress that damages myelin and axons,
leading to axonal loss and disease progression. Nitrosative stress is present in MS even
in early stages of disease even before inflammation and the myelin destruction. The
currently approved therapeutics to treat MS are effective at slowing disease progression
but not preventing or reversing it, presumably because these strategies target the
autoimmune response but do not address the accompanying oxidative/nitrosative
stress.
Photobiomodulation (PBM) is a therapeutic strategy shown to have to ameliorate
chronic inflammatory and neurodegenerative conditions. During PBM, light is absorbed
by cytochrome c oxidase (CCO) producing an increase in ATP production and
improvement of mitochondrial function. Previously, our lab reported that 670nm light
administered over the course of disease resulted in reduced IFN-ɣ, TNF-α, and
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nitrosative stress, and increased IL-4, IL-10, which correlated with the reduction in
disease severity in the Experimental autoimmune encephalopathy (EAE) model of MS.
Here, we evaluated the effect of PBM with different wavelengths of light
administered at different doses on the immune response and nitrosative stress in MS
subjects. The production of pro- and anti-inflammatory cytokines and the generation of
nitrosative stress was measured in cell culture supernatants collected from peripheral
blood mononuclear cells (PBMC) or isolated CD4+ T cells over the course of in-vitro
treatment with light. The effect of PBM was dependent on the cell population (i.e.,
PBMC or CD4+ T cells); the wavelength of light; the dose of light administered; and
severity of disease as assessed by the Patient Determined Disease Steps (PDDS)
scale. The production of IFN-ɣ was higher by CD4+ T cells (735nm at 3J/cm2 and
10J/cm2) and PMBC (simultaneous 640/875/905nm, 1J/cm2 and 3J/cm2 in MS subjects
with PDDS=0 compared to MS subjects with PDDS ≥1). Conversely, CD4+ T cells
isolated from subjects with PDDS≥1 responded with higher levels of IL-10 compared
with subjects with PDDS=0 after PBM treatment at 670nm (3J/cm2).
Photobiomodulation was effective at reducing the generation of nitrite by cells
isolated from subjects with MS compared to cells not receiving light treatment. The
treatment of PBMC with 830nm (10J/cm2) resulted in reduced (p=0.0153) nitrite in
comparison with controls (no light treatment). In addition, the effect of PBM with 830nm
light on nitrite reduction correlated with the modulation of cytokines. Treatment of PMBC
with 830nm light (10J/cm2) resulted in significantly reduced nitrite and increased IL-10
(p=0.0271). These same conditions likewise reduced IFN-ɣ produced by PBMC to a
reproducible not statistically significant level (p=0.1940).
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The results to evaluate PBM on muscle fatigue showed that all MS subjects were
able to recover strength within 12% of their initial strength after a single PBM treatment
with the energy dose of 120J. Extended PBM treatment showed improvement in muscle
recovery in some patients, however statistical significance was not achieved. The
systemic effect of regional PBM therapy was assessed by measuring serum cytokines
following light treatment. Most of the IFN-ɣ, IL-6 and IL-10 values on serum samples
from MS subjects were below the limit of detection, which correlates with an absence of
active disease. Values of TGF-β were lower in patients with higher disability status
(PDDS≥1). The extended PBM treatment with the active device increased TGF-β levels
in patients with higher disability status (PDDS≥1) compared to the inactive device,
however, the increase was not significant.
Collectively, the results presented show the potential of PBM to modulate
immune response, reduce nitrosative stress, and improve muscle recovery. Future
experiments with a more extended PBM treatment, subjects with higher disability status,
and more sensitive methods to evaluate muscle recovery are needed.
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CHAPTER 1. GENERAL INTRODUCTION. MULTIPLE SCLEROSIS (MS), NITRIC
OXIDE (NO), AND PHOTOBIOMODULATION (PBM).

1.1 Multiple Sclerosis (MS)
Multiple Sclerosis (MS) is a CD4+ T cell-mediated autoimmune disease
characterized by the development of plaques (lesions) in the central nervous system
(CNS). These plaques consist of a demyelinated area with axonal damage and
presence of activated macrophages with degraded myelin-derived proteins such as
myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG), proteolipid
protein (PLP) [1]. The destruction of the myelin sheath interrupts the transmission of
nerve impulses from the CNS to other parts of the body causing the symptoms of MS
including anxiety, depression, motor dysfunctions, tremor, pain, numbness, sexual
dysfunction, weakness, and muscle fatigue (chronic fatigue) [2]. MS is not a fatal
disease, but MS subjects present a reduction in life expectancy between 7 to 14 years
[3].

1.2 Types of MS
Four subtypes of MS have been established based on the clinical course.
Relapsing-Remitting MS (RRMS) is characterized by the sudden appearance of MS
symptoms (attacks, relapses, or exacerbations) which remain for few days or months
and then disappear for long periods of time (months or years), known as remission
periods. Most of the MS subjects (80-85%) are initially diagnosed with RRMS [1]. RRMS
subjects progress within 5-10 years of diagnosis to Secondary-Progressive MS (SPMS),
which is characterized by slow but constant disease progression. In SPMS, the relapses
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are not as intense as in RRMS, however, patients no longer fully recover from relapses
(constant progression). The progression of the disease leads to a permanent disability
due to irreversible neurological damage and axonal loss [1]. Primary-Progressive MS
(PPMS) is diagnosed in approximately 10% of MS subjects who are not diagnosed with
RRMS. PPMS presents a stable and continuous deterioration in neurologic disability
since the onset of the disease without relapses and remission periods [2]. ProgressiveRelapsing MS (PRMS) is diagnosed in approximately 5% of MS subjects who are not
diagnosed with RRMS. PRMS is characterized by the continuous worsening of the
symptoms since the onset of disease, relapses with and without remission can be
present during all the progression of the disease [2].

1.3 MS Epidemiology
MS affects approximately 400,000 people in the US and 2.5 million worldwide [1].
MS appears between 20 and 40 years of age and affects women more frequently than
men (2:1) [4]. The etiology of MS remains unclear. It has been suggested that a
combination of different factors including place of birth (region), genetic susceptibility,
race, environmental factors, and exposure to pathogens are involved in the acquisition
and development of the disease [5-8]. For example, regions with higher incidence of MS
include both Northern regions of Europe and the US with approximately 30 cases per
100,000 people. In both southern regions of Europe and the US, the incidence of MS is
around 5-30 cases per 100,000 people. In central and South America, the MS incidence
is approximately 10-20 cases per 100,000 people. Areas with low incidence of MS
include the regions of Asia and some countries from South America with approximately
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5 cases per 100,000 people [5]. Races such as African American, Native American,
Mexican, Puerto Rican, Japanese, Chinese, and Filipino present less MS incidence in
comparison to Caucasians [5].

1.4 Genetics and MS
Genetics play a role in the onset and development of MS. For instance, firstdegree relatives of MS subjects have from 2.5 to 5% of increased risk of developing
MS. Meanwhile the identical twin of someone with MS has a risk of 25% [4].
Researchers previously performed genome-wide association studies (GWAS) to identify
the genetic factors involved in MS susceptibility, clinical phenotypes, and response to
treatment [11]. GWAS are typically carried out in two phases: the discovery phase and
the replication or confirmatory phase. GWAS generally uses microarray analysis or
other large-scale gene assay to analyze thousands or millions of single-nucleotide
polymorphism (SNPs) per genome in samples from several patients. These studies
compare the allelic frequencies of SNPs distributed throughout the genome between
samples of unrelated MS subjects and samples from control individuals [11]. The
identified SNPs can be either causative SNP or tag SNP for the causative
polymorphism. Causative polymorphism may affect the function, activity, timing, or
location of the gene’s product [11]. Current GWAS catalogs provide information of at
least 100,000 SNPs and all SNP-trait associations with P values bellow 1x10-5, as well
as important MS clinical associations, including IgG levels, response to drug therapy
(i.e. IFN-β), disease severity, brain lesion load, age of onset, brain glutamate levels, and
normalized brain volume [11, 12].
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GWAS

confirmed

the

significant

association

between

MS

and

Major

Histocompatibility Complex Class II (MHC-II). Some of the genes highly associated to
MS include: HLA-DRB1 class II gene with a level of association of p<4x10-225 for
rs3135388) and p<10-320 for non-attributed SNP tagging the same DRB1 gene [13, 14].
The HLA-DRB1 class II gene is located on chromosome 6 and belongs to the family of
genes known as human leukocyte antigen (HLA) complex also known as major
histocompatibility complex (MHC). The main function of the HLA complex is to
participate with the immune system to identify the proteins that are produced by the
body and foreign proteins produced by pathogens. MHC class II proteins are located on
the surface of antigen presenting cells (APCs) in order to present the foreign peptides
which can be recognized by the immune system and initiate an immune response [7].
The allele DRB1*1501 has been identified as the variant highly linked to MS (p<4x10225

). Other genes include HLA-DRB1 (allele *0301), HLA-DQB1 (allele *0201), HLA-

DRA (allele *0101), and HLA-DRB1 (allele *1303) [14]. Studies with transgenic mice
that express the molecule alleles DRA*0101 and DRB1*1501 (humanized mouse
model) have shown that after the administration of myelin basic protein (MBP) the
transgenic mice developed inflammation in CNS, demyelination and clinical symptoms
in a very similar way to those observed in MS [15]. GWAS studies also identified other
genes related to MS for which the level of association was also highly significant
(p<5x10-8). Some of these genes include: TCF7 which is a transcription factor that
participates in T cell differentiation and survival of CD4+ and CD8+ T cells; cytokines
and their interleukin (IL) receptors (IL-12R, IL7R and IL2R, TNFRSF1A); costimulatory

4

molecules CD58 and CD86; T cell regulatory protein TAGAP, CD6 receptor (located on
T cell surface [11, 16, 17].

1.5 MS Pathogenesis
The hallmark of disease pathogenesis of MS is the development of plaques or
lesions in the CNS white matter, including the optic nerves, brain stem, cerebellum and
spinal cord (SC). A plaque consists of a demyelinated area with relative axonal
preservation, as well as the presence of macrophages containing myelin-derived
proteins such as MBP, MOG, and PLP [18]. MS is a CD4+ T cell-mediated autoimmune
disease. This concept is based on research using the experimental autoimmune
encephalomyelitis (EAE) model. EAE is the primary animal model for MS, induced by
the immunization of animals (generally mice) with a combination of myelin-derived
proteins for example MBP, MOG, and PLP. EAE is characterized by inflammation in the
CNS and demyelination leading to the development of relapsing-remitting or chronic
progressive diseases stages similar to those in MS [19]. In addition, animal studies
demonstrate that the adoptive transfer of activated myelin-specific CD4+ T cells from
EAE-mice on wild type mice lead to the development of EAE [20].

1.6 T cell activation in MS.
The first step in the pathogenic mechanism of MS is the activation of naïve
autoreactive T cells in the periphery and their migration into the CNS [21]. Activation of
naïve T cells is carried out by a three signals mechanism. The first signal is made by the
T cell receptor (TCR) by recognizing the peptides presented by the MHC on antigen
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presenting cells (APCs). T cells with CD8 receptor molecules (CD8+ T cells, cytotoxic T
cells) recognize MHC class I. T cells with CD4 receptor molecules (CD4+ T cells, helper
T cells) recognize MHC class II [22]. MHC class I are located on the surface of
nucleated cells, while MHC class II are present on professional APC (i.e. dendritic cells,
B cells, macrophages) [23]. The second signal is carried out when the co-receptor
molecules CD80 and CD86 on APCs (i.e. dendritic cells) bind to CD28 molecules
located on T cells. The second signal produces the release of cytokines by the T cell.
The binding of these cytokines to their specific receptors on T cells (signal three) will
produce the final activation of T cells. For instance, IL-12 leads to Th1 differentiation
and IL-4 leads to Th2 cell differentiation [22]. Once activated in the periphery, T cells
are able to cross the blood brain barrier (BBB) and enter the CNS. Once in the CNS,
resident APCs (microglia, B cells, astrocytes, which possess MHC class II), present
myelin antigens to the autoreactive T cells, leading to reactivation and triggering the
recruitment of immune cells that contribute to demyelination, loss of oligodendrocytes,
and loss of axons leading to the signs and symptoms of MS [21, 24].

1.7 T cell tolerance and MS
Tolerance is the process by which autoreactive T cells that can potentially lead to
autoimmune diseases are eliminated (i.e. central tolerance) or

made functionally

unresponsive (i.e., peripheral tolerance). When cells escape tolerance, the result is the
presence of autoreactive cells in the periphery and the potential development of
autoimmune disease [23, 26, 27]. Central tolerance mechanism is carried out in the
thymus by the process of negative selection, which leads to the destruction of T cells
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with high avidity interactions with self-antigens presented by the MHC complexes on
APCs. The degree of avidity depends on two factors 1) the degree of affinity between
the T cell receptor (TCR) and the antigen (i.e. myelin epitope) presented on the MHC
complexes; and 2) the number of complexes (MHC-epitope) formed between the APC
and the T cell [23, 26, 27]. Therefore, two possible mechanisms of escape from central
tolerance include: 1) weak interactions between the TCRs and the antigen presented by
the MHC complexes, and 2) the presence of few antigen-MHC complexes between T
cells and APCs [24]. Previous studies investigated the interaction between MHC
complexes and MBP peptides of different sizes. Harrington, C.J., et al., observed that
the MBP121-140 formed a complex with MHC with a half-life of 177 hours and induced
tolerance. On the other hand, MBPAC1-11 formed a complex with MHC with a half-life of
15-30 minutes and tolerance was not produced. The results suggested that in the
thymus, myelin-specific T cells can escape central tolerance mainly due to low affinity
[28, 29].
Peripheral tolerance mechanisms are carried out when self-reactive T cells
escape from central tolerance. These mechanisms include: destruction of auto-reactive
cells (also known as deletion) and inhibitory mechanisms (i.e. anergy) [23, 26, 27].
Destruction of autoreactive cells results from the interaction between Fas (CD95
molecule) and its ligand to promote apoptosis. T cells express Fas on their surface.
When T cells become activated by the antigen and IL-2 presence, the expression of Fas
ligand is induced. The interaction of Fas and its ligand triggers the formation of the
intracellular death-inducing signaling complex (DISC) which activates caspases to
promote apoptosis [27]. T cells from MS subjects present a deregulation in the
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activation of the DISC due to a reduction in the expression of Fas on the cell surface
and therefore a reduction in both the Fas-ligand interaction and the activation of
caspases [30, 31].
T cell activation requires the presence of the TCR signal and the costimulatory
signal produced during CD28 ligation. These signals lead to the production of IL-2 which
will activate the PI3KAKT-mTOR pathway to sustain cell activation. However, when the
second signal is absent, a state of hyporesponsiveness known as T cell anergy results.
T cell anergy is characterized by repression of TCR signaling and IL-2 expression [26].
Another inhibitory mechanism involves the CD152 molecule also known as cytotoxic-Tlymphocyte-associated protein 4 or CTLA-4, which is located on the surface of T cells
and binds with higher affinity to the costimulatory receptor CD28. Binding of CTLA-4 by
CD28 inhibits the activation of T cells [26]. MBP-specific T cells from MS subjects are
able to become active even when CD28-mediated costimulation is blocked or absent
[32-35]. This suggests that in MS subjects, T cells can escape the peripheral tolerance
mechanisms because T cells are less sensitive to the lack of costimulation or these
mechanisms are compromised [32-35].
The specific agents involved in the activation of T cells in the periphery by CNS
antigens have not been established. One theory suggests that the presence of
infectious agents could produce the activation. For example, the similarity in the
structure between pathogen antigens and the structure of myelin proteins could produce
the activation of T cells (molecular mimicry). Some of the pathogens implicated in
activation of myelin-reactive T cells and the initiation of MS include the Epstein Barr
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virus (EBV), influenza, herpes simplex virus, human papilloma virus, and human
herpesvirus-6 [23].

1.8 Blood brain barrier disruption by T cells
Once activated in the periphery, activated autoreactive T cells migrate to the
blood brain barrier (BBB). Autoreactive T cells adhere to the endothelium of the BBB via
adhesion molecules to initiate transendothelial migration through the BBB [36]. Some
endothelial molecules that participate in T cell migration include: the vascular cell
adhesion molecules (VCAM), and intracellular adhesion molecule (ICAM) both
expressed on endothelial cells, the α4 integrin (VLA-4, very late antigen) and the
leukocyte functional antigen (LFA-1, or leukocyte function associated antigen) both
expressed on T cells [21, 36].
The presence of chemokines increases both the binding affinity between T cells
and the endothelium cells as well as the reversible binding between T cells and the
endothelium

(ICAM-1/LFA-1 and VCAM-1/VLA-4 interaction complexes). Once

autoreactive T cells are firmly adhered to the endothelial surface, they start to travel on
the endothelial surface looking for inter-endothelial junctions (tight junctions). T cells
penetrate the endothelial basement membrane and enter the perivascular space. This
migration is facilitated by matrix metalloproteinases (MMP) produced by the microglia
and astrocytes which function to fracture the BBB [21, 36, 37]. Once in the CNS,
autoreactive T cells are reactivated by the recognition of myelin antigens. The
reactivated T cells further differentiate into CD4+ Th1 or Th17 T cells producing of proinflammatory cytokines (IFN-ɣ, IL-23, TNF-α, lymphotoxin) and chemokines (RANTES,
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IP-10, IL-8) which further activate microglia and astrocytes, and recruit immune cells
(monocytes, CD8+ T cells, B cells, mast cells) from peripheral blood into the CNS to
initiate the formation of the inflammatory lesion [21, 36, 37].

1.9 Pro-inflammatory cytokines in EAE and MS
T cells are the main player in the pathogenesis of MS, thus it is necessary to
understand the different T cell types, the cytokines produced by them, and their role in
MS and EAE. Lymphocytes consist of the thymus-derived T cells, bone marrow-derived
B cells, and natural killer (NK) cells. T cells are divided in 3 categories, CD4+ T cells (T
helper), CD8+ T cells (cytotoxic), and regulatory T cells (T regs). Each category
differentiates in different cell subsets depending on the presence of cytokines,
chemokine receptors, transcription factors, and epigenetic modifications [23, 38]. Each
cell subset produces different cytokines and performs specific functions in the immune
response. Naïve CD4+ T cells in the presence of IL-12 differentiate in Th1 cells, or in
the presence of IL-6, TGF-β, and IL-23 differentiate to Th17 cells. Both Th1 and Th17
cell subtypes are considered pathogenic in MS and EAE because they promote the
development and progression of disease through the production of pro-inflammatory
cytokines. Th1 cells produce TNF-α, IFN-γ and IL-2. Th17 cells produce IL-17, IL-6, IL21, IL-22, and TNF-α [23, 38].
TNF-α is pro-inflammatory cytokine that participates in the development of MS
and EAE. Korner et al, reported that the administration of TNF receptor (55kDa)-IgG
infusion protein (TNFR-IgG, TNF-α blocker) in rats prevented the clinical signs of
induced EAE without affecting the migration of CD4+ T cells to the CNS [39]. Additional
10

experiments showed that the timing is critical for the effectiveness of TNFR-IgG in EAEinduced rats. When TNFR-IgG infusion was administrated before the onset of disease,
a reduction in the clinical signs as well as a reduction of inflammatory leukocytes in the
CNS were achieved. However, if the infusion was administrated once the clinical
disease was established, the disease progressed as usual. This data suggested that
TNF-α plays a role in early events of disease development but not during the acute
neurological deficit which is characteristic in EAE-induced rats [40]. Similarly, additional
studies showed that TNF-KO C57BL/6 mice immunized with MOG35-55 to induce EAE
presented a delay in the onset of disease as well as a reduced migration of
inflammatory leukocytes into the CNS parenchyma during the onset and the peak of the
disease [41]. TNF-α interacts with 2 receptors, both of which are implicated in MS and
EAE. TNF-receptor-1-KO mice showed a less severe EAE characterized by a reduction
in demyelination. On the other hand TNF-receptor 2 KO mice develop a more severe
EAE with higher demyelination [42]. Additional studies showed that subcutaneous
injections of the soluble TNF-receptor (sTNFrl) during 15 days starting the day of
immunization, provided an effective inhibition of EAE induction in SJL/J mice [43].
Similarly, C57BL/6 TNF-receptor-1-KO mice immunized with MOG35-55 were protected
against disease, characterized by a marked reduction in demyelination and lymphocyte
infiltration in CNS [44].
Even though data support the role of TNF-α as pro-inflammatory cytokine that
participates in the development of EAE and MS, there are studies that show that TNF-α
can play a protective role, too. For instance, in one study, TNF-KO-C57BL/6 mice were
immunized with MOG35-55 to induce EAE. TNF-KO-C57BL/6 mice with EAE developed
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more severe neurological damage, higher mortality, more severe inflammation and
demyelination than controls (C57BL/6 mice with EAE). Further treatment with TNF-α
reduced disease severity in TNF-KO-C57BL/6 mice [45]. These data support previous
findings that indicated that TNF was not necessary for induction, inflammation and
demyelination but showed that TNF might play a role in limiting the degree of severity
and duration of EAE and MS [45].
IFN-ɣ is another pro-inflammatory cytokine that participates in the development
of EAE and MS. Studies demonstrated a positive correlation between high levels of IFNɣ and the clinical manifestation in EAE and MS [46-52]. In an early study, 18 RRMS
subjects received recombinant IFN-ɣ at 3 different doses: low (1mcg); intermediate
(30mcg); and high (1000mcg). The results showed that serum levels of IFN-ɣ were
proportional to dose administrated. Seven out of 18 RRMS subjects presented
exacerbation during the treatment [51]. The exacerbations occurred in all 3 dosage
groups and they were not dose-related. The results suggested that the administration of
IFN-ɣ activated the immune response and disease activity in the CNS, further
suggesting that the attacks were immunologically mediated [51]. In a subsequent
clinical trial, 45 patients with secondary progressive MS (SPMS) were divided in 3
groups of 15 patients and each group received antibodies to IFN-ɣ, TNF-α, or a placebo
for 12 months. The patients taking the IFN-ɣ antibody were the only group that showed
a significant improvement in disease supported MRI data in the reduction in the number
of active lesions, reduction in TNF-α, and IFN-ɣ, suggesting that the use of antibodies
against IFN-ɣ could be a potential treatment for SPMS subjects [52].
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On the other hand, several studies demonstrated a protective role of IFN-ɣ in
EAE [53-65]. For instance, Billiau et al., showed that injection of IFN-ɣ in EAE mice
resulted in a reduction in disease severity, symptoms, morbidity and mortality [56]. The
authors studied the effects of anti-IFN-ɣ antibody treatment in 2 different EAE models
using SJL/J and C57BL/6J mice [56]. SJL/J mice show high incidence, a highly
aggressive EAE and 100% mortality, under the same conditions, C57BL/6J mice are
less susceptible to EAE, present lower incidence rate (20-40%), lower disease scores,
and lower mortality rate. EAE was induced by injection of spinal cord homogenate, in
combination with Bordetella pertussis and Freund’s adjuvant. Anti-IFN-ɣ antibodies
were injected intraperitoneally into EAE-induced C57BL/6J mice on days -6, 0, 7, and
14 relative to the time of immunization (EAE induction). These mice presented with
increased incidence and mortality in comparison with controls. Histopathological
examination showed that there was a positive correlation between clinical disease
scores and the extent of histopathological findings. The results showed that anti-IFN-ɣ
antibody treatment increases disease severity in low-EAE-susceptibility mice (C57BL6J
mice) [56]. On the other hand, SJL/J mice received intraperitoneal injections of anti-IFNɣ antibody on days -3, 0 and 3 relatives to EAE induction. Anti-IFN-ɣ antibody did not
show any effect on SJL/J mice in comparison with controls. Interestingly, when EAE
induced-SJL/J mice received intraperitoneal injections of rDNA-derived IFN-ɣ on days 1, 0, 1, 3, 5, 7, and 9 relative to EAE induction, the systematic administration of IFN-ɣ
produced a relative protection characterized by a reduction in the clinical scores and
mortality rate [56]. These data show that it is important to differentiate between the local
and systemic effects of IFN-ɣ. The local IFN-ɣ promotes inflammation whereas
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systemically, it produced an anti-inflammatory effect. Based on the results obtained, the
authors proposed that anti-IFN-ɣ antibodies were able to reach and neutralize the IFN-ɣ
present in the circulation and peripheral body compartments but not that produced
locally in the CNS, which is difficult to reach due to the presence of the blood brain
barrier. Therefore, the blocking of the systemic IFN-ɣ suppresses the anti-inflammatory
properties of IFN-ɣ, leading to increase of EAE severity. The endogenous IFN-ɣ formed
during the induction or development of EAE can play a disease-limiting role, and thus
this production should not be blocked during the inflammation of CNS. In addition, the
systematic administration of IFN-ɣ may be used to reduce disease severity [56].
In additional experiments, the Billiau group investigated the role of IFN-ɣ in a
chronic relapsing remitting model of EAE using SJL/J mice [61]. SJL/J mice were
immunized with spinal cord homogenate in combination with Freund’s incomplete
adjuvant, and Mycobacterium tuberculosis on day 0 and 7, to induce EAE, presenting
with mild EAE on day 21. The mice were divided in 3 groups and re-immunized on day
21. Group 1 received anti-IFN-ɣ antibody on days 21 and 27 (injected intraperitoneally),
while Groups 2 and 3 received intraperitoneal injections of saline or rat IgG antibody (rat
IgG2A). A few days after re-immunization the 3 groups presented EAE symptoms.
Group 1 (anti-IFN-ɣ antibody) presented higher incidence, higher severity of attacks,
and faster progression of the relapses than Group 2 and 3. The authors concluded that
the induced relapses are facilitated by the administration of anti-IFN-ɣ antibody in the
disease-free interval. The data showed that the enhancing effect of anti-IFN-ɣ antibody
administrated before and during the primary attack did not carry over to the relapses.
The data also suggested that the IFN-ɣ produced endogenously by the mice provided
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some protection against disease progression [61]. Similarly, other authors also showed
that the use of anti-IFN-ɣ antibody increased EAE severity [57, 58, 62]. In addition,
several studies showed the protective role of IFN-ɣ in the EAE model using KO-IFN-ɣ
mice. The lack of IFN-ɣ led to the development of EAE even in strains that are normally
resistant to EAE [53-55, 63, 64].
Other studies reported that IFN-ɣ plays a role in the reduction in disease severity
in EAE induced mice. One study reported that IFN-ɣ completely prevented the clinical
disease in EAE-induced Lewis rats receiving IFN-ɣ into the ventricular system of the
CNS on day 8 after EAE induction (just 2 days before the expected onset of clinical
signs of EAE) [60]. Conversely, intraperitoneal injection of rats with IFN- on d8 resulted
in a more severe disease course with high percentage of relapses [60]. These data
suggest that the IFN-ɣ produced within CNS plays a disease–limiting role whereas
peripheral IFN exacerbates disease [60].
Furlan et al., further investigated the specific and localized over expression of
IFN-ɣ in the CNS of EAE-induced mice [65]. The authors used an IFN-ɣ gene-containing
vector inserted in Herpes simplex virus type 1 (HSV-1) which was injected
intracisternally in C57BL/6 mice (6-8 weeks of age). Mice were injected twice (days 0
and 7) and they were sacrificed at week 1 and 3. To confirm IFN-ɣ overexpression,
qPCR analysis showed that mice that received the injections of vector expressing IFN-ɣ
presented a significant increase of IFN-ɣ mRNA in the brain and spinal cord in
comparison with controls (HSV-1 without IFN-ɣ vector). The increase in IFN-ɣ levels
lasted between 3-4 weeks after vector injection. When mice received one intracisternal
injection with the IFN-ɣ containing vector 1 week after EAE onset, mice partially
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recovered from disease within 25 days after vector injection. On the other hand, control
mice receiving the vector without the IFN-ɣ gene never recovered from EAE. When
mice received intracisternal injection of the IFN-ɣ vector or control vector before the
EAE onset (on the day of EAE induction and another one 7 days later), EAE-mice
receiving the IFN-ɣ containing vector showed earlier disease onset, milder disease
course, and increased apoptotic T cells compared to control mice. Furthermore, 83% of
mice completely recovered from disease between day 22 and 28 post EAE
immunization. Control mice showed later disease onset, higher EAE score, and never
recovered from disease [65]. Histopathological exams performed 60 days after EAE
induction on mice that received the treatment prior to disease onset showed a reduction
in inflammatory infiltrates, less demyelinated areas, and reduction in axonal loss in
comparison with controls. The authors conclude that their results challenged the general
idea that the presence of IFN-ɣ in EAE/MS leads to the worsening of disease [65].
Altogether, the data suggest that, depending of disease stage and site of production
(systemic or local), IFN-ɣ can play a dual role in MS and EAE: 1) a protective role to
reduce disease severity or 2) a pathogenic role which participates in the progression
and development of disease. Thus, the modulation of IFN-ɣ at any stage of MS or EAE
(before, during or after relapse) could be potentially useful to reduce the clinical
symptoms during the progression of the disease.
IL-6 is anti-inflammatory cytokine that participate in the development of human
diseases. IL-6 secreted by immune cells such as T cells, B cells, macrophages and
microglia, but also by non-immune cells such as muscle cells, adipocytes fibroblast,
endothelial cells and neurons [66, 67]. IL-6 transmits its signals using a cell surface
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type-I receptor complex, which include a ligand-binding glycoprotein known as IL-6
receptor (IL-6R) and a signal-transducing component gp130. There are 2 types of IL-6R
the membrane bound (mIL-6R) and the soluble (sIL-6R). The sIL-6R is produced from
the mIL-6R by proteolytic cleavage of metalloproteinases gene family members such as
ADAM10 and ADAM17 or by splicing of IL-6R mRNA [68]. There are 2 ways IL-6
stimulates a response in a target cell. The classical signaling occurs when IL-6 binds to
the membrane bound IL-6R which induces the dimerization of gp130 and then the
subsequent downstream signaling. The trans-signaling occurs when sIL-6R forms a
complex with IL-6 and stimulates distant cells that expresses gp130 but not the
membrane bound IL-6R (i.e. neuronal cells, endothelial cells, oligondendrocytes) [69,
70]. Once the complex IL-6-IL-r-gp130 is formed, this leads to the activation on the
transcription factor JAK than in turns activates different transcription factors and signal
pathways such as STAT3, MAPK, and NfkB which participates in different pathological
conditions such as cancer, multiple sclerosis, rheumatoid arthritis, diabetes, Alzheimer
disease (AD) [67].
Studies using the EAE model have shown that IL-6 plays a role in MS and EAE
development. Some studies have showed that IL-6 knockout mice were resistant to
EAE [71-73]. Samoilova et al., evaluated the role of IL-6 in the development of EAE
[71]. IL-6 deficient B6.129 mice (IL-6-/-) and control mice (IL-6+/+) were immunized with
MOG38-50 peptide. All control mice showed signs of disease 7 days after immunization.
None of the IL-6 deficient mice developed EAE. Brain and spinal cord samples were
collected at 10 and 28 days after immunization and used for histologic examination. The
samples form the control group showed inflammatory lesion and severe demyelination.
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No inflammatory lesions nor demyelination were found in samples from IL-6 deficient
mice. The results suggested that in the absence of IL-6, EAE may not be induced. Next,
the authors evaluated if the lack of IL-6 affect the differentiation myelin-specific cells T
cells into effect T cells. Splenocytes were collected from control and IL-6 deficient mice
10 days after immunization. Cells were cultured with MOG38-50 peptide to evaluate cell
proliferation and cytokine production. Splenocytes from control mice showed high
proliferation and production of Th1 (IL2, IFN-ɣ) and Th2 (IL-4) cytokines. Splenocytes
from IL-6 deficient mice showed reduced proliferation and low production of TH1 and
Th2 cytokines [71]. Eugster et al., also observed that IL-6 deficient mice were resistant
to MOG-induced EAE and spinal cord tissue showed no inflammatory lesion nor
demyelination [73]. In addition, the authors observed that the spinal cords from MOGinduced control mice presented high expression of the adhesion molecules VCAM-1
and ICAM-1 but basal expression on IL-6 deficient mice. The entry of myelin-specific T
cells into the CNS depended on the interaction of T cell VLA-4 with the adhesion
molecules VCAM1 and ICAM-1 on endothelial cells. Thus, the results suggested that
the low entry of myelin-specific T cells into the CNS was in part due to the low
expression of VCAM1 and ICAM-1 on IL-6 deficient mice [73].
Serada et al, evaluated the role of IL-6 on Th17 cell differentiation and EAE
induction [74]. The authors immunized C57BL/6J mice with MOG35-55 peptide with
CFA, followed by an intraperitoneal injection of anti-IL-6R antibody or control rat IgG the
same day of immunization. The mice that received the anti-IL-6R antibody presented a
reduced incidence in EAE, delayed onset of disease, and reduction in the clinical score
in comparison with the control group (control rat IgG). Histological examination of brain
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tissue and spinal cords collected 19 days after immunization (peak of disease) showed
that mice that received the anti-IL-6R antibody reduced cellular infiltration, and no
demyelination in comparison with control group. These results were consistent with the
reduction in the clinical score observed previously. Mononuclear cells from spinal cords
were used for flow cytometry analysis. The results showed that control mice presented
CD4+ T cells, CD8+ T cells, B cells, and macrophages; conversely, these cell
populations were dramatically reduced in mice that received the anti-IL-6R-antibody. In
addition, intracellular cytokine staining and FoxP3+ staining of spinal cord infiltrating
cells, showed high infiltration of Th17, Th1 and Foxp3+ cells (Tregs) in control mice,
meanwhile in anti-IL-6R antibody mice these cells were practically absent [74]. The
authors collected lymph nodes from both groups 8 days after antigen stimulation
(priming stage). The lymphocytes were cultured in combination with MOG35-55 peptide
for 72h. Flow cytometry analysis showed that Th17 and Th1 cells were suppressed in
anti-IL6R antibody mice compared with control mice. In addition, CFSE analysis showed
that anti-IL-6R antibody reduced cell proliferation of MOG35-55 CD4+T cells in vitro.
Interestingly, even though the antibody-IL-6R antibody treated group presented a
reduction in cell number, these cells presented a higher population of FoxP3+ Reg T
cells (Treg cells) and a lower population of Th17 cells [74]. To investigate the effects of
IL-6 blockage against MOG35-55 peptide on cytokine production, lymph nodes from the
anti-IL-6R antibody treated group and control group were collected at day 8, 19, and 30
(acute period or priming, peak of disease, recovery period). Cells were incubated with
MOG35-55 for 72 and supernatant were used to measure cytokines. IL-17 and IFN-ɣ
were suppressed in all stages in anti-IL-6R antibody treated mice. Serum samples
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collected also at day 8, 19 and 30 showed also suppression of cytokines IL1β, IL-6,
IL17, and TNF-α in the s stages in comparison with control group. The results
suggested that the suppression of Th17 and Th1 cells by IL-6 blockage provide a
protective effect against the development of EAE [74].
Elevated values of IL-6 are present in serum, plasma, cerebrospinal fluid (CSF),
and brain plaques in patients with MS [75-78]. Lanzillo et al carried out a study where
45 RRMS subjects under IFN-β-1a treatment were monitored and different
immunometabolic markers were measured in order to evaluate them with disease
activity and progression over time. The authors found that MS subjects with higher
levels of IL-6 in serum presented a higher relapse rate [77]. Maimone et al., using an
immunochemistry assay, detected the presence of elevated levels of IL-6 in acute and
chronic active plaques from the brain of MS subjects. IL-6 was located mainly within
resident glial cells, which were located at the sites of active demyelination and immune
cell damage [78]. In an EAE study Lubina-Dabrowska et al., investigated the effect of
IFN-β-1a and IFN-β-1b on cytokines and myelin proteins levels in EAE-induced Lewis
rats. EAE-rats received IFN-β1a or IFN-β-1b treatment 3 times per week starting 8 days
prior EAE induction and continued until 14 days after EAE induction. EAE- rats were
euthanized on day 14, and brain tissue was collected for quantitative RT-PCR analysis.
The results showed significant increase of IL-1β, IL-6, TNF-α, and iNOS in brain tissue
from control EAE-rats which correlated with the manifestation of disease. On the other
hand, EAE rats receiving either IFN-β-1a or IFN-β-1b showed a reduction in IL-1β, IL-6,
TNF-α, and IFN-ɣ, decreased the activation of astrocytes, and reduced demyelination,
which correlated with the reduction in the severity of disease. In addition, IFN-β-1a
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reduced iNOS expression and increased IL-10. On the other hand, IFN-β-1b reduced IL10, and did not produce any change in iNOS [79].

1.10 Anti-inflammatory cytokines in EAE and MS
Naïve CD4+ T cells in presence of IL-4 can differentiate to Th2 or in presence of
TGF-β and IL-2 can differentiate into regulatory T cells (Tregs) which are considered
protective against the disease due to their production of anti-inflammatory cytokines [23,
38]. Th2 cells produce IL-4, IL-5, IL-6, and IL-10. Tregs cells produce TGF-β and IL-10.
Th22 and Th9 cells are the other two subcategories that have been identified in MS,
however, their role in MS is not yet established [23, 38]. Bitan et al., reported the
participation of Th2 cells in the amelioration of EAE [80]. In that particular study, the
authors studied the role of heparanase (a protein that promotes cell adhesion and
migration) in autoimmunity using the EAE model. The authors found that the
intraperitoneal injections of heparanase in EAE mice reduced the clinical signs of
disease in a dose depend manner, increased anti-inflammatory cytokines IL-4, IL-6, and
IL-10, and reduced Th1 cells pro-inflammatory cytokines TNF-α, IFN-ɣ, and IL-1[80].
Similarly, Zhang et al, evaluated the immunosuppressive properties of glucosamine in
EAE mice. The authors found that oral, intraperitoneal, or intravenous administration of
glucosamine in EAE mice reduced the signs of disease, CNS inflammation,
demyelination, IFN-ɣ, IL-17, and increased Th2 cell cytokines IL-5 and IL-10 [81].
IL-4 has demonstrated protection in the EAE model. One study reported that
C57BL/6 IL-4-KO mice immunized with guinea-pig myelin to induce EAE presented a
more severe disease. This was correlated with higher cellular infiltration in the CNS and
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increased mRNA expression of IFN-ɣ and TNF-α in spinal cord tissue in comparison
with wild type (WT) controls [82]. Studies by Furlan et al., showed that the localized
administration of IL-4 in the CNS provided protection against EAE. The authors injected
in the cisterna magna of EAE mice a non-replicative herpes simplex virus (HSV) type-1derived vector containing the IL-4 gene. The IL-4 delivery induced the localized
production of IL-4 by the CNS, leading to a delay in the onset of disease, reduction in
the clinical score (severity of disease), mortality, the duration of first attack and relapse,
and reduced infiltrating mononuclear cells (i.e. macrophages), and microglial activation.
These factors contributed to decreased production of pro-inflammatory cytokines and
reduced demyelination and axonal loss in treated animals [83, 84].
The number of PBMC secreting IFN-ɣ and IL-4 was quantified in PBMC from MS
subjects during relapse (n=13), in chronic stage (n=24), and healthy controls (n=20) by
immunospot assay [85]. The results showed higher numbers of PBMC secreting IFN-ɣ
in samples from MS subjects experiencing a relapse. The number of PBMC secreting
IL-4 was higher and in comparable quantities in both MS subjects experiencing a
relapse as well as the MS group on chronic stage in comparison with the control group.
Additional in-vitro experiments using PBMC from the 3 groups plus myelin basic protein
(MBP) to produce the activation of PBMC showed that PBMC from the MS subjects
experiencing a relapse and the MS on chronic stage presented higher production of
IFN-ɣ in comparison with controls, with the highest levels of IFN-ɣ produced by cells
isolated from subjects experiencing a relapse [85].
Studies investigating the roles of IL-10 and IL-4 on EAE mice showed the
protective role of these anti-inflammatory cytokines in disease development [86, 87]. IL-
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10 deficient mice, but not IL-4 deficient mice, presented with accelerated EAE onset in
comparison with WT mice. This acceleration in disease onset was associated with a
reduction in IL-4 and increase in IFN-ɣ after MOG immunization [86]. Interestingly,
spontaneous recovery was present in WT and IL-4 deficient mice but recovery was not
present in IL-10 deficient mice [86]. Additional studies showed that the activation of T
cells from IL-10-KO mice with encephalitogenic peptide presented a stronger antigenspecific proliferation, produced higher levels of IFN-ɣ and TNF-α, and were able to
induce severe EAE when they are transferred to WT mice [87]. Interestingly, the overexpression of IL-4 in transgenic mice led to a similar EAE disease course that WT mice,
but the over expression of IL-10 in transgenic mice led to resistance to EAE
development [87]. Altogether, these data indicate that IL-10 plays a role in progression
and recovery of EAE.
Studies in MS subjects also showed increments in IL-10 levels during T cell
activation. CD4+ and CD8+ T cells isolated from stable RRMS subjects and healthy
controls were activated with CD3 monoclonal antibody (mAb) for 48h, then the
supernatants were collected to measure cytokines. The results showed an increase in
IFN-ɣ produced by both CD4+ and CD8+ T cells and increased production of IL-10 by
CD4+ T cells [88]. Quantification of serum IFN-ɣ, TNF-α, IL-4, and IL-10 from MS
subjects during relapse (n=42) showed higher levels of these cytokines in comparison
with healthy controls (n=12). These data indicate the simultaneous activation of
elevated levels of Th1 and Th2 cells during the acute stages of the disease [89]. In
another study, the authors quantified serum and CFS levels of TNF-α, IL-10, and nitric
oxide (NO) in 17 MS subjects during active relapse [90]. The results of serum and CSF
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samples showed higher levels if TNF-α, IL-10, and NO in comparison with healthy
subjects. Interestingly, 2 subjects showed higher levels of NO in CSF than in serum
which indicates that a high and active production of NO in CNS can be present
simultaneously as in serum. The results also showed that Th1 and Th2 cell activation is
present simultaneously during an active relapse [90].
TGF-β is an anti-inflammatory cytokine that plays an important role in cell
development, differentiation and immune regulation. There are 3 different isoforms of
TGF-β: TGF-β1, TGF-β2 and TGF-β3. The presence of TGF-β1 in the immune system
is abundant but the present of TGF-β2 and TGF-β3 is minimal [91]. Kehrl et al., reported
one of the main roles TGF-β in the regulation of T cells is inhibition of IL-2 production
and subsequently T cell proliferation [92]. The addition TGF-β to cultures of human T
lymphocytes stimulated with Concanavalin A and IL-2 inhibited DNA synthesis between
60-80%. Some of the events related the mechanism of action of TGF-β included down
regulation of IL-2 and transferrin receptors, and a five to six-fold increase in the number
of TGF-β receptors per cell after cellular activation. The authors observed that activated
T cells produced TGF-β mRNA and that TGF-β activity was present in supernatants
suggesting that after activation, T cell themselves are a source of TGF-β. In additional
experiments,
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phytohemagglutinin (PHA). TGF-β activity in supernatants showed to be increased 1050-fold. The results suggested that TGF-β may be an antigen-nonspecific regulator of
human T cell proliferation and it may participate in the modulation of T cell subtypes
[92]. Bright et al., reported the mechanism by which TGF-β1 inhibits Th1 cell activation
[93]. The authors reported that the activation of T cells with IL-12 led to tyrosine
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phosphorylation and activation of the kinases Jak-2 and Tyk-2 as well the activation of
transcription factors STAT3 and STAT4. The addition of TGF-β1 inhibited both Jak-2
and Tyk-2 kinases, and subsequently the phosphorylation of STAT 3 and STAT4. This
inhibition produced a reduction in T cell proliferation and IFN-ɣ production and increase
in apoptosis [93].
Gorelik et al., reported that TGF-β is necessary for immune regulation and its
absence leads to the development of an autoimmune response [94]. In order to study
the effects of TGF-β on the regulation of T lymphocytes the authors created transgenic
mice expressing dominant-negative TGF-β receptor which blocked TGF-β signaling but
allowed the expression of CD4+ and CD8+ T cells but not B cells [94]. The transgenic
mice lived without any detectable problems during 3-4 months of age. After that time
they developed signs of sickness, wasting and diarrhea. Histological examination
showed cellular infiltration in several organs. In addition, circulating autoimmune
antibodies were detected, and T cells were able to differentiate spontaneously in Th1
and Th2 cells subsets. The data suggested that the presence of TGF-β signaling is
required for the regulation of T cells and immune response [94].
Several studies evaluated the role of TGFβ1 in the EAE model [95-98]. Kuruvilla
et al, evaluated the anti-inflammatory role of TGF-β1 on EAE [95]. The authors reported
that a daily intraperitoneal injection of TGF-β1 on SJL/j mice for 2 weeks starting the
day of EAE induction delayed the onset of symptoms for 2-3 days in comparison with
controls (EAE mice with no TGF-β treatment). TGF-β treatment after the first attack of
EAE reduced the severity of the second episode. In an additional experiment, TGF-β
was administrated daily starting 35 days after the beginning of their first episode and
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continuing for at least 4 weeks. TGF-β treatment prevented the development of
spontaneous relapses [95].
In another study, Racke et al., evaluated the immunosuppressive effect of TGFβ1 on chronic EAE [96] . In in-vitro experiments, TGF-β1 inhibited the activation and
proliferation of myelin-basic protein specific lymph nodes cells. EAE induction was
reduced when these cells were transferred to naive mice. In an additional experiment,
EAE mice received TGF-β1 resulting in a reduction in the severity of the disease
(clinical score), reduction of cellular infiltration in CNS, reduction in the expression of
cell adhesion surface molecule lymphocyte function-associated Ag-1 (LFA-1), and
reduction of MHC-II on antigen presenting cells in comparison with EAE mice without
TGF-β1 treatment [96].
In MS and EAE, myelin specific effector Th1 cells participate in the inflammation
in the CNS. Huss et al., studied the effect of TGF-β on effector Th1 cells using the EAE
model. [99]. Splenocytes from myelin-specific T cell receptor transgenic (TCR-Tg) mice
that recognize myelin basic protein peptide Ac1-11 (MBP Ac1-11) were differentiated
with Ag alone or in combination with IL-12 and TGF-β. Cells in presence of MBP alone
or in combination with IL-12 produced a robust Th1 response characterized by the
proliferation of IFN-ɣ+ cells and absence of IL-17 cells. The addition of TGF-β reduced
the number of cell producing IFN-ɣ and the total amount of IFN-ɣ produced [99]. Next,
the authors evaluated the role of TGF-β on the encephalitogenic capacity of myelinspecific T cells. TCR-Tg splenocytes were differentiated in vitro with Ag alone or in
combination with IL-12 and TGF-β. After 72h of stimulation the cells were transferred to
transgenic B10.PL mice and EAE development was monitored for 20 days. Mice that
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received T cells stimulated with Ag alone or in combination with IL-12 developed a
severe EAE. Mice that received T cells stimulated with Ag+TGF-β prevented the
development of EAE, suggesting that the presence of TGF-β suppressed the
encephalitogenicity capacity of the cells. The results from the in-vitro and in-vivo
experiments suggested the presence of TGF-β during the primary differentiation on
naïve
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production,
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encephalitogenicity [99]. Next, the authors compared the effects of TGF-β on effector
cells versus naïve cells. The authors differentiated TCR-Tg splenocytes in-vitro with
MBP and IL-12 to create effector Th1 cells. These cells produced high amounts of IFN-ɣ
and no IL-17. After 72h of stimulation, cells were rested alone for 72-96h and then restimulated with Ag alone or in combination with TGF-β or anti-TGF-β antibody.
Reactivated Th1 cells in presence of TGF-β showed increased proliferation and
increased IFN-ɣ production. Meanwhile the presence of anti-TGF-β antibody reduced in
cell proliferation. These results indicated that TGF-β has opposite effects on the
activation and proliferation of naïve CD4 T cells vs. effector Th1 T cells. The results
showed that the presence of TGF-β during the secondary simulation increased
proliferation and increased IFN-ɣ production, thus the authors hypothesized that the
transference of these reactivated Th1 cell would produce a higher encephalitogenic
effect in naïve recipient mice. To test their hypothesis the authors transferred effector
Th1 cells restimulated with Ag alone or in combination with TGF-β or anti-TGF-β
antibody into naïve B10.PL mice. Interestingly, effector Th1 cells restimulated with Ag +
TGF-B reduced the capacity to cause CNS inflammation and demyelination. On the
other hand, Th1 cells restimulated with Ag in combination with anti-TGF-β antibody
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increased disease severity. In vitro experiments showed that Th1 cells reactivated with
Ag + TGF-β produced IL-10 , reducing the encephalitogenic capacity of these cells [99].
The results from these studies suggested that the immunosuppressive role of TGF-β
can be used in the treatment of MS.

1.11 Nitric oxide (NO)
Nitric oxide is a multifunctional gaseous molecule that participates in multiple
cellular processes, including the immune response, signal transduction, and regulation
of mitochondrial function. NO is produced by the oxidation of L-arginine to L-citruline by
the nitric oxide synthase (NOS) family of enzymes [100]. Three NOS isoforms have
been identified: neuronal (nNOS), endothelial (eNOS), and induced (iNOS). nNOS is
located in central and peripheral neurons, the cerebellum, cerebral cortex, and
hypothalamus. NO produced by nNOS participates in the communication between
neurons. eNOS is expressed in endothelial tissue of blood vessels, where the NO
produced participates in vasodilatation and muscle relaxation. nNOS and eNOS
produce NO constitutively in a Ca2+ dependent manner; therefore, antagonists of Ca2+
reduce NO production [101].
iNOS is expressed in immune cells (i.e. macrophages, neutrophils), where it is
central in the oxidative burst mediated by macrophages and neutrophils during the
immune response against pathogens. NO production in these cells is Ca 2+-independent
[101]. The levels of NO produced by nNOS or eNOS are between 0.2-2 nM [102].
Normal levels of NO produced by iNOS are 2-20 nM. When iNOS is stimulated (i.e.
inflammation) NO levels are 20-200 nM [103]. In macrophages, gene expression of
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iNOS is regulated by the CD14 receptor and toll like-receptors (i.e. TLR-4). Pathogens
or lipopolysaccharides (LPS) bind to TLR-4 and CD14 receptor leading to the
phosphorylation and activation of the IkB kinase (IKK) to phosphorylate the IkB-NFkB
complex. The IkB complex is degraded in the cytosol and then NFkB can travel to the
nucleus to induce the expression of genes, including iNOS. Similarly, interferon gamma
(IFN-ɣ) binds to the IFN-ɣ receptor in the cell membrane, leading to the phosphorylation
of the transcription factor STAT1, which travels to the nucleus to activate iNOS
expression [104].

1.12 Role of NO on T cell differentiation and immunity.
NO produced by myeloid cells (i.e. macrophages, neutrophils, and monocytes)
through the action of iNOS mediates the destruction of pathogens [105-109]. In addition,
NO is an important regulator of the immune response. In particular, evidence supports
that NO as a critical regulator of autoimmunity. For instance, different studies
demonstrated that NO produced by iNOS participates as a negative regulator of the Th1
cell response, thus protecting against autoimmune attack [110-115]. Studies showed
that iNOS deficient mice (iNOS-/-) develop an enhanced Th1 cell response after infection
and antigenic stimulation leading to an increase in the production of IFN-ɣ and a
reduction in IL-4 in comparison with unaltered iNOS mice (WT mice) [113-115]. iNOSdeficient mice were susceptible to Leishmania major infection, developing significant,
strong Th1 type immune response characterized by higher production of IFN-ɣ and
reduction in IL-4 in comparison with WT mice [113]. In an animal model of bacterial
septic arthritis, iNOS deficient mice infected with Staphylococcus aureus presented with
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higher incidence of disease with faster development, higher septicemia, more severe
arthritis, and higher mortality in comparison with infected WT mice [114]. iNOS-deficient
mice expressed higher levels of TNF-α, IFN-ɣ, and reduction in IL-4 in comparison with
infected WT mice, correlating with more robust Th1 cell responses. Altogether, the data
suggested that NO plays a role in synovial defense against Staphylococcus aureus
infection [114]. Infection of iNOS deficient mice with herpes simplex virus (HSV-1)
showed a delay in the clearance of the disease, as well as increase in the frequency of
virus reactivation in comparison with WT mice [115]. iNOS deficient mice showed an
enhanced Th1 immune response in the spleens characterized by higher concentrations
of IL-12 than WT mice [115].
Previously it was established that the immunization of animals with complete
Freund's adjuvant (CFA) produced resistance to subsequent attempts to induce
autoimmune diseases meanwhile animals immunized with incomplete Freund's adjuvant
(IFA) remain susceptible [116-120]. Studies by Kahn et al., evaluated if the
immunoprotective effect of CFA before EAE induction required functional iNOS [111].
The response of C57BL/6J mice to a single subcutaneous injection of CFA was
compared to naïve mice not challenged with CFA. Lymph nodes and spleen were
isolated to evaluate mRNA expression by qPCR. In CFA immunized mice, iNOS
expression was elevated by 28 days after immunization and remained elevated for 14
months. Serum samples collected one week after CFA challenge demonstrated higher
levels of nitrite (NO2) levels by Griess reaction compared to [111]. Next, the authors
evaluated the requirement of IFN-ɣ and TNF-α for iNOS induction by CFA. The authors
immunized C57BL/6, C57BL/6IFN-ɣ-/-, and C57BL/6TNFR1-/- with CFA then lymph
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nodes and spleens were isolated 28 days after immunization to evaluated iNOS
expression by qPCR. The results showed that C57BL/6IFN-ɣ-/-, and C57BL/6TNFR1-/presented lower levels of iNOS in comparison with naïve C57BL/6 mice [111]. To
investigate whether iNOS induced by CFA induction would reduce EAE severity in mice,
C57BL/6 mice received intraperitoneal injection of CFA 28 days before MOG-EAE
induction. Mice without CFA injection before MOG-EAE induction were used as control
group. Mice that received CFA pre-immunization presented with reduced disease
severity (clinical score) in comparison with control group. Furthermore, C57BL/6NOS-/mice pre-immunized with CFA showed a lower clinical score in comparison with the no
pre-immunized CFA C57BL/6NOS-/- mice. However, the clinical score of both groups
was higher than the pre immunized CFA WT C57BL/6 mice group. These results
showed that the pre-immunization with CFA on iNOS-/- mice does not provide the same
level of protection than in the C57BL/6 mice [111].

In additional experiments, the

authors observed that WT C57BL/6 mice pre-immunized with CFA presented elevated
levels of IgG and reduction in reduction in cell infiltration in spinal cords in comparison
with the pre0mmunized CFA C57BL/6NOS-/- mice. All together, the results support the
role of NO produced by iNOS in the modulation of immune response in CFApreimmunized mice [111].

1.13 Regulatory mechanism of NO-iNOS in immune cells.
Th1 cells play a role in the development of inflammatory diseases, including MS
and EAE. The IFN-ɣ produced by Th1 cells activates macrophages to induce the
expression of iNOS, leading to production of high amounts of NO. Studies showed that
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high amounts of NO produced by iNOS can inhibit the expansion of Th1 cells by
negative feedback mechanism whereby activated macrophages inhibit IL-12, which is
necessary for Th1 differentiation [121]. Fenyk-Melody et al. showed that iNOS-deficient
mice presented with more severe disease compared to WT mice in the EAE model,
suggesting that the NO produced by iNOS in the WT mice-EAE immunized prevented
CD4+ T cells from differentiating into pathogenic Th1 cells [122, 123]. Therefore, the
modulation of NO to control the immune response may be an approach to ameliorate
inflammatory conditions such as MS and EAE.
Niedbala et al., carried out experiments using CD4+ and CD8+ T cells isolated
from the spleen and lymph nodes from BALB/c mice to determine the effects of low and
high concentrations of NO on Th1 differentiation [112]. Graded concentrations of the NO
donor S-nitroacetyl-penicillamine (SNAP) were used on CD4+ T cells cultures with
BALB/c spleen cells as antigen presenting cells (APC), ovalbumin peptide, plus IL-12
(to induce Th1 line) or IL-4 (to induce Th2 line). High concentrations (500μM) of SNAP
inhibited the production of IFN-ɣ by the Th1 cell line, whereas low concentrations
(10μM) increased the synthesis of IFN-ɣ by Th1 cell line. In addition, low concentrations
(10μM) of SNAP synergistically increased the production of IFN-ɣ induced by IL-12.
These results showed that NO play a role in the modulation of the immune response
[112].
In further studies, Niedbala et al. evaluated the effect of low concentrations of NO
in human CD4+ T cells purified from human cord blood. Cells were induced to a Th1 cell
phenotype using phytohemagglutinin (PHA), IL-12, and anti-IL-4 antibody [124]. Th1 cell
differentiation was enhanced with the presence of low concentrations (5mM) of the NO
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donor, 2,2’-(hydroxynitrosohydrazino)bis-ethamine (NOC-18 known also as DETA-NO),
and suppressed by higher concentrations (>40mM) of NOC-18 [124]. The data obtained
from the human and mouse studies correlated. However, human CD4+ T cells were
more sensitive to the graded (low) concentrations of NO than mouse T cells.
The next step was to investigate the mechanism of how different concentrations
of NO induced Th1 cell differentiation [124]. CD4+ T cells purified from spleen and
lymph nodes from BALB/c mice were cultured with a combination of anti-CD3
antibodies, IL-12 and anti-IL-4 antibody (to induce Th1 cell differentiation). Graded
concentrations of the NO donor NOC-18 (5, 10, 20, 100μM) were included to evaluate if
NO activates soluble guanylyl cyclase (sGC), leading to increase production of cyclic
guanosine monophosphate (cGMP). The results showed an increase of intracellular
cGMP in CD4+ T cells under the Th1 differentiation conditions at low doses of NOC-18
(5 and 10μM). The levels of cGMP were reduced at higher concentrations of NOC-18
(100μM). The levels of IFN-ɣ correlated with the low levels of NOC-18 and higher
activity of cGMP [124]. Next, the authors tested the 1-H-oxodiazolo-(1,2,4)-(4,3-a)
guinoxaline-1-one (ODQ), a competitive inhibitor of the activation of cGMP. CD4+ T
cells and CD8+ T cells cultured with ovalbumin (OVA), plus IL-12, with anti-IL4 antibody
(TH1 cell differentiation conditions), or IL-4 plus anti-IL12 and anti-IFN-ɣ antibodies (Th2
cell differentiation conditions), NOC-18, and ODQ (10-40μM). ODQ (at 20μM)
suppressed Th1 cell differentiation but had no effect on Th2 cell differentiation at any
dose. In additional experiments, ODQ also suppressed Th1 cell differentiation from
CD4+ T cells in the absence of antigen presenting cells (APC). The results suggested
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that at NO at low concentrations participates in Th1 differentiation by cGMP activation
and this effect is exerted directly on Th1 cells and not via APC [124].
Next the authors evaluated the effect of low concentrations of NO on the
selective cell differentiation of CD4+ T cells and CD8+ T cells [124]. CD4+ T cells and
CD8+ T cells were cultured under Th1 and Th2 cell differentiation conditions, NOC-18
(10μM), and activated with anti-CD3 antibodies. Cells were harvested at 16h and mRNA
was used to measure the levels of IL-12Rb2, IL-18Ra, and IL-4R by rtPCR. IL-18Ra (in
Th1 cells) and IL-4r (in Th2 cells) did not show change compared to controls. On the
other hand, Th1 cells showed increase levels of IL-12Rb2 suggesting that low levels of
NO selectively and preferentially enhance the expression of IL-12Rb2 during Th1 cell
differentiation. All the data put together indicates that at low concentrations of NO, NO
activates sGC, leading to up-regulation of the cyclic guanosine monophosphate
(cGMP), which induces IL-12 receptor β2 in T cells, producing IL-12 and TCR
engagement finally leading to Th1 differentiation [124].
Similarly, Bingisser et al., studied the role of NO produced by macrophages in
the modulation of the T cell inflammatory response [125]. Th1 cell activation involves IL2R ɣ-chain, the Janus kinase 3(Jak3) and the signal transducer and activator of
transcription 5 (STAT5). For T cell activation, STAT5 has to be activated
(phosphorylated) by Jak3. Once STAT5 is activated, it travels to the cell nucleus and
functions as transcription factor to induce cell activation [125]. Activated T cells are
unable of proliferate in the presence of NO produced by alveolar macrophages despite
the presence of IL-2R and secretion of IL-2. Supporting in vitro experiments showed
similar
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acetylpenicillamine (NO donor), whereas T cell proliferation occurred in presence of
NG-methyl-L-arginine (NO synthase inhibitor). Immunoprecipitation assays with T cell
lysates showed a significant reduction of tyrosine phosphorylation of Jak3 and STAT5 in
the presence of NO. This NO-mediated T cell suppression was reversible by guanylate
cyclase inhibitors methylene blue and LY-83583. Additional in vitro experiments showed
that NO-mediated T cell suppression was reproduced using a cell membrane analogue
to cyclic GMO, suggesting that guanylcyclase activation is a critical step in the inhibition
of T cell activation by NO [125]. Similarly, independent studies by Mazzoni and Sato
groups found that NO produced by myeloid suppressor cells (MSC) participated in the
inhibition of T cells [126, 127]. The NO produced by MSC suppressed the activity
(phosphorylation) of Jak1, Jak3, STAT5, extracellular signal–regulated kinase (Erk) and
Akt [126, 127].

1.14 Axonal degeneration in MS
The formation of lesions or plaques in the CNS is the pathologic hallmark of MS.
The development of these plaques involves the breakdown of the BBB, multifocal
inflammation, demyelination, loss of oligondendrocytes, reactive gliosis and axonal
degeneration. Even though all these events are involved in the development of MS, the
progressive axonal loss is the main cause of neurological disability in MS [1]. Some of
the changes present in MS lesions which indicate acute damage in axons include:
increased distribution of Na+ channels along the axons, axonal transport alterations i.e.,
accumulation of amyloid precursor protein (APP), axonal transections, axonal loss and
axonal degeneration [1, 128-131].
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1.15 Increased distribution of Na+ channels along the axons
The destruction of myelin is a pathological hallmark present in the progression of
MS. Under normal or healthy conditions, neurons contain axons which are covered
(insulated) by myelin sheaths. The myelin sheaths are a lipid-rich extension of plasma
membrane produced by Schwann cells in the peripheral nervous system (PNS), and by
oligodendrocytes in the CNS. The myelin sheath along the length of the axon is
interrupted by regions known as nodes of Ranvier which serve to facilitate the rapid
conduction of nerve impulses or action potential (messages) along the axon from one
neuron to another [132]. The saltatory conduction of action potentials (jumps) from one
node of Ranvier to another is carried out due to the proper insulation or covering
provided by the myelin sheaths as well as the high concentration of voltage-gated Na+
channels at the nodes of Ranvier [133]. In normal conditions, the Na+/K+ ATPase is in
charge of pumping out the excess of Na+. However, when demyelination is present,
there is an increase in the expression and distribution of the Na + channels along the
axon in order to keep the salutatory conduction of action potentials [133]. This increase
in Na+ produces an increase in the activity of the Na+/K+ ATPase and ATP consumption.
Therefore, the cell increases the number of mitochondria, and activates glycolysis in
order to compensate for the increase in energy demands. When the ATP demands
exceed the production of ATP by the mitochondria, the activity of Na +/K+ ATPase is
reduced, leading to intracellular accumulation of Na+ and membrane depolarization
[134]. A high concentration of Na+ will lead to reverse the Na+/Ca2+ charger, causing to
the transport of Ca2+ to inside the cell. Intracellular accumulation of Ca2+ induces
mitochondrial dysfunction and cell death [134]. The accumulation of Ca2+ in the
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axoplasm leads to activation of Ca2+-dependent enzymes (i.e. calpain, phospholipases,
protein kinase C, NO-synthase) to produce axon damage [135]. The high concentration
of Ca2+ in the axoplasm produces the influx of the Ca2+ into the mitochondria [136]. The
increase of Ca2+ in the mitochondria induces the opening of the permeability transition
pore (PTP) which will induce mitochondrial dysfunction by the swelling of the matrix,
rupture of the outer mitochondrial membrane, releasing cytochrome C and activating the
apoptotic pathway to produce cell death [136].

1.16 Axonal transport alterations
Demyelination can be present during active or inactive inflammation. Studies on
active cerebral MS lesions showed a positive correlation between axonal damage and
the degree of inflammation in active MS lesions, as determined by quantification of
proteins that are transported in the axons. Accumulation of such proteins allows for the
evaluation of disturbances of axonal transport or axonal transection. One common
protein used in this analysis is the amyloid precursor protein (APP). Immunochemistry
using an antibody recognizing APP showed that APP accumulated in the axons due to
disruption of axonal transport and presence of axonal transections. Investigators noted
increased accumulation of APP in damaged axons within acute multiple sclerosis
lesions in advanced stage of disease and at the borders of less acute lesions [128,
130].
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1.17 Axonal transection
Magnetic Resonance Spectrophotometry (MRS) and Magnetic Resonance
Imaging (MRI) studies demonstrate that axonal degeneration is present in absence of
active inflammation since early stages of MS. This early axonal loss contributes to the
permanent disability produced in chronic stages of the disease [137]. In one study,
Trapp, B.D., et al., evaluated changes in axon morphology at different stages of MS
using brain tissue samples obtained from MS subjects. The authors collected 14 active
lesions, 33 chronic active lesions, and samples from the white matter without presence
of lesions. The sections were evaluated by immunochemistry and confocal microscopy
to evaluate the degree of demyelination, inflammation and pathologic changes in axons
[131]. All 47 lesions presented axonal transection characterized by the presence of
terminal axons ovoids. The number of transected axons was positively correlated with
the degree of inflammation in the lesions. The quantification of transected axons in
active lesions showed the presence of 11,236 transected axons/mm 3 on average, the
border of chronic lesions presented 3,138 transected axons/mm 3, the center of chronic
active lesion presented 875 transected axons/mm 3, and normal white matter samples
presented less than 1 transected axons/mm3 [131]. The results indicate that axonal loss
is present in active lesions since the early stages of the disease.

1.18 Axonal loss and axonal degeneration
The degeneration of axons in MS presents rapid Wallerian degeneration which is
distal to the site of transfection. On the other hand, the myelin present in CNS can
remain for a longer period of time after proximal fiber transfection. The remaining myelin
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sheaths will be present as empty tubes or they will degenerate to ovoids [130].
Interestingly, axonal damage has been observed in MS normal appearing white matter
(NAWM), even though active lesions were not present on MRI images or histological
examination. For example, it was reported that NAWM samples from the lateral column
cross-sectional area from MS subjects in an early stage of disease showed a reduction
in total nerve fiber density from 19 to 42% [138]. In another study, axonal loss and
axonal degeneration was quantified in cervical spinal cords samples obtained from
SPMS subjects. Samples of plaques with presence of demyelination, NAWM, and
control samples were used in the immunostaining analysis of the neurofilaments. The
results showed a reduction in axonal density (number of axons/mm2) in both
demyelinated plaques (61% of reduction) and NAWM samples (57% of reduction). The
results support that axon degeneration is present in apparently uninjured samples
(NAWM) but its progression leads to the irreversible disability [139]. These results were
corroborated in subsequent studies, were axonal loss was quantified in 10 chronic
inactive samples obtained from MS subjects with chronic disease (12 to 39 years). The
authors found that the samples showed an average of 68% axonal loss and a reduction
of 58% in axonal density [140].

1.19 Additional mechanism involved in axonal degeneration
Interestingly, the protein, cyclophilin D (CyPD), which is a structural protein of the
PTP, is an important element in the formation and regulation of the opening of PTP
[142, 143]. Under normal conditions, PTP allows the transport of Ca2+ from the
mitochondria to the cytoplasm and vice versa. Mice deficient in CyPD due to targeted
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disruption of the CyPD gene (CyPD-KO mice) were still capable of the formation of the
PTP pore, but the mitochondria maintain a double concentration of Ca2+ in the
cytoplasm [142]. This indicates that more Ca2+ is needed to open the PTP, suggesting
that CyPD participates as a regulator of the PTP-opening. Interestingly, mitochondria
obtained from liver, heart, and brain of CyPD-KO mice were resistant to Ca2+ overload,
mitochondrial swelling, permeability transition, and whole cells were resistant to cell
death induced by oxidative stress [142]. In another study, EAE was induced in CyPDKO mice (CyPD-KO-EAE mice). Mice presented with the typical clinical signs of EAE
model, However, CyPD-KO-EAE mice presented a less severe disease. The spinal
cords obtained from the CyPD-KO-EAE mice showed similar inflammation but a
reduction of axonal loss in comparison with EAE mice [143]. In addition, induced mice
were resistant to nitrosative stress produced by reactive oxygen species (ROS) and
reactive nitrogen species (RNS) [143]. The results suggest that the lack of CyPD helped
to maintain proper mitochondrial function fundamental to reduce axonal destruction.
Some studies have used different animal models to study axon damage. For
instance, in myelin associated glycoprotein (MAG)-deficient mice, the lack of MAG
produces a progressive reduction in the caliber of the axon, neurofilament spacing,
phosphorylation in the neurofilaments, and Wallerian degeneration at 90 days of age
[144]. Another model is the cyclic nucleotide phosphodiesterase (CNP)-null mice. In the
oligodendrocytes, CNP is necessary for axonal survival but not for myelin assembly.
Therefore,

CNP-null

mice

present

with

axonal

swelling,

neurodegeneration,

hydrocephaly, and premature death [145]. Another model is the proteolipid protein
(PLP)-null mice model. In the PLP-null mice, the oligodendrocytes are able to produce
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compacted myelin sheaths on the axons. However, the stability of the myelin sheaths is
lost, the lack of stabilization leads to myelin break down, demyelination, and
oligodendrocytes death. Therefore, one of the functions of PLP is to hold together the
myelin sheaths on the axons to maintain its integrity independently of its roles in the
production of myelin [146]. The results of the studies carried out on the MAG-, CNP-,
and PLP-knock out mouse models suggest that the axon degeneration is produced not
due to the lack of myelin production but by the loss of trophic support necessary for
axon survival [144-147].

1.20 Compensatory mechanisms during axonal loss and axonal degeneration
Studies in the EAE model further investigated the effect of chronic demyelination,
axonal damage, and axonal loss in disease progression. Wujek, J.R., et al., showed that
the clinical score assigned to each mouse (i.e. disease severity) correlated with axonal
loss in the inflammatory lesions present in the spinal cords (SC) of affected mice, from
the beginning through the last stages of the disease [148]. For example, EAE mice in
chronic stages of the disease with a clinical score of 4 (permanent limb paralysis)
presented a total axonal loss of 43% and 60% in lumbar and cervical SCs respectively.
On the other hand, EAE mice with a clinical score of zero (no signs present) presented
an axonal loss on average of 30% in cervical SCs and 15% in lumbar SCs, indicating
that even in the absence of clinical signs, pathologic consequences of the disease
process were evident [148]. The results also suggested that adaptive mechanisms exist
to delay the presentation of clinical signs and permanent disability, but once the
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threshold is exceeded the disease will worsen and neurological disability will be present
[148].
Axonal degeneration is present in MS beginning with the onset of the disease. It
has been proposed mitochondrial dysfunction participates in the degeneration of axons
and axonal dysfunction at the onset of MS. N-acetyl aspartate (NAA) is a metabolite
produced from aspartate and acetyl CoA in the mitochondria of neurons, dendrites, and
axons. MRS and MRI studies demonstrated reduced levels of NAA in brain of RRMS
and SPMS subjects which correlated with the progression of disability, functional
impairment, axonal damage, and axonal loss [149-152]. Therefore, NAA reduction may
be a possible marker to detect mitochondrial dysfunction and axonal damage.
Reversible acute inflammatory events are characteristic of RR-MS. The amelioration of
the inflammatory attacks is established by the resolution of the clinical symptoms.
Mechanisms involved in the resolution of the clinical symptoms include remyelination,
compensatory cortical adaptation, and redistribution of the Na+ channels along the axon
[153-155]. Reddy et al., evaluated if cortical adaptive responses contributed to the
maintenance of normal motor function in MS subjects [155]. The authors used MRSI
and functional MRI (fMRI) on MS subjects with unpaired hand function. The results
showed that simple hand movements increased until 5 fold the activity of the ipsilateral
sensorimotor cortex in comparison with healthy controls. The increase correlated with a
reduction in the levels of NAA in brain [155]. This study suggests that cortical adaptive
responses are activated to compensate for the brain damage and clinical disability
noted in MS. However, once the damage and axonal loss exceed the compensatory
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mechanisms in CNS, the worsening of the clinical symptoms and irreversible disability
result, leading to the progression from RRMS to SPMS [147, 155] .

1.21 Mitochondrial function
The mitochondrion is the cellular organelle responsible for the production of ATP
via the process of oxidative phosphorylation. The process begins in the cytosol, where
glucose is converted to pyruvate. Pyruvate is transported to the mitochondrion to be
metabolized to acetyl coenzyme A (CoA), which is used in the tricarboxylic acid cycle to
produce nicotine adenine dinucleotide (NADH) and flavin adenine dinucleotide (FADH2).
NADH and FADH2 are used in the mitochondrial respiratory chain to produce ATP [156].
The respiratory chain is constituted of 5 complexes: NADH dehydrogenase (complex I),
succinate dehydrogenase (complex II), cytochrome c reductase (complex III),
cytochrome c oxidase (CCO, complex IV), and ATP synthase (complex V). NADH and
FADH2 are oxidized by complex I and II respectively. The electrons released are
transported by 2 electron transporters: coenzyme Q10 transports electrons from
complex I and II to complex III, and cytochrome c transports electrons from complex III
to complex IV (CCO) [156]. During the transport of electrons, energy is released and is
used to transport protons (H+) from the mitochondrial matrix to the mitochondrial
intermembrane space (IMS), creating a proton gradient throughout the mitochondrial
inner membrane (MIM). The proton gradient force is used by complex V to produce
ATP. The ATP produced is then transported by the adenine nucleotide translocator to
the cytosol for use in cellular reactions [156].
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Cytochrome c oxidase (CCO or complex IV) is a key regulatory component in the
respiratory chain. CCO contains two oxygen binding sites: the iron heme a 3 (reduced
site) and the copper (CuB, oxidized site). Under normoxic conditions (20-130 mM O2),
the oxygen binds to these two binding sites. CCO catalyzes the reduction of oxygen to
produce water [157-159]. During this reaction, there is transfer of electrons to ATP
synthase, with the subsequent production of ATP. The leakage of electrons leads to the
production of different reactive oxygen species (ROS) [i.e. superoxide (O2-), peroxide
(H2O2), and hydroxyl (OH-)]. Nitric oxide (NO) also plays a role as regulator of cellular
respiration. Under either hypoxic conditions or high concentration of NO, NO competes
with oxygen and binds reversely to the iron heme a 3 (CCO-NO). This leads to the
inhibition of CCO and the reduction of ATP production [160-162].
In addition, NO at high concentrations reacts with oxygen to produce reactive
nitrogen species (RNS) such as nitrite (NO2-), dinitro trioxide (N2O3), peroxynitrite
(ONOO-), and S-nitrosothiols (RSH). NO also participates in the production of ROS
such as superoxide (O2-) and peroxide (H2O2) [164-166]. The excess of NO and RNS
inhibits the activity of complexes I, II, IV and V of the respiratory chain leading to
mitochondria dysfunction and reduction in ATP production [167-169].

1.22 NO and glutamate excitotoxicity in MS
NO and glutamate are involved in MS development and progression and the
common pathway that they share is the damage to mitochondria (mitochondrial
dysfunction. Studies of mechanisms of neurodegeneration demonstrate the role for high
levels of NO, ROS and RNS in the death of neurons. Microglia are the resident
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macrophages of the CNS and a common source of ROS/RNS. Microglial activation is
frequent in CNS pathologies, including MS, leading to the elevated production of NO via
iNOS. In vitro experiments showed that the activation of microglia and the high levels of
NO produced lead to the inhibition of cellular respiration (depletion of ATP) in cocultured neurons, leading to the release of glutamate from the neurons and contributing
to cell death by excitotoxicity [170-173].
Glutamate is an excitatory neurotransmitter which binds to the α-amino-3hydroxy-5-methyl-4-isozolepropionic acid (AMPA) and N-methyl-D- aspartate (NMDA)
receptors located on the post-synaptic membrane of neurons The binding of glutamate
to the AMPS and NMDA produces the transmission of stimulus and also allows the
opening of ion channels in order for Na+, K+, and Ca2+ to transmit the impulse [173].
Excitotoxicity results when excessive glutamate is released, reaching high synaptic
concentrations. The overstimulation of NMDA and AMPA receptors leads to excessive
stimulation of ion channels and cell death.
In MS, the presence of high concentrations of glutamate produced by microglia,
produce a deregulation in the ion gradients. At high concentrations of glutamate, Ca2+
can enter to the mitochondrion, producing the opening of the permeability transition
pore (PTP) and release of CCO into the cytosol producing mitochondrial dysfunction
[174]. The accumulation of Ca2+ in the mitochondria produces an increase in the activity
of the reversal ATP synthase in order to compensate the entrance of Ca 2+ leading to a
depletion in ATP. The depletion of ATP will lead to a deregulation of Ca 2+ via inhibition
of the plasma Ca2+-ATPase and inhibiting the activity of the enzymes involved in the
glycolysis pathway [175]. High levels of Ca2+ due to activation of NMDA receptors leads
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to the activation of the protease calpain I, located in the cytoplasm of neurons. Calpain I
activation induces the degradation of cytoskeleton, neurofilaments, and ion channels,
leading to cell death. Moreover, it has been found that Calpain I induces the cleavage of
the apoptosis-inducing factor (AIF) and its translocation from the mitochondria to the
nucleus inducing cellular death [176]. During the translocation of AIF to the nucleus,
there is also a translocation of the proapoptotic factor BH3-interacting domain death
agonist (Bid) to the mitochondria. Bid is a member of the bcl-2 family, the accumulation
of Bid in the mitochondria leads to loss of the integrity of the mitochondrial membrane
and therefore its destruction [177].

1.23 Nitrosative stress and mitochondrial dysfunction in MS and EAE
MS studies demonstrated that mitochondrial dysfunction is produced in part by
high concentrations of ROS and RNS, leading to the generation of nitrosative stress
[147, 178-184]. Using immunohistochemistry assays, Lu et al. observed an increase in
the oxidative damage of mitochondrial DNA (mtDNA) in cells from chronic active
plaques obtained from MS subjects. The oxidative damage in mtDNA correlated with
reduced activity of complex I (NADH dehydrogenase) of the respiratory chain and a
possible compensatory increase in the activity of complex IV (CCO) [178]. The results
suggested that the oxidative damage in mitochondria was related to the chronic
inflammatory process in the CNS [178]. To support the role of mitochondrial dysfunction
in axon degeneration in MS, Dutta et al. used microarray assays to compare the
expression of 33,000 genes in postmortem motor cortex samples from 6 MS subjects
and 6 healthy controls. The authors found that 488 transcripts were reduced and 67
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were increase in MS samples in comparison to controls. From these, 26 mitochondrial
genes were reduced, as well as the activities of the complexes I and III of the
respiratory chain. These results indicate that mitochondrial dysfunction in demyelinated
axons leads to reduced ATP production and participates in the progression to
permanent disability in MS [179].
Immune cell infiltration is considered the main contributor to axonal destruction.
However, studies by Qi et al. in the EAE model showed that mitochondrial dysfunction
due to oxidative stress was present in the CNS of immunized mice before the infiltration
of immune cells [180]. EAE was induced in DBA/1J mice by immunization with spinal
cord homogenate emulsified in complete Freund’s adjuvant (CFA). DBA/1J mice
injected just with CFA were used as controls. Three days after sensitization, mice were
euthanized and the optic nerves, retinas, brains, and spinal cords were obtained [180].
None of the mice showed clinical signs of EAE disease at this time-point. The ROS
activity in tissue samples was evaluated by the presence of nitrated proteins. Nitrated
proteins were detected in all of the samples obtained from the mice primed with
autoantigen. On the other hand, nitrated proteins were not detected in the CFA-only
immunized control mice. Interestingly, the samples from immunized mice did not contain
inflammatory cells. The identity of nitrated proteins in samples from neuroantigenprimed mice was further analyzed by mass spectrophotometry analysis of isolated
mitochondria. These experiments showed that the nitrated proteins corresponded to
heat shock protein 70, NADH dehydrogenase (complex I), cytochrome c oxidase (CCO,
complex IV), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The authors
next measured mitochondrial ATP production and found that the ATP production in the
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optic nerve, retina and brain did not show significant differences in samples from SChomogenate primed mice in comparison with control tissues. On the other hand, ATP
production in samples from the spinal cords of immunized mice was reduced 79% in
comparison with control tissues [180]. Spinal cord samples showed a significant
reduction of mitochondrial membrane potential (MMP), to approximately 33% (p<0.05)
in comparison with controls. The loss of MMP leads to DNA fragmentation and
apoptosis. This led the authors to evaluate apoptosis in the samples from immunized
mice using TUNEL staining. They found TUNEL-positive cells in optic nerve, retina,
brain and SCs samples. Immunofluorescent microscopy revealed that the TUNELpositive cells were oligodendrocytes. Furthermore, tissues isolated from mice primed for
EAE,

but

not

adjuvant-inoculated

control

animals,

showed

positive

iNOS

immunofluorescence and the presence of iNOS by immunoblot assay. Histological
analysis of spinal cords from diseased mice showed the presence of mitochondrial
vacuolization and dissolution of cristae, but this was not observed in controls. These
changes in the structure of mitochondria correlate with the presence of oxidative stress
and the degeneration of axons at early stage of EAE [180]. Collectively, these results
demonstrate the presence of nitrosative stress, oligodendrocyte death, and axonal
degeneration an early stage of EAE (3 days post sensitization) in the absence of
immune cells [180]. These authors subsequently observed H2O2 and superoxide in the
mitochondria from the optic nerve obtained from EAE mice collected 3 days after
sensitization. As observed previously, ROS production was present in absence of
inflammatory cell infiltration [181]. Moreover, apoptotic oligodendrocytes were observed
in the retina and optic nerve of the EAE mice by immunohistochemical methods.
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Interestingly the suppression of SOD2 gene in the eyes of EAE mice increased the
damage in myelin fibers by 27%. On the other hand, the overexpression of SOD2 in the
eyes of EAE mice reduced the damage in myelin fibers by 51%. Therefore the authors
suggest that the overexpression of SOD2 can be used to reduce the optic neuritis
produced due to oxidative stress in EAE mice [181].
Lewis rats immunized with myelin basic protein, complete Freund adjuvant are
characterized by a monophasic disease, full recovery, do not relapse, and develop
resistance to further reinduction of disease. O’Brien et al. used this model to investigate
the role of NO in disease development [182]. The authors observed elevated serum
NO2- during the active period of disease which persisted into the recovery period. The
results suggested that NO plays a role in the development of disease especially during
an active state [182]. In separate experiments, Jolivalt et al. investigated the effect of
the nitric oxide scavenger NOX-100 on EAE induced in SJL/J mice [183]. The authors
found that NOX-100 reduced disease progression, CNS inflammation, pro-inflammatory
cytokines and iNOS. The results suggest that therapies to reduce oxidative stress can
be a suitable approach to reduce the progression of EAE and MS [183].
Calabrese et al. evaluated different nitrosative stress markers in cerebrospinal
fluid and plasma samples collected from MS subjects and matched healthy controls
[184]. Western blot analysis using CSF showed that samples from MS subjects
presented an increase of approximately 24% in iNOS activity in comparison with
controls. The use of aminoethylisothiourea (ITU), an iNOS inhibitor, on CSF samples
from MS reduced the iNOS activity to similar levels to control samples. Nitrotyrosine
immunostaining of CSF proteins was elevated in MS patient but was not detectable in
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controls. CSF samples were used to measured nitrite levels by Griess reaction and
peroxynitrites by luminol dependent enhanced chemiluminescence. Nitrite and
peroxynitrites were elevated by 81% and 61% respectively in samples form MS patient
in compassion with controls. CSF samples also showed an increase of approx. 38% in
S-nitrosothiol is MS samples in comparison with controls. Levels of the antioxidant
glutathione were reduced in CSF and plasma in MS samples in comparison with healthy
controls. All these results supported the participation of nitrosative stress in the
development of MS [184].

1.24 MS therapies
Therapeutic agents currently approved for the treatment of MS affect disease by
modulating or suppressing the immune system in general or the autoreactive T cells,
specifically. These drugs are approved for the treatment of RRMS, characterized by the
inflammatory demyelination. They act to reduce the frequency and number of relapses
and the number and size of the lesions present in the CNS, reduce disability, and slow
the progression of disease [185, 186]. However, they do not prevent long-term disability
and are ineffective for the treatment of progressive disease because they fail to offer
significant neuroprotection as well as reduction in nitrosative stress that is mainly
present in chronic stages [185, 186]. Neuroprotective strategies that can be used
throughout

the

disease

process

are

urgently

needed.

The

combination

of

neuroprotection and immune modulation are considered necessary to target the innate
and adaptive responses that arise during the progression of the disease and guard
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against the axonal loss contributing to disease progression. The primary therapeutic
agents currently approved are summarized below and in Table 1.
Interferon beta (IFN-β). The critical step in the pathogenic mechanism of MS is
the activation of naïve autoreactive T cells in the periphery which then migrate to the
CNS to cause disease [21]. This naïve T cell activation is carried out by the three
signals mechanism discussed above. Briefly, the first signal in T cell activation occurs
when TCR on CD4+ T cells recognizes the myelin peptides or their mimics presented by
the MHC-II located on APC (i.e. dendritic cells, B cells, macrophages) [22, 23]. The
second signal is carried out when the co-receptor molecules CD80 and CD86 on APCs
(i.e. dendritic cells) bind to CD28 molecules located on T cells. The second signal
produces the release of cytokines by the T cell. The binding of these cytokines to their
specific receptors on T cells (signal three) will produce the final activation of T cells, for
instance, IL-12 leads to Th1 differentiation and IL-4 leads to Th2 cell differentiation.
Once activated in the periphery, T cells are able to cross the blood brain barrier (BBB)
and enter the CNS [22].
IFN-β is available as IFN-β-1a (Avonex®, Rebif®, and Plegridy®) and IFN-β-1b
(Betaseron®). Human IFN-β is a polypeptide of 166 amino acids forming five α helices
naturally produced by human fibroblasts, dendritic cells, and retinal glial cells. IFN-β-1a
is produced in Chinese hamster ovary cells, and it is pharmacologically identical to the
natural form (found in humans). IFN-β-1b is produced in E, coli, and it has 165 amino
acids instead of 166 (Met1 is absent) and the amino acid Cysteine at position 17 is
replaced by Serine [187]. Betaseron® and Rebif® are administrated subcutaneously
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every other day. Avonex ® is administrated intramuscularly once a week. Plegridy® is
administrated subcutaneously every 2 weeks [188].
IFN-β affects disease pathogenesis by multiple mechanisms. The drug reduces
the inflammatory T cell response by inhibiting the stimulation and activation of T cells.
Specifically, IFN-β reduces the expression of MHC-II as well as the co-stimulatory
molecules CD80 on APCs and CD28 on T cells [186, 189-191]. Th1 and Th2 subsets
play and important role in MS development: Th1 cells participate during the initial phase
of inflammation, while Th2 mediated response is important during recovery. IFN-β
produces changes in the Th1/Th2 cell balance, leading to a shift from Th1 cell
phenotype to a Th2 cell phenotype characterized by a reduction Th1 cell proinflammatory cytokines (IL-2, IL-12, IFN-ɣ, TNF-α) and an increase in Th2 cell antiinflammatory cytokines (IL-4, IL-10, TGF-β) [186, 191, 192]. IFN-β also affects cell
migration into the CNS by reducing the expression of the adhesion molecule VLA-4
located on the surface of activated T cells. This prevents the adhesion of activated T
cells to the surface of the BBB [189]. Finally, IFN-β reduces the expression of matrix
metalloproteinases (MMP) by microglia and astrocytes, which participate in breaking
down of the BBB. These actions prevent the entrance of activated T cells and immune
cells into the CNS where they can cause damage [189].
A five year clinical study reported that IFN-β-1b reduced the exacerbation rate
and MRI lesion burden compared to placebo [193]. Another study also reported the use
of IFN-β-1b produced a reduction in the exacerbation rate in comparison with placebo
group and most of the patients that received IFN-β-1b were relapse free at 2 years
compared with the placebo group [194]. In another clinical trial IFN-β-1a (Avonex®) was
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administrated intramuscularly once per week to RRMS subjects with Expanded
disability status scale (EDSS) ≤ 3.5 or >3.5. patients with a EDSS ≤ 3.5 % presented a
31.7% reduction in relapse, RRMS patient with EDSS> 3.5 presented a reduction of
37% in relapse [195].
Glatiramer acetate (GA) (Copaxone®) is a synthetic polymer made of four
amino acids (L-glutamate, L-lysine, L-alanine and L-tyrosine) that mimics the primary
structure of myelin basic protein (MBP). This similarity in structure allows GA to
compete with MBP to bind to MHC-II on APCs as well as displace the MBP already
bound to MHC-II. In fact, GA binds to MHC-II with higher affinity and faster rate than
MBP [185, 186]. The GA binding to MHC-II produces a shift in T cell responses, from
Th1 to Th2 cell phenotype. This was demonstrated in the EAE model by the reduced
clinical severity, proliferation of MOG-reactive T cells, Th1 cell response, and IL-2
production after GA administration [196-198]. Similarly, human studies on MS subjects
showed that GA treatment led to a shift in T cell responses from Th1 to Th2, evidenced
by reduced Th1 cell pro-inflammatory cytokines (IFN-ɣ) and increased Th2 cell antiinflammatory cytokines (IL-4, IL-5, IL-10) [199-201]. In the brain, GA is able to induce
the production of brain derived neurotrophic factor (BDNF) by Th2 cells that might be
neuroprotective [202]. One study showed that the administration of GA to EAE mice
provided neuroprotection. The administration of GA at different points of the disease
provided a reduction in the neuronal and axonal damage in comparison with the control
group. In addition, cell proliferation, migration and cell differentiation (neurogenesis) of
oligodendroglial and neuronal progenitor cells were elevated in EAE mice with GA
treatment in comparison with control group [203].
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A clinical trial used 20 mg of GA or placebo administrated daily on subcutaneous
injections on RRMS for 2 years showed that RRMS presented a 29% reduction in the
annual relapse rate (ARR) [204]. Another study showed that RRMS subjects receiving
GA presented with a reduction in the total number of gadolinium-enhancing lesions,
reduction in the size of lesions, and reduction in the number of new lesions observed by
MRI. These trials also demonstrated a reduction in the relapse rate in comparison with
placebo group [205]. A long term (15 years) follow up study showed that patients on GA
presented a reduction in relapse rates, reduction in disability progression and reduction
in the transition to SPMS in comparison with placebo group [206].
Fingolimod (Gilenya®) is a synthetic sphingosine-1-phosphate (S1P) analogue.
S1P is a signaling molecule that participates in the regulation of trafficking of T cells and
B cells from the blood to the lymph nodes. Activation of S1P receptors expressed by T
cells and B cells leads to the migration of these cells from peripheral blood and
sequesters them within the secondary lymph organs, thus reducing the numbers of T
cells and B cells in the blood [207, 208]. Similarly, FTY720 binds to S1P receptor
preventing the exit of naïve T cells form the lymph nodes and sequesters them within
the secondary lymph nodes [207-210]. This reduces the number of T cells that can
cross the BBB and reach the CNS where they can potentially being activated to produce
inflammation and damage [207-210].
An early study investigating the effects of FTY720 on EAE in Lewis rats
demonstrated that starting FTY720 treatment the same day of EAE induction led to
dramatic protection against disease. [210]. This protection was associated with the
reduction

in

the

number

of

T

cells
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in

the

spinal

cords

evaluated

by

immunohistochemistry. The RT-PCR analysis of spinal cords also showed a reduction
in the mRNA of Th1 cell cytokines, IL-2, IL-6, and IFN-ɣ. In addition, passive transfer of
T cells isolated from FTY72-treated EAE rats into naïve rats, produced EAE with low
incidence and disease severity [210]. The results showed that FTY720 produced an
anti-inflammatory effect due to the reduction of T cell responses, their migration to the
CNS, and reduction in Th1 cell pro-inflammatory cytokines [210]. Another study
demonstrated that FYT720 promoted remyelination, the extension of oligondendrocytes
progenitor cells, the maturation of oligondendrocytes, and increased the number of
microglia cells in organotypic mouse cerebellar slice cultures [211].
Two clinical trials have evaluated the effects of FTY720 in RRMS in comparison
with placebo. In the first clinical trial, RRMS subjects received a daily dose of 0.5mg or
1.25 mg/day for a period of 12 months. Patients on FTY720 showed a reduction in the
annual relapse rate in comparison with the placebo group [212]. In the FREEDOMS
trial, RRMS subjects received a daily dose of FTY720 0.5mg/day or 1.5 mg/day for a
period of 4 years. Patients receiving FTY720 showed a reduction in the annualized
relapse rate (ARR) of approximately 50%, a reduction in the brain volume loss (BVL). In
addition, more patients were free from 3-month confirmed disability progression (CDP)
in comparison with the placebo group [213]. MRI showed a reduction in both new
enhancing and non-enhancing lesions in patients on FTY720 in comparison with the
placebo group [213].
Dimethyl fumarate (DMF) (Tecfidera ®) is a methyl ester of fumaric acid. This
drug treatment focuses on the reduction of oxidative stress, dendritic cell maturation
and subsequent T cell activation. DMF reduces the production of pro-inflammatory
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cytokines (i.e. IFN-ɣ, TNF-ɣ, IL-6) and nitric oxide (NO), and increases the production of
nicotinamide adenine dinucleotide phosphate quinone reductase 1 (NQO1), a
detoxification enzyme, and glutathione, an antioxidant. Glutathione and NQO1
participate in the reduction of free radicals and RNS which potentially can cause
damage in the CNS [214-218].
Peng et al. evaluated the effect of DMF on dendritic cell maturation and the
subsequent T cells responses mediated by dendritic cells [218]. Bone marrow-derived
dendritic cells from C57BL/6 mice were stimulated with LPS in the presence or absence
of DMF. Cytokine analysis at 6 and 24h showed that DMF significantly reduced the
production of the pro-inflammatory cytokines, IL-12 and IL-6, which participate in Th1
and Th17 differentiation, respectively. Flow cytometry analysis showed that LPS
stimulation enhanced the expression of MHC-IIhigh, CD80, and CD86high, but the
presence of DMF completely inhibited the up-regulation of the surface molecules [218].
The cytokine and flow cytometry data suggested that DMF inhibits the maturation of
dendritic cells by preventing the expression of surface markers required for effective
presentation of antigens to T cells and the subsequent the suppression of proinflammatory cytokines IL-12 and IL-6 needed for Th1 and Th17 differentiation [218].
Next, the authors evaluated whether DMF affected the activation of T cells by dendritic
cells. Dendritic cells were stimulated with LPS in presence (LPS/DMF-DCs) or in
absence (LPS-DCs) of DMF for 24h, then, washed to remove LPS and DMF. The
treated dendritic cells were then co-cultured with T cell receptor transgenic T cells
specific for MOG35-55 in the presence of MOG35-55 peptide for 72h. Flow cytometry data
showed that LPS/DMS-DCs generated a lower percentage of CD4+ T cells expressing
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the CD44 maker in comparison with those exposed to LPS/DCs [218]. IFN-ɣ and IL-17
were reduced in supernatants from LPS/DMF-DCs + MOG35-55-specific T cells. In
addition, T cells co-cultured with LPS/DMF-DCs presented with reduced cell
proliferation. These data suggested that DMF is able to reduce dendritic cell maturation,
and subsequent T cell activation, leading to a reduction in cytokines production and cell
proliferation of MOG-specific T cells [218]. To investigate the how DMF impairs the
maturation of dendritic cells, the authors evaluated the NF-kB pathways which
participate in the maturation of dendritic cells by Toll-like receptors. The authors found
that DMF reduced the nuclear translocation and phosphorylation of p65 unit, which
inhibited NFkB signal pathway. Thus, the results suggested that DMF suppresses the
NFkB pathway, inhibiting dendritic cell maturation, and subsequently Th1 and Th17
differentiation [218].
Studies in the MOG35-55-induced model of EAE in mice with showed that DMF
administrated twice per day starting 3 days after MOG immunization produced a
reduction in the clinical score and macrophage infiltration in the spinal cords, and
increased plasma IL-10 [219]. In a human study, the authors evaluated the effect of
DMF on the production of cytokines and development of Th subsets. The authors
collected peripheral blood mononuclear cells and CD4+ T cells from healthy donors,
and cells were activated with CD2/CD8 monoclonal antibody in presence and absence
of DMF. The presence of DMF increased IL-4 and IL-5 without affecting the levels of -2
and IFN-ɣ. Next, the authors activated PBMC with mycobacterium tuberculosis, which
induces a Th1 cell response characterized by high production of IFN-ɣ. Similar to results
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with CD4+ T cells, cultures with DMF exhibited increased IL-4 and IL-5 and no changes
in IFN-ɣ, suggesting a shift from Th1 to Th2 cell response [220].
In a clinical trial evaluating the effect of DMF on RRMS, subjects were divided
into 4 groups, each receiving a different dose of drug: 1) 120mg, once a day, 2) 120mg
2 times per day, 3) 240mg 3 times a day, 4) placebo. The results showed that groups
receiving 240mg 3 times per day presented with a 69% reduction in the mean number
of enhancing lesions on MRI as well as a reduction of 32% in the annual relapse rate
[221]. Two additional clinical trials evaluated the effect of DMF on RRMS using doses of
240 mg two times per day, 3 times per day and placebo. The results showed a
reduction of the annual relapse day of 44% (2 times/day dose) and 51% (3 times/day
dose), reduction in disability progression in 21% (2 times/day dose) and 24% (3
times/day dose), and both groups also showed a reduction in the number of new or
enlarging lesions by MRI [222-225].
Teriflunomide (Aubagio®) inhibits the proliferation of T and B cells by interfering
with the cell cycle. When lymphocytes are activated, they undergo cell division. The
synthesis phase (S phase) is the portion of the cell cycle when DNA is copied. The S
phase requires pyrimidine and purine bases for DNA synthesis. Terifluonomide blocks
the synthesis of pyrimidine by inhibiting the mitochondrial enzyme, dihydroorotate
dehydrogenase (DHODH). This enzyme is necessary for the de novo synthesis of
pyrimidine ribonucleotides and is highly expressed in proliferating lymphocytes [226228]. Resting or naïve lymphocytes use nucleotides from degrading DNA and RNA
(nucleotide salvage pathway) and do not need DHODH, therefore the immune
responses are preserved and the viability of immune cells is not affected [226].Thus, the
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suppression of DHODH by stopping mitosis reduces the proliferation of activated T cells
and B cells in the periphery, reducing the number of cells that can reach and cross the
BBB. All these events protect the CNS from autoimmune damage [229].
In-vitro studies using cultured rat microglia demonstrated that Teriflunomide was
not cytotoxic to microglia but reduced the co-stimulatory molecule CD86, and increased
IL-10 production after lipopolysaccharide activation [230]. The drug also decreased
microglial

proliferation

in

a

dose

dependent

manner.

Teriflunomide

at

low

concentrations (0.25-1μM) did not have an effect on activation or proliferation of
microglia, while Teriflunomide at 5μM produced a reduction in proliferation of
approximately 30%. All together the results suggested that Teriflunomide can reduce
microglial proliferation (activation) and produce anti-inflammatory effect due to the
production of IL-10 [230].
Animal studies showed that Teriflunomide reduced damage to axons within the
spinal cords in the EAE induced in dark Agouti rats [231, 232]. Rats treated with oral
Teriflunomide everyday starting either on the day of immunization or the day of disease
onset

presented

with

a

reduction

on

EAE

clinical

score,

improvement

of

neurophysiological status of descending motor tracts, and reduction in axonal damage
compared to placebo treated rats. The results suggested that the reduction in axonal
loss and improvement in motor functions may be due to a reduction in both
inflammation and demyelination in the CNS [231, 232].
Human studies showed that MS subjects on Teriflunomide experienced a
reduced annual relapse rate, a longer time to first relapse, and reduction in disability
progression and lesions detected by MRI in comparison with the placebo group. [233,
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234]. In one study, 1088 RRMS patients between 18-55 years of age with a score of 0
to 5.5 in the expanded disability status scale and 1-2 relapses in the previous 2 years
were recruited to evaluate the effects of Teriflunomide in a period of 108 weeks [233].
Patients were divided into 3 groups: group 1 received a dose of 7mg/day; group 2
received 14 mg/day; and group 3 received a placebo. The results showed that subjects
receiving Teriflunomide experienced reduction in the annualized relapse rate with
relative risk reductions of 31.2% (group 1) and 31.5% (group 2) compared to subjects
receiving placebo. Similarly the proportion of subjects with confirmed progression of
disability was 21.7 (group 1 7, mg/day, 20.2% (group 2 14mg/day) and 27.3% (group 3,
placebo) [233]. In a second study, the effects of Teriflunomide administered at 7 and
14mg/day on RRMS for a period of 48 weeks was evaluated. The authors also found
that 7 and 14 mg/day doses produce a reduction in the annual relapse rate in
comparison with placebo. The 14mg/day also reduced disability progression in
comparison with the placebo. The 7mg/day dose did not reduce disability progression in
comparison with the placebo group [234].
Ocrelizumab (Ocrevus®, Genentech, Inc., San Francisco, CA, USA). B cells
also play an important role in the development of MS. In MS, B cells express higher
surface levels of MHC-II and co-stimulatory molecules which participate in the activation
of T cells. In addition, B cells also produce antibodies that participate in the proinflammatory and demyelination processes in the CNS. Thus, ocrelizumab has been
used to reduce the number of B cells in MS [186, 235]. Ocrelizumab is a humanized
monoclonal antibody that targets the surface molecule CD20 on B cells causing their
elimination. Ocrelizumab does not eliminate plasma cells and hematopoietic stem cells
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because they do not express CD20 molecule [235]. One clinical trial compared the
effect of Ocrelizumab and IFN-β1a on RRMS subjects [236]. Patients were divided in 2
groups: group 1, received an intravenous dose of 600 mg of Ocrelizumab every 24
weeks for 96 weeks; Group 2 received a subcutaneous dose of 44μg of IFN-β-1a 3
times per week. Both groups received treatment and were monitored for 96 weeks. The
results showed that the group on Ocrelizumab in comparison with the IFN-β-1a group
presented a 46% lower rate in the annual relapse rate, a lower disability progression at
12 weeks (9.1% vs 13.6%) and 24 weeks (6.9 vs 10.4) of treatment, a reduction in the
number of lesions detected by MRI, as well as improvement in walking speed, upperlimb movements and cognition tasks [236]. In a second clinical trial, RRMS subjects
were divided in 2 groups: group 1 received Ocrelizumab at 600 mg; group 2 received a
placebo. Both groups received treatment every 24 weeks for at least 120 weeks [237].
The results showed that after 12 weeks of treatment, the percentage of patients with
confirmed disability progression on ocrelizumab was 32.9% in comparison 39.3% with
the placebo group. At week 24, the percentage of patients with confirmed disability was
29.6% in comparison to 35.7% with placebo. At 120 weeks, patients on ocrelizumab in
comparison with the placebo group, presented an improvement in the 25-foot walk, a
reduction in the rain lesions and brain loss detected by MRI [237].
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Drug
IFN-β®

Glatiramer
acetate
(Copaxone®)
Fingolimod
(Gilenya®)

Dimethyl
fumarate
(Tecfidera®)

Teriflunomide
(Aubagio®)
Ocrelizumab
(Ocrevus®)

Table 1. Mechanism of Action for MS
Mechanism of action
Inhibits stimulation and activation of Th1 cells [186, 189-191].
Shift T cell responses from Th1 to Th2 [186, 191, 192].
Prevent the expression of cell adhesion molecule VLA-4 and reduces
the expression of metaloproteinases [189].
Inhibits of T cell activation.
Shift T cell responses from Th1 to Th2 [196-198].
Reduces Th1 cell pro-inflammatory cytokines (IFN-ɣ) and an increase
in Th2 cell anti-inflammatory cytokines (IL-4, IL-5, IL-10) [199-201].
Prevent the exit of CD4+ and CD8+ t cells and B cells from
secondary lymph tissues which reduces the number of cells thatn can
cross the reach and cross the BBB to produce damage in the CNS
[207-210].
Inhibits MHC-II expression which prevents T cell activation.
Reduces the production of pro-inflammatory cytokines (i.e. IFN-ɣ,
TNF-ɣ, IL-6) and nitric oxide (NO), and increases the production of
nicotinamide adenine dinucleotide phosphate quinone reductase 1
(NQO1) [214-217].
Reduces the production of the pro-inflammatory cytokines IL-12 and
IL-6 which participate in Th1 and Th17 differentiation [218].
Inhibits MHC-II expression on antige presenting cells preventing the
activation of T cells [218].
Inhibits NFkB signal pathway which inhibits dendritic cell maturation,
and subsequently Th1 and Th17 differentiation. [218]
Inhibits T cells and B cells proliferation by blocking the synthesis the
mitochondrial enzyme dihydroorotate dehydrogenase (DHODH). This
reduces the number of cells that can reach the CNS. [226-228].
Monoclonal antibody that targets the surface molecule CD20 on B
cells causing their elimination. The reduction of B cells prevents the
activation of T cells and production of antibodies against myelin-like
proteins [235].

1.25 Photobiomodulation (PBM)
Photobiomodulation (PBM) is a therapeutic approach shown to have beneficial
effects in the treatment of different pathologies, including wound healing, chronic
inflammatory conditions, and neurological disorders [238]. PBM has been used in the
biomedical field since the invention of the ruby laser and the helium-neon laser in the
early 1960’s. The light applied by PBM devices is absorbed by the tissue, leading to a
biological effect. The wavelengths used in PBM fall into the visible red (VIS) and near
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infrared (NIR) wavelengths, 600-1100 nm, which is known as the ―optical window‖ [238].
The mechanisms of action of PBM are still under investigation.
It is proposed that the biological effects of PBM are elicited through improvement
of mitochondrial function. Previous studies demonstrated that VIS/NIR light is absorbed
by cytochrome c oxidase (CCO, complex IV) located in the inner membrane of the
mitochondrion [239-242]. Absorption of light by CCO initiates as cascade of events
culminating in increased transcription and translation of mitochondrial proteins, and
increased ATP production [239-242]. Initial experiments to investigate the mechanism of
PBM Greco et al., evaluated the effect of light treatment on the synthesis of RNA and
proteins by the mitochondria. Isolated mitochondria obtained from rat liver received
light treatment He-Ne laser lamp at 632.8 nm, 4mW/cm2, 5J/cm2. After light treatment,
the mitochondria showed increase in synthesis of both RNA and protein (transcription
and translation of proteins) [240]. In an additional study, He-Ne laser (632nm, 10mW,
200s, 2J/cm2) administered to mitochondrial extract from rat liver led to an increase in
electron transfer (proton pumping activity), CCO activity, and ATP production [242].
Pastore et al studied the effect of light treatment on cytochrome C oxidase (CCO).
Purified CCO solution received light treatment at 632.9nm using 10mW/cm2.
Subsequent experiments showed that light-treated CCO was able to oxidize cytochrome
C faster compared with control (no light treated CCO) [239].
Wong-Riley et al., carried out in-vitro studies to evaluate the effect of PBM at
670, 728, 770, 830, and 880nm (power intensity of 50mW/cm 2, energy density of
4J/cm2) on CCO activity and ATP production in primary neuronal cultures from rat visual
cortex [243]. Primary neuronal cultures were incubated with tetrodotoxin (TTX)
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(concentration of 0.4 μM), a sodium channel blocker which reduces neuronal impulse
activity, CCO activity, and ATP consumption. PBM treatment at 670nm and 830nm was
the most effective in recovering CCO activity and ATP production to similar levels to
those observed in controls (cultures incubated with TTX without PBM treatment).
Conversely, PBM treatment at 728nm failed to show a significant effect. The action
spectra of CCO activity and ATP content in neuronal culture subjected to the five PBM
treatments were plotted in order to determine the relationship with the action spectra of
the CCO. The plot showed that there is positive correlation between the action spectra
of CCO activity and the ATP content (at 670nm and 830nm) with the absorption
spectrum of CCO, while there was a smaller correlation at 728 nm [243].
Hu et al., investigated the potential effect of PBM on cell proliferation and the
possible mechanism involved [245]. After treating the melanoma cell line A2058 with
He-Ne laser (632.8nm, 10mW/cm2, 0, 5, 1, 2J/cm2), the authors observed increased cell
proliferation, CCO activity, mitochondrial membrane potential (MMP), ATP, cAMP, and
activation of the Jun N-terminal kinase (JNK) and the transcription factor, AP-1 [245].
The experiments showed that the increased cAMP was due to increased ATP
production induced by PBM. Moreover, the cAMP induced the increased activation of
JNK/AP-1 after light treatment. AP-1 is a transcription factor that induces the expression
of genes related with cell proliferation, survival and angiogenesis. Therefore, increased
activation of A-A1 by PBM is responsible for many of the noted effects of attributed to
PBMT [245]. Karu et al., also investigated the role of the mitochondrion in the
mechanism of action of PBM using HeLa cells. Immediately after treating HeLa cells
with He-Ne laser (632.8nm, 100J/m2, 10s) the authors measured ATP production using
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a luciferin-luciferase bioluminescent assay. The log phase reached the maximum peak
20min after PBM treatment. The increase of ATP production correlated with the
increase in cell proliferation reaching the highest peak at 170.8% in comparison with
controls (no PBM treatment). ATP production returned to base levels 60min after the
light treatment [246].

1.26 PBM parameters
In order for PBM to produce a therapeutic effect, it is necessary to apply the
correct light dose. Energy [Joules (J)] is used to define the light dose administered
during light treatments, where Energy (J) = Power (Watts) x Time (s). The amount of
power and the time used are fundamental to define the amount of energy that is
administrated and the biological effects obtained. If two treatments provide the same
amount of energy (J) but in one treatment the amount of power is twice folded and the
time is reduced to half then a different or non-effect will be produced [244]. The dose
parameters involved in PBM are presented in Table 2.

Parameter
Irradiance, intensity
or power density
Energy
Energy density
fluence
Irradiation time

or

Table 2. Light dose parameters [247].
Units
Description
2
2
Watts/cm
Power (in watts) of light treatment divided by the area (cm )
Joules (J)
Joules/cm

2

Seconds (s)

Power (watts) of light treatment applied multiplied by time of
treatment. Energy (J) = Power (Watts) x Time (s).
Used to describe the dose applied during light treatment
Time used during the application of light treatment

1.27 Biphasic dose response in Photobiomodulation (PBM)
Photobiomodulation (PBM) exhibits a biphasic or inverted U-shape dose
response curve. A biphasic curve indicates that at low energy doses, there is not
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enough energy to produce an effect (below threshold). When the energy dose is
increased, the energy threshold is achieved and a biologic effect is observed. If more
energy is administered, the threshold is crossed, and the biologic effect is inhibited
(Figure 1). Several lines of research have studied the effects of biphasic dose

Response

responses in different systems [244, 248-252].

Energy dose

Figure 1. Biphasic dose response curve observed in PBM [244].

Sharma et al, studied the effects of 810nm laser on primary cortical neurons
[248]. Pregnant female C57BL/6 mice were sacrificed at 16 weeks post-conception.
Primary cortical neurons were isolated from the brains from embryonic mice. Brain
tissue was triturated, washed, and cells obtained were platted and maintained for 8
days before the PBM treatment. Light treatment was applied using diode laser at 810nm
in a continuous wave mode with a power density of 25 mW/cm 2 and different energy
densities (0.03, 0.3, 3, 10 and 30 J/cm2) [248]. Intracellular levels of reactive oxygen
species (ROS), nitric oxide, and calcium, ATP production, and mitochondrial membrane
potential were measured 5 min after PBM treatment. The results showed that PBM at
lower fluences (0.03, 0.3 and 3 J/cm2) produced an increase in ATP and mitochondrial
membrane potential in comparison with base line being the 3 J/cm 2 the best dose.
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However, PBM effect on ATP and mitochondrial membrane potential was reduced or
returned to basal levels at higher energy densities (10, 30 J/cm2) [248]. PBM led to
increased ROS at all doses, reaching a double peak at 3 and 30 J/cm2. Nitric oxide
production showed a similar double peak as ROS but the increase was less significant.
High levels of ROS production, mitochondrial membrane potential and ATP coincided at
3J/cm2. The results suggested that low levels of energy delivered by PBM treatment can
be enough to induce the activation of cell signals which participate in the modulatory
effects of PBM. The results also showed that there is a threshold where PBM can
produce an effect of cells. Once the threshold is passed, the activity or induction of
cellular mediators will be reduced and possibly detrimental mediators such as ROS and
nitric oxide can be elevated or induced [248].
Chen et al., evaluated the effect of PBM at 810nm on the transcription factor
NFkB [249]. Mouse embryonic fibroblasts (MEFs) from pregnant female HLL mice
(NFkB luciferase reporter mice, C57B6/DBA background) were used in the study. PBM
treatment was applied using 810nm (1 to 30 mW/cm 2) using energy densities of 0.003,
0.03, 0.3, 3 and 30 J/cm2. After PBM treatment cells lysates were collected and used to
measure luciferase activity [249]. The results showed a biphasic dose curve. Low
energy doses produced increased NF-kβ activation, reaching the maximum at 0.3
J/cm2, then going down at 3 and 30 J/cm2. The increase in the activation of NFκβ
reached its highest expression at 10 hours after PBM treatment and returned to basal
levels at 24h (Figure 2). The addition of antioxidants blocked the activation of NFκβ,
indicating that the activation of NFκβ was mediated via mitochondrial ROS. ROS
production in response to PBM also demonstrated a biphasic dose response. ROS
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production was measured 30 min after PBM, 0.3, 3 and 30J/cm 2 produced a significant
increase in comparison with no PBMT treatment, being 3J/cm2 the energy density with
the highest ROS generation (Figure 2). PBM also resulted in increased ATP production.
The maximum production of ATP was reached 5 min after PBM treatment and it
returned to its basal levels in 4 hours [249]. The results suggested that PBM at low
doses of energy improve mitochondrial function and induced the production of small
amount of ROS that might participate as signal molecules. For example, it was already
established that ROS activate NFkβ pathway [254]. Some of the cellular targets of the
NFκβ include chemokines, immune receptors, adhesion molecules, stress response
genes, apoptosis regulators, transcription factors, growth factors, enzymes cell cycle
regulators [255]. Thus, it could be possible that small amount of ROS is needed to
activate the NFkβ pathway, but high amount of energy leads to the production of high
amount of ROS that can produce damage in the cell [253].
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A

B

C

D

Figure 2. Biphasic dose curve for NfkB activation, ROS generation and ATP production.
Light treatment (810 nm laser irradiation) on mouse embryonic fibroblast using different energy doses
2
(0.3, 3, 30J/cm ) A) Changes in NFkB activation, (B) Changes in ROS levels, C) ATP production at
2
different energy doses, D) ATP production overtime using 3Jcm . (CHI= cycloheximide, NFκβ inhibitor)
[249].

1.28 Effects of PBM on Nitric oxide (NO).
Data supports the notion that NO is a key mediator of the beneficial effects
produced by PBM. Several studies demonstrate increased NO production immediately
after PBM treatment, suggesting the release of NO from an intracellular source rather
than de novo synthesis resulting from increased expression of NOS enzymes. For
instance, Ball et al., carried out in vitro studies to characterize the effects of PBM on the
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CCO-H2O and CCO-NO reactions previously discussed (mitochondrial function section)
[256]. Under hypoxic conditions, NO production by mouse brain mitochondria increased
in presence of succinate (nitrite donor) and L-NAME (iNOS inhibitor) which was
dependent on a source of NO2-. The results suggested that these mitochondria
produced NO independently from iNOS in this experimental system. The authors also
observed increased NO synthesis when a CCO donor (detergent solubilized
mitochondria, TMPD, and cytochrome c) was added to the system. These results
indicated the presence of CCO/NO activity due to CCO in mouse brain mitochondria. In
further experiments, the authors evaluated the effect of PBM on the activity of CCO-NO
of mouse brain mitochondria. They found that He-Ne light at 590nm (40W/m2) increased
CCO-NO activity, increasing NO production. However, the PBM did not have any effect
on CCO-H2O reaction (consumption of oxygen). Because the CCO/H2O reaction was
not affected during PBM, this indicates that there is not an increase in the rate of
electron transference chain. Therefore, the rate of transference of electrons in CCO/NO
is not affected either. These results suggest that CCO-NO reaction does not participate
in the generation of NO. These observations therefore suggest that the increase of NO
is due to the dissociation of NO from the complex CCO-NO [256]. This wavelength (i.e.,
590nm) correlates with the stimulatory range of absorption of heme-proteins, (509691nm) [257]. Additionally, the results showed that under hypoxic conditions, the
production of NO after light treatment is dependent of both CCO and NO 2-. Due to the
observations, it has been proposed that the PBM induces the dissociation of NO from
CCO producing its release to participate in different functions including signal molecule,
vasodilator, messenger, and anti-cell adhesive.
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Zhang et al., investigated the effect of PBM treatment on hypoxic and
reoxygenation-induced injury in vitro using Sprague-Dawley rat cardiomyocytes [258].
The results showed that PBM treatment (670nm, 5, 25, 50mW/cm2) applied 5 min after
hypoxic and re-oxygenated injured cardiomyocytes reduced cell membrane injury,
apoptosis, increased survival rate, NO production, and ATP production in comparison
with control (no PBM treatment) [258]. The authors found that PBM treatment led to the
release of NO bound to CCO. In addition, measuring NO following light treatment in the
presence of different combinations of NO scavengers and NOS inhibitors demonstrated
a reduction in NO and in the beneficial effects of PBM, suggesting that NO is produced
by NOS and other NO stores and supporting the role of NO in the therapeutic
mechanism of PBMT [258].

1.29 Photobiomodulation (PBM) on neurodegeneration.
Photobiomodulation (PBM) therapy is proving effective at ameliorating pathology
and clinical severity for various neurodegenerative conditions, including traumatic brain
injury (TBI), acute ischemic stroke (AIS), familial amyotrophic lateral sclerosis (FALS),
spinal cord injury (SCI), Alzheimer disease (AD) and Parkinson disease (PD), [250, 259268]. Yu, Z., et al studied the neuroprotection mechanisms involved during PBM on
neurodegenerative conditions [259]. The authors evaluated if PBM at 810nm was able
to reduce the mitochondrial dysfunction in neurons subjected to hypoxia/ischemia
damage. The authors used an in vitro model to mimic conditions presented in
neurodegenerative conditions such as stroke, brain trauma and neurodegeneration.
Primary cortical mouse neurons were deprived of oxygen and glucose for 4h and then
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reoxygenated for 2h, followed by PBM applied in a single treatment for 2min (810nm,
25mW/cm2). Neurons that received PBM treatment presented with increased
mitochondrial viability and a reduction in neuronal death. Furthermore, PBM led to an
increase in mitochondrial membrane potential (MMP) ATP production compared to
neurons without PBM treatment (control). The results suggest that one possible
mechanisms of neuroprotection of PBM is by ameliorating mitochondrial dysfunction
and restoring the depletion of energy as a consequence of oxygen and glucose
depravation [259].
Xuan, et al. evaluated the effect of PBM on traumatic brain injury (TBI) using a
BALB/c mice model. Mice were subjected to TBI induced by controlled cortical impact
and subsequently divided into 4 experimental groups: 1) no PBM treatment, 2) a single
PBMT treatment 4h post TBI, 3) 3 PBM treatments per day, 4) 14 PBM treatments per
day. PBM was applied transcranially using 810nm laser (25.8mW/cm 2, 38s, 18J/cm2)
starting 4 h post TBI. Mice were sacrificed at 0, 4, 7, 14 and 28 days post-TBI for
histology, histomorphometry. In addition, mice were injected with bromodeoxyuridine (at
day 21-27) to allow the identification of proliferating cells [250]. Mice that received a
single and 3 daily PBM treatments presented improved pathology as evidenced by
reduced neurological severity score (NSS) and wire-grip and motion test (WGMT)
scores. Mice that received 14 daily PBM treatments did not present significant change
in comparison with control group [269]. Mice that received a single and 3 daily PBM
treatments presented reduced lesion size and fewer degenerating neurons at 28 days
after TBI induction in comparison with 14 daily PBM treatment and control group. In
addition, histological assay showed that mice receiving single and 3 daily PBM
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treatments presented BrdU-positive cells in the site of lesion in comparison with the 14
daily PBM treatments, and control group, suggesting that PBM treatment increased
neurogenesis. The authors suggest that PBM may be effective for the treatment of TBI
as long as the appropriate PBM treatment protocol (dose and time period) is used [250].
Familial amyotrophic lateral sclerosis (FALS) is characterized by the
presence of oxidative stress, mitochondrial dysfunction, loss of motor neurons, and
neuronal death. Moges et al. used the transgenic G93A SOD1 mouse model to study
the therapeutic potential of PMBT for the treatment of FALS. This model presents with
similar signs and symptoms to those patients with FALS, including hind limb weakness,
walking problems, paralysis, neurogenic atrophy, and the inability to drink and eat,
leading to severe weakness. PBM with 810nm light (140mW/cm2, 2min, 12J/cm2) for 3
consecutive days per week for a total of 7 weeks resulted in improved motor function
early in disease in comparison with mice without PBM treatment (Sham controls) [261].
Alzheimer disease (AD) is characterized by the formation of plaques composed
of amyloid-β (Aβ) peptide in the brain made of patients. The analysis of brain tissue
samples from AD patients showed that Aβ protein plaques contain high numbers of
activated of microglia and astrocytes that produce NO via iNOS-NFkβ activation [270272]. Microglia activation produces tumor necrosis factor-alpha (TNF-α), which also
increases NO production [273]. In addition, the neurofibrillary tangles (NFTs) found in
the hippocampus of AD patients showed high expression of iNOS [274, 275]. Activated
microglia participate in the activation of inflammatory mediators such as NADPH
oxidase (PHOX), which activates NFκβ-iNOS increasing NO production [276]. High
levels of NO produce nitrosylation and nitrotyrosination of proteins contributing to AD
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pathology. RNS mediate glutamate excitotoxicity, inhibition of the complexes I and IV
(CCO) of the respiratory chain, and organelle fragmentation (mitochondria and Golgi
apparatus) [277]. PBM studies on AD demonstrate beneficial effect. One study using
the APP/PS1 mice and NIR light at 670 nm (90 s, 4 J/cm 2, 5 days/week) for 4 weeks
found that PBM reduced the clinical pathology. The size and number of Aβ plaques in
neocortex and hippocampus of APP/PS1 mice were reduced following PBMT [266].
Another study, using transcranial laser therapy at 808 nm (1.2 J/cm 2, 3 times/week/6
months) on the Aβ protein precursor (AβPP) transgenic mouse model, showed a
reduction in Aβ plaques and plasma and cerebrospinal fluid (CSF) Aβ levels and
improved mitochondrial function, ATP production, and neurological functions [278]. A
third study showed that PBM at 1072 nm (1.8 J/cm 2, 5 mW/cm2, 6min, two consecutive
days, 5 months) on TASTPM mice increased heat shock proteins (HSP), and reduced
tau-phosphorylation, Aβ proteins in plasma and CSF, and Aβ plaques in the cerebral
cortex. These results suggest that the increase in HSP prevents the misfolding of
proteins avoiding their precipitation, aggregation, and formation of plaques [267].
Parkinson’s disease (PD) is characterized by oxidative stress and mitochondrial
dysfunction leading to a reduction in axonal transport and loss of dopaminergic neurons
within the substantia nigra [268]. Several lines of investigation using different models of
PD suggest that PBMT is affective against disease progression [268, 279-286]. For
instance, Trimmer et al., used neuronal cell cultures obtained from PD patients and
healthy donors to evaluate the effect of PBM treatment on mitochondrial velocity
(mitochondrial movement). PBM at 810nm (50 mW/cm 2, 40s) was applied to neuronal
cultures and cells were stained with MTRed. Mitochondrial movement was recorded for
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2h with a microscope equipped with epifluorescence. The velocity of mitochondria was
reduced in neurons from PD patients in comparison with neurons obtained from healthy
donors. However, after the light treatment the velocity of mitochondria from PD-patients
was significantly increased and comparable to the velocity of mitochondria from healthy
controls. The results indicate that PBM improves mitochondrial function which might
increase axonal transport [268].
A second study suggested that PBM treatment could reduce dopaminergic cell
loss in the substantia nigra pars compacta (SNc). Local inflammation and microglial
activation was induced in male Sprague-Dawley rats following intracranial injection of
after lipopolysaccharide (LPS) [284]. Rats were divided in 3 groups: group 1) vehicle
only injection no PBM treatment; group 2) LPS injection no PBM treatment; group 3)
LPS injection with PBM treatment. Intracranial injection was applied using 10 or 20μg of
LPS. PBM treatment (670nm, 50mW/cm2, 88s) was applied 1cm above the head, 2
times/day (9 am and 6pm) for a total of 7 days starting the day of injection. Rats were
sacrificed 7 days after administering LPS, and brain tissue was extracted and stained
with tyrosine hydroxylase. The results showed that PBM treatment prevented
dopaminergic cell loss in rats receiving 10μg of LPS, but not in rats receiving 20μg. In
addition, rats that received 10μg of LPS and PBM treatment presented with improved
motor function in comparison with those with 20μg of LPS with or without PBMT
treatment. The results suggested that PBMT provided protection against cellular death,
however there is a threshold of nigral inflammation and cellular death at which PBM
stop its therapeutic effect to prevent cell death [284].
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One study evaluated the effect of PBM on a PD animal model using the
neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) [285]. MTPT produces
damage in the nigrostriatal dopaminergic pathway as well in the vasculature of the
brain. C57BL/6 mice were injected with MPTP or isotonic saline (controls) and perfused
with fluorescein isothiocyanate FITC-labeled albumin at different time points during the
course of the experiment. The PBM treatment group received daily transcranial PBM
treatment (670nm, 50mW/cm2, 3min/day) starting 24h after MPTP injection. Seven days
after MPTP injection, mice presented leakage of FITC labeled albumin in the substantia
nigra and caudate putamen complex (located in the center of the brain). Mice receiving
PBM treatment presented with reduced leakage of FOTC-labelled albumin in the
substantia nigra and caudate putamen complex. The results suggested that PBM has
the potential to reduce neuronal and vascular damage in the brain [285]. A small pilot
study evaluated the effect of PBM on eight late stage PD patients, each patient during 2
weeks received daily PBM treatment on the brain stem and lobes including bilateral
occipital, parietal, temporal and frontal lobes. The results showed that all patients
compared to baseline presented an improvement in gait, cognitive function, and speech
[286].

1.30 PBM on Experimental Autoimmune Encephalomyelitis (EAE)
Previously, our laboratory studied the effects of PBM in the EAE model of MS
[287, 288]. C57BL/6 wild-type (WT) mice were immunized with MOG peptide 35-55 to
induce EAE. Peripheral lymph nodes (PLN) were isolated 10 days after the
immunization,

and

the

lymphocytes

obtained
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were

cultured

with

MOG35-55,

Concanavalin A (ConA, a mitogen), or no stimulation. Beginning on the first day of
culture and continuing daily for 96 hours, the cells received light treatment at 670 nm
(LED array 75cm2, fluence of 5J/cm2). Cell cultures without light treatment were used as
controls. Supernatants were collected every 24h and cytokines production was
analyzed by ELISA. The results showed an antigen-specific effect of light on the
cytokine production in cells cultured with MOG35-55. Light treatment produced a
significant reduction of IFN-ɣ (P<0.0001, pro-inflammatory cytokine) and a significant
increase in IL-10 (P<0.0001, anti-inflammatory cytokine) expression in comparison with
untreated light cells (Figure 3). However, PBM of lymphocytes incubated with ConA did
not result in significant changes in IL-10 expression in comparison with similar cultures
without light treatment. On the other hand, there was a significant increase in IFN-ɣ in
cell cultures incubated with Con A and light treated just at 96h in comparison with
similar groups without light treatment. The results suggest that the PBM effect on
cytokine production was antigen-specific [287].
The in vitro experiments demonstrated that PBM at 670 nm modulates the
immune response in a manner predicted to ameliorate clinical disease. Therefore, these
experiments were extrapolated to in vivo experiments, where MOG 35-55 immunized mice
received PBM treatment at 670 nm (5 J/cm2, LED lamp, applied on the dorsal surface of
mice) starting the day after immunization for a total of 10 days (suppression protocol).
Mice without light treatment were used as controls. The results showed that mice on
PBM treatment presented a reduction in the clinical severity of the disease in the acute
phase of disease in comparison with mice without PBM treatment. The clinical score of
mice receiving light treatment was reduced (score range 2 to 3.5) in comparison with
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mice without light treatment (score range 3 to 4) (P<0.01). However, by the end of the
experiment, the clinical score of mice on PBMT treatment went back up to similar levels
to controls (Figure 3). In additional experiments, a new PBM treatment protocol was
developed. MOG35-55 immunized mice received PBM at 670 nm for 7 days starting on
the day of disease onset (onset protocol). The results showed reduction in the clinical
severity of the disease similar to the suppression light treatment protocol (data not
shown) [287].
A

B

C

D

Figure 3. Modulation of cytokine production and clinical severity by PBM at 670 nm. Lymphocytes
from PLN from EAE mice were incubated with MOG35-55 and light treated at 670 nm every 24 h for a total
of 96. PBM at 670 nm produced a significant reduction on IFN-γ (A) and IL-10 (B). MOG35-55 immunized
2

mice received PBM at 670 nm (5 J/cm starting the day after immunization for a total of 10 days
(suppression protocol) (C) or for 7 days starting the day the initiation of the clinical symptoms followed by
7 days without light treatment and then 7 more days of light treatment (double-treatment protocol) (D).
The double treatment protocol showed to produce a more significant reduction in the clinical score of
disease in comparison with the suppression protocol [287].
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The results obtained led to the development of a new treatment protocol with the
goal of having a longer lasting effect on the disease. The double treatment protocol
consisted of the application of light for 7 days starting with the day of onset of clinical
signs, followed by a period of 7 days without light treatment, with light treatment
resuming on days 8 through 14 [287]. The results showed that mice that received the
double-treatment protocol presented a more significant reduction in the clinical severity
of the disease (score range 1 to 2) in comparison with light untreated mice (score range
3 to 4) (P<0.01), and the effect was sustained (Figure 3). Moreover, the reduction in
clinical severity was more significant in comparison with mice that received the
suppression protocol.
PLNs and SCs were obtained from EAE-affected mice over the course of light
treatment experiments. Gene expression was quantified by qPCR. In both PLNs and
SCs, the suppression protocol produced a significant down regulation of IFN-ɣ and
TNF-α (pro-inflammatory cytokines), and a significant up-regulation of IL-4 and IL-10
(anti-inflammatory cytokines) (Figure 4) [287].
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Figure 4. Modulation of immune response in EAE mice on PBM at 670 nm with suppression
protocol. Suppression protocol on EAE-induced mice produced a significant reduction during chronic
stage of disease on IFN-γ (A) and significant reduction in both acute and chronic stages of disease on
TNF-α (B), IL-4 (C) and IL-10 (D) [287].

On the other hand, the double-treatment protocol did not produce significant
changes in IFN-ɣ and TNF-α at any point of the disease (Figure 5), but it did produce a
significant up-regulation of IL-4 (during the acute stage) and IL-10 (during the chronic
stage) (Figure 5) [287]. Even though the double treatment protocol did not produce
significant changes in the levels of pro-inflammatory cytokines, it is important to point
out that the up regulation of IL-4 and IL-10 was approximately 100 times increased. This
huge increase in the expression of anti-inflammatory cytokines correlates the reduction
of clinical severity showed in EAE mice that received the double treatment protocol
(Figure 5) [287].
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Figure 5. Modulation of immune response in EAE mice on PBM at 670 nm with double treatment
protocol. Double treatment protocol did not produce significant changes on IFN-γ (A) and TNF-α (B) at
any at either acute or chronic stage of disease. Double treatment protocol produced a significant increase
of IL-4 (C) and IL-10 (D) during the acute and chronic stages respectively [287].

Nitrosative stress and mitochondrial dysfunction are linked to the pathogenic
progression of EAE and MS. The observed effect of PBM on the clinical course of EAE
demonstrated a significant beneficial effect on the progression of disease. Thus, the
effect of the double treatment protocol with 670 nm light on the modulation of nitrosative
stress using the EAE model was evaluated. C57BL/6 mice were immunized with
MOG35-55 and the PLN were removed at 10 days post immunization. The isolated
lymphocytes were cultured with MOG35-55 or ConA and were light treated at 670 nm
beginning 2 hours after plating cells and continuing every 24h, for a total of 96h. Extra
sets of lymphocytes cultures with MOG35-55 or ConA without light treatment were used
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as controls. The supernatants were collected every 24h and nitrite (NO2-) levels were
measured using a colorimetric assay based on the Griess reaction. Cell cultures
incubated with MOG35-55 receiving PBM treatment showed a significant reduction in
NO2- over the course of the whole experiment in comparison to cells without PBM
treatment (P<0.0001) (Figure 6). Interestingly, the lymphocytes incubated with ConA
receiving PBM treatment showed a reduction in the levels of NO2- at 72h (p<0.0001).
These results support previous findings suggesting that the effect of PBM was antigen
specific [288].
The effect of PBM on iNOS gene expression over the course of EAE in light
treated mice was also evaluated. Spinal cords were obtained from mice receiving the
double treatment protocol over the course of the disease, and iNOS gene expression
was analyzed by qPCR. The results showed no significant changes on iNOS expression
during the acute phase of the disease, however there was a significant down-regulation
in the chronic phase of the disease (p<0.05) (Figure 6) [288]. In order to further
investigate the role of iNOS in the EAE model, iNOS knockout (iNOS-/-) mice and WT
C57BL/6 mice were immunized with MOG35-55 and were subjected to the double light
treatment protocol. The double light treatment protocol produced amelioration in the
clinical severity of the disease in WT mice but did not produce amelioration in iNOS -/mice. These results suggest that the presence of NO produced by iNOS (NO-iNOS) is
necessary in the beneficial effects of PBM in our model (Figure 6). To further
investigate, LN-lymphocytes were obtained from MOG35-55 immunized iNOS-/- mice. The
lymphocytes were incubated with MOG35-55 antigen or Con A and treated daily with light
at 670 nm for a total of 96 h. The results showed no significant increase in nitrite
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production at any time point in any of the cell cultures (data not included). Together,
results obtained in vivo and in vitro suggest that the NO produced by iNOS is necessary
for the amelioration of EAE by PBM [288].

A

C

B

-

Figure 6. PBM at 670 nm reduces nitrosative stress. A). PBM at 670 significantly reduced NO2 in
PLN-lymphocytes obtained from EAE-mice. B) Double treatment protocol on EAE mice produced a
significant reduction in the gene expression of iNOS. C) Double treatment protocol did not reduce the
-/clinical score on iNOS -EAE mice [288].

1.31 Photobiomodulation on chronic fatigue and muscle performance
Approximately 80% of MS subjects present with muscle weakness and fatigue
due to a combination of events, including alterations in both the central motor drive and
intramuscular function [223, 289-294]. Fatigue is additionally related to alterations in
skeletal muscle, such as reduction in the size of muscle fibers and the levels of
mitochondrial

enzymes

involved

in

energy

production,

including

succinic

dehydrogenase (SDH) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
[294]. Studies show that PBM reduces skeletal muscle fatigue, exercise-induced
oxidative stress, improves strength, increases exercise performance, and enhances
muscle rehabilitation [295-303].
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PBM treatment of skeletal muscle improves muscle performance, delays and
reduces skeletal muscle fatigue, and reduces the accumulation of biochemical markers
related to muscle damage (i.e. creatine kinase activity, C-reactive protein, lactate
dehydrogenase) [295-298]. The effect of PBM on muscle fatigue and performance was
investigated in professional volleyball players. During the first session, all players
performed as many voluntary biceps contractions as possible with a load of 75% of the
maximal voluntary contraction force (MVC). One week later, players (N=12) were split
into 2 groups, with one group received PBM (655nm, 20J, 6.7min) and the other
receiving placebo before the exercise. The group that received active PBM showed a
significant increase in the number of repetitions compared to session 1 compared the
placebo group [295]. In further experiments, the authors tested PBM (810nm, 60J,
2.5min) on volleyball players in a crossover study to evaluate muscle performance and
biochemical markers for muscle recovery [297]. PBM treatment produced an increase in
exercise performance (number of repetitions), reduced muscle fatigue, and reduction in
serum levels of creatine kinase activity and C-reactive protein [297] compared to
placebo. Baroni et al., evaluated the effects of PBM on LDH and CK serum levels, both
of which are direct markers of muscle damage [298]. PBMT (810nm, 180J, 6min, n=18)
and placebo treatment (device turned off, n=18) were applied to the knee of healthy
men before knee extensor eccentric exercise. PBM produced an increase in the
maximal voluntary contraction (MVC) and significant reduction on the levels of LDH and
CK at 24 and 48h in comparison with the placebo group [298]. Similarly, Toma et al.,
studied the effect of PBM treatment on skeletal muscle fatigue in elderly women (60-70
yoa) [299]. PBMT (808nm, 56J, 10min, n=12) and placebo treatment (device turned off,
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n=12) were applied to the rectus femoris muscle of the dominant leg immediately before
the fatigue protocol which consisted in voluntary isotonic contractions of knee flexionextension performed with a load corresponding to 75% of one maximal repetition during
60s. Patients that received PBM treatment showed an increase in the number of
repetitions in comparison with placebo [299]. All together these results showed the
potential use of PBMT to improvement in muscle performance and faster recovery.
In a crossover study designed to evaluate the effect of PBMT on exercise
performance and oxidative stress, 22 male untrained volunteers received PBM
treatment (810nm, 30J, 2.5min) or placebo treatment 5min before a standardized
progressive running protocol. PBM treatment compared to placebo improved exercise
performance, reduced the super dismutase enzyme, lactate dehydrogenase (LDH),
further supporting the ability of PBMT to improve in muscle performance and decrease
exercise-induced oxidative stress [300].
In conclusion, PBM is a new alternative therapeutic approach with tremendous
potential for the biomedical field, including the resolution of chronic inflammation and
treatment of neurodegenerative diseases. Previous data from our lab showed that the
application of 670 nm light modulated the mechanisms involved in EAE pathogenesis
leading to amelioration of clinical signs. The next step in our line of research was to
extrapolate these experiments to in vitro and in vivo assays using samples as well the
participation from MS subjects. The goal of this project was to characterize the potential
effect of PBM treatment on MS subjects. We hypothesized that PBM treatment would
reduce pro-inflammatory cytokines, nitrosative stress, muscle fatigue, and increase antiinflammatory cytokines in MS subjects.
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CHAPTER 2. CHARACTERIZATION OF THE EFFECTS OF PHOTOBIOMDULATON
ON IMMUNE CELLS OBTAINED FROM HEALTHY DONORS AND MULTIPLE
SCLEROSIS SUBJECTS.

2.1 Abstract
Multiple Sclerosis (MS) is a CD4+ T cell-mediated demyelinating autoimmune
disease characterized by the development of plaques in the central nervous system
(CNS). Currently, there is no cure for MS. Available drug treatments focus on the
modulation of the immune response during initial stages of disease in order to slow
down its progression but they are not effective in chronic stages. Therefore, the
development of alternative approaches to effectively treat acute or chronic stages of
disease is needed. Photobiomodulation (PBM) is a therapeutic approach proving
effective at ameliorating various neurodegenerative conditions. It is proposed that the
therapeutic effects of PBM are produced by the improvement of mitochondrial function,
mediated by the absorption of VIS/NIR light by cytochrome c oxidase (CCO, complex
IV). Previously our lab showed that PBM at 670nm on the Experimental Autoimmune
Encephalopathy (EAE) model of MS, reduced IFN-ɣ and TNF-α and increased IL-4 and
IL-10 which correlated with a reduction in the severity of disease.
Here we studied the effects of PBM on immune cells from MS subjects.
Peripheral blood mononuclear cells (PBMC) and CD4+ T cells from MS subjects were
activated with phytohemagglutinin (PHA) or CD3/CD28 activator, respectively, and
received different PBM treatments. MS subjects were divided in 2 groups based on the
Patient Determined Disease Steps (PDDS) scale: PPDS=0 and PDDS≥1. The results
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revealed that the severity of disease affected the response to PBM. MS subjects with
higher severity in disease (PDDS≥1) presented an anti-inflammatory effect after PBM
treatment, while those with normal functions (PDDS=0) presented with a proinflammatory response. For instance, PBM treatment with 735nm light (3J/cm2 or
10J/cm2) and type 2b device (640/87/905nm, 1J/cm 2 or 3J/cm2) increased the
production of IFN-ɣ by CD4+ T cells and PBMC from MS subjects with PDDS=0, but not
PDDS≥1. PBM with 670nm light (3J/cm2) produced no change in IFN-ɣ production by
PBMC and CD4+ T cells but increased in IL-10 by CD4+ T cells in MS subjects with
PDDS≥1 but not PDDS=0. The results suggest that PBM has the potential to participate
in the modulation of the immune response in MS subjects. The clinical stage of disease
for each patient has to be considered before the administration of PBM treatment.

2.2 Introduction
Multiple Sclerosis (MS) is a CD4+ T cell-mediated autoimmune disease
characterized by the development of plaques (lesions) in the central nervous system
(CNS) [1]. The destruction of the myelin sheath interrupts the transmission of nerve
impulses from the CNS to other parts of the body causing the symptoms of MS [2].
CD4+T cells are the main player in the pathogenesis of MS and its animal model,
Experimental Autoimmune Encephalomyelitis (EAE). Naïve CD4+ T cells activated in
the presence of myelin protein and IL-12 differentiate in Th1 cells, or in the presence of
IL-6, TGF-β, and IL-23 differentiate to Th17 cells. Both Th1 and Th17 cell subtypes are
considered pathogenic in MS and EAE because they promote the development and
progression of disease through the production of pro-inflammatory cytokines. Th1 cells
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produce TNF-α, IFN-γ and IL-2. Th17 cells produce IL-17, IL-6, IL-21, IL-22, and TNF-α
[23, 38]. Studies demonstrated a positive correlation between high levels of IFN-ɣ and
the clinical manifestation in EAE and MS [46-52]. Conversely, studies demonstrated the
role of IL-10 in the amelioration of EAE and MS and EAE [86, 87].
Currently, there is no cure for MS. Current treatments focus on early stages of
disease to suppress the immune system, but they are not effective in stopping the
progression of disease nor are they effective against chronic disease. It is necessary to
develop

treatments

to

reduce

progression

and

symptoms

at

any

stage.

Photobiomodulation (PBM) is a new therapeutic approach proven to be effective in the
treatment of different pathologies, including wound healing, chronic inflammatory
conditions, and neurological disorders [238]. In particular, PBM therapy is proving
effective at ameliorating pathology and clinical severity for various neurodegenerative
conditions, including traumatic brain injury (TBI), acute ischemic stroke (AIS), familial
amyotrophic lateral sclerosis (FALS), spinal cord injury (SCI), Alzheimer disease (AD)
and Parkinson disease (PD) [250, 259-268]. It is proposed that during PBM, VIS/NIR
light is absorbed by cytochrome c oxidase (CCO, complex IV) leading to improvement
of mitochondrial function and increased ATP production [239-242]. Our lab previously
reported that PBM treatment with 670nm light of MOG-induced EAE in C57BL/6 mice
reduced pro-inflammatory cytokines (IFN-ɣ, TNF-α) and nitrosative stress and increased
anti-inflammatory cytokines (IL-4, IL-10), which correlated with a reduction in the
severity of disease [287, 288]. Here, we report the first studies investigating the effect of
PBM on cytokine production by peripheral blood mononuclear cells (PBMC) and CD4 + T
cells isolated from MS subjects and healthy donors. Based on data from our animal

88

studies, we hypothesized that PBM would reduce IFN-ɣ and increase IL-10 in PBMC
and CD4+ T cells from MS subjects. We found that 735nm light (3J/cm 2 or 10J/cm2) and
type 2b device (640/87/905nm, 1J/cm2 or 3J/cm2) increased IFN-ɣ by CD4+ T cells and
PBMC from MS subjects with PDDS=0. Meanwhile, 670nm light (3J/cm 2) increased IL10 production by CD4+ T cells and produced no change in IFN-ɣ production by PBMC
and CD4+ T cells in MS subjects with PDDS≥1.

2.3 Materials and Methods
Subject population. Recruitment of subjects was carried out following the guidelines of
the Institutional Review Board of the University of Wisconsin Milwaukee (IRB# 18.020)
and Marquette University (IRB# HR-1710020115). All patients were informed about the
project and consent forms were signed by the patient and the lab personnel providing
the information. Inclusion criteria (RRMS, n=23): Relapsing-remitting MS (RRMS) male
and female subjects between 18-80 years of age with no history of relapse or
immunosuppressive therapy in the previous 6 months. Any current disease-modifying
treatment was recorded. Exclusion criteria: RRMS subjects with any current infection,
any additional neurodegenerative, autoimmune, or mitochondrial disease. Healthy
donors (control group, n=17) between 18-80 years of age with no history of
neurodegenerative disease, autoimmune disease, or current infection were included
(Table 3). Selection of RRMS and healthy donors was carried out using a questionnaire
in order to evaluate optimal state of health. Measurement of hematocrit was performed
before the collection of blood in order to document that anemia was not present.
Hematocrit was obtained by finger stick. Briefly, the fingertip of the index finger was
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wiped with an alcohol pad and pricked with a sterile lancet. The first 2-3 drops of blood
were discarded and the hematocrit tube was filled until the two-thirds of capacity. Two
hematocrit tubes were filled to validate results. One side of the tubes was sealed and
spun down in a microhematocrit centrifuge for 5 min at high speed. Hematocrit values
were measured using a ruled hematocrit reader. The normal ranges considered were:
male 42-54%, female 38-46%.

Table 3. MS and Healthy subjects
recruited.
# Healthy men above 50yo=
# Healthy women above 50yo=

1
7

Total
# Healthy men below 50yo=

8
6

# Healthy women below 50yo=

3

Total
# MS men above 50yo=
# MS women above 50yo=
Total

9
2
12
14

# MS men below 50yo=

2

#MS women below 50yo=

7
Total

# Healthy subjects in total
# MS subjects in total

9
17
23

Total

40

MS subject classification. MS subjects were classified based on the Patient
Determined disease steps (PDDS) scale. PDDS scale is a subject reported outcome of
disability of multiple sclerosis. PDDS scale is based on motor and ambulatory
dysfunction present in MS subjects. PDDS scale has 7 levels ranging from 0= normal to
6= Confined to wheelchair. A summary of PDDS scale is presented in Table 4, a
complete PDDS scale form can be found in the indicated references [304, 305].
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Score
0
1

2
3

4

5

6
U

Table 4. Patient Determined disease steps (PDDS) scale [304, 305].
Disability status
Characteristics
Normal
Normal motor functions. Minor abnormalities on examination. The course is
relapsing-remitting with a return to baseline with or without treatment.
Mild disability
Mild symptoms or dysfunctions present. No visible problems of gait. Some
findings include: sensory abnormalities, minor incoordination, weakness,
and fatigue. The pattern of disease is relapsing-remitting, but patients may
not have a full return to baseline following attacks.
Moderate
Visible problems of gait present. Patients do not require ambulation aids.
disability
The pattern of disease is relapsing-remitting or progressive.
Early cane
Intermittent use of cane or other unilateral support. Patient use unilateral
support for longer distances, but they are able to walk at least 25 feet
without it. The pattern of disease is relapsing-remitting or progressive.
Late cane
Constant use of cane or unilateral support. Patients cannot walk 25 feet
without support. Use of a scooter for greater distances The pattern of
disease is relapsing remitting or progressive.
Bilateral
Patients require bilateral support to walk 25 feet (eg, two canes or two
support
crutches or a walker). They may use a scooter for greater distances. The
pattern of disease is relapsing-remitting or progressive.
Confined to
Constant use of a wheelchair or scooter. Patients may walk a few steps but
wheelchair
are unable to walk 25 feet, even with bilateral support.
Unclassifiable
Patients who cannot be classified in any of the previous scores. Patients
present significant cognitive or visual impairment, fatigue, bowel or bladder
impairment, etc.

Cell isolation and cell culture conditions. Blood (50ml) from RRMS or healthy donors
was drawn into vacutainer tubes containing EDTA (BD Vacutainer, Franklin lakes, NJ
US). Peripheral blood mononuclear cells (PBMC) were isolated by ficoll-paque (MPBiomedicals, Solon, OH) gradient centrifugation (400g, 30min) and washed with PBS.
CD4+ T cells were isolated from PBMC using EasySep Human CD4+ T cell isolation kit
(Stemcell Technologies, VA, CA) following manufacturer instructions. PBMC and CD4+
T cells were cultured (300,000 cells/ml) and activated with phytohemagglutinin (PHA
10μg/mL, MP-Biomedicals, Solon, OH) or CD3/CD28 complex (50μg/mL, Stemcell
Technologies, Cambridge, MA), respectively in RPMI medium [supplemented with 10%
FCS, penicillin (100U/ml)/streptomycin (100Mg/mL), L-glutamate (2mM), sodium
pyruvate (0.1mM), 2-mecarptoethanol (50mM)] with 1% AB human serum and
incubated at 37C, 10% CO2. Cells received PBM treatment every 24h for a total of
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120h. Cells and supernatants were collected at 48, 72 and 120h. Supernatants were
stored at -80°C until analysis.
Photobiomodulation. Two types of light devices were used (Table 5). Type 1 devices
emitted a continuous wave of light at 670, 735, or 830nm (VIS, light emitting diode
[LED]) (Quantum Devices, Barneveld, WI). Type 2 devices emitted a pulsed wave of
light (Multiradiance Medical, Solon OH). Type 2 devices were divided in two groups
depending on the wavelengths delivered. Type 2A delivers a single pulsed wavelength
at 640nm (VIS, light emitting diode [LED]). Type 2B delivered 3 pulsed wavelengths
simultaneously: 640nm (VIS, light emitting diode [LED]), 875nm (NIR; LED) and 905nm
light (NIR; super-pulsed Galium Arsenic laser). Dosing parameters applied for each
device are summarized in Table 5. All PBM treatments were applied every 24h for a
total of 120h starting 2h after initial plating. Light devices were placed on the top of the
covered cell culture plate during treatment.

Wavelength
670 nm
830 nm
735 nm
Type 2A
640 nm
Type 2B
640 nm
875 nm
905 nm

Table 5. Photobiomodulation parameters
Device
Power Density
Time (sec)
2
(W/cm )
2
LED (QBMI
0.010 W/cm
300 sec
2
2
Spectralife, 75cm )
0.028 W/cm
360 sec
2
LED (QBMI
0.010 W/cm
300 sec
2
2
Spectralife, 75cm )
0.0333 W/cm
300 sec
2

LED (QBMI
2
Spectralife, 75cm )

0.010 W/cm
2
0.0333 W/cm

Pulsed LED (MRM)

0.0025 W/cm

LED
LED
Superpulsed laser
(MRM)

0.033 W/cm
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2

2

Energy Density
2
(J/cm )
2
3 J/cm
2
10 J/cm
2
3 J/cm
2
10 J/cm
2

300 sec
300 sec
400 sec
1200 sec

3 J/cm
2
10 J/cm
2
1 J/cm
2
3 J/cm

10 sec
31 sec
91 sec
304 sec

0.3 J/cm
2
1 J/cm
2
3 J/cm
2
10 J/cm

2

Carboxyfluorescein diacetate succinimidyl ester (CFSE) staining. Cell proliferation
resulting from the activation of PBMC with PHA (MP-Biomedicals, Solon, OH) and
CD4+ T cells with CD3/CD28 activator (Stemcell Technologies, Cambridge, MA) was
monitored every 24h by flow cytometry using CFSE staining. CFSE dye penetrates the
cell membrane and binds to long-lived intracellular molecules to produce fluorescence.
The fluorescence intensity is reduced by half in new clones during each cell division.
The decreasing fluorescence intensity, indicative of cell division, is monitored by flow
cytometry until 8 cell divisions, at which point the fluorescence is reduced to background
of unstained cells [306]. CFSE staining was carried out following an standardized
protocol [306]. Briefly, CFSE (LifeTechnologies, Eugene, OR) was diluted in DMSO to
get a stock concentration of 5 mM. The PBMC or CD4 + T cells were suspended in PBS
at 50x106 cells/ml, and CFSE was added to obtain a concentration of 1µM. The cells
with the CFSE were incubated for 5min at RT, washed 3 times with 10 volumes of PBS
containing 5% (v/v) heat inactivated fetal calf serum (HI-FCS), and centrifuged at 500g
for 10min at RT. The CFSE labeled cells (PBMC or CD4+ T cells) were cultured with
PHA or CD3/CD28 activator accordingly, at 300,000 cells/well in 48wells/plate. PBM
treatment was applied every 24h. The cells were harvested every 24h and cell
proliferation analyzed by flow cytometry on a FACSCalibur (BD Biosciences, San Diego,
CA). The decrease in the fluorescence intensity of CFSE was analyzed by FlowJo
(FlowJo software LLC, Ashland, OR).
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Flow cytometry. After CD4+ T isolation, flow cytometry staining was carried out in
order to determine the purity of isolated cells. Cell purity was typically 90-95%. Surface
markers used to identify cell populations included anti-human CD3 (T cells), anti-human
CD4 (CD4+ T cells), and anti-human CD19 (B cells) antibodies (BioLegend, San Diego,
CA). Cell staining was performed using standardized protocols in our lab. Briefly, after
CD4+ T isolation, 100,000 isolated CD4+ T cells were washed with FACS buffer
(phosphate buffer saline, 0.1% sodium azide, 1% fetal bovine serum, 3000g, 5min),
suspended in 100μL FACS buffer and split in 2 tubes (negative and positive staining).
Next, 200μL of human Fc receptor binding inhibitor were added to each tube and
incubated in ice for 20min. Cells were centrifuged and washed once with FACS buffer
(3000g, 5min, 4°C). Cells were resuspended in 50μl FACS buffer, then the antibodies
anti-human CD3, anti-human CD4, and anti-human CD19 antibodies were added
(Positive Sample). Fluorochrome-matched mouse IgG isotype control antibodies (K,
heavy, and light chain) were used as negative control. Cells were incubated on ice for
30min, and washed twice with FACS buffer. Cells were resuspended in 500μL FACS
buffer and analyzed using a FACS Calibur flow cytometer. Data analysis was done
based on 10,000 cells collected using BD Cell Quest Pro 5.1.1 software.

Cytokine

quantification

by

ELISA.

Collected

supernatants

were

used

for

quantification of IL-10 (<31.3pg/mL detection limit) and IFN-ɣ (<15.6 pg/mL detection
limit) by ELISA (Duoset Elisa, R&D systems, MN) following manufacturer instructions.
Absorbance was measured using a plate reader (Bio-Tek, model KC4, Winooski, VT) at
450nm, levels of cytokines were calculated according to a standard curve.
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Data analysis. Data were analyzed with GraphPad Prism 7 (La Jolla CA, USA).
Statistical analysis was performed with SAS 9.4 (Cary, NC). Fisher exact test was
performed as appropriate. P<0.05 was considered significant. Statistical analysis was
carried out by Chi Cho, MS, in the college of Health Sciences, University of Wisconsin
Milwaukee.

2.4 Results
Photobiomodulation treatment modulates cytokine production in PBMC and CD4+
T cells in MS subjects and healthy subjects.
Blood samples from healthy subjects were collected and PBMC and CD4+ T
cells were isolated, activated, and received PBM treatment as indicated in materials and
methods. We first investigated whether the effect of PBM on the modulation of cytokines
differed between MS subjects and healthy subjects. In order to determine the effect of
PBM treatment on cytokine production, the production of cytokines (IFN-ɣ or IL-10) after
PBM treatment was obtained by subtracting the production of cytokines under no PBM
treatment (no light treatment or control). Due to significant variation in the absolute
values of IFN-ɣ and IL-10 detected, data was analyzed based on a ±20% change in
cytokine production over the baseline (no light treatment). Significant results are
summarized in Table 6. All other conditions tested failed to result in a significant
difference in cytokine production between MS subjects and healthy donors.
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Table 6. Photobiomodulation effect on cytokine production by PBMC and CD4+ cells from MS
subjects and healthy donors.
Cells
Device
Energy Density
Time
P value (Fisher
Outcome
2
cytokine
(J/cm )
point
exact test)
2
CD4-IFNɣ
670nm
10 J/cm
48h
0.042229
Significant

PBMC-IFNɣ

CD4-IL10

Type 2B device
(640/875/905nm)
Type 2B device
(640/875/905nm)
Single pulsed 640nm
Type 2B device
(640/875/905nm)
670nm

3 J/cm

2

10 J/cm
3 J/cm

48h

0.031929

Significant

120h

0.012516

Significant

48h

0.021625

Significant

2

120h

0.040956

Significant

2

72h

0.044509

Significant

2

2

0.3 J/cm
10 J/cm

Patient distributions for PBM treatments that showed significant results are presented in
Tables 7 to 12. For instance, 670nm (10J/cm2, 48h, Table 7) and Type 2b device
3J/cm2, 48h, Table 8) increased IFN-ɣ by CD4 T cells in 41.67% and 54.55% of MS
subjects respectively. The response from healthy donors was mixed, with cells from the
majority of subjects increasing IFN-ɣ in response to this dose of 670nm light.
2

Table 7. Effect of 670nm (10J/cm , 48h) on IFN-ɣ production by CD4+ T cells from MS subjects and
healthy donors - Patient distribution. P=0.042229 (Fisher exact test).
Patient
Increase
NO CHANGE
Reduction
Total
20%
(-20% TO 20%)
20%
Healthy
7
3
5
15
46.67%
20.00%
33.33%
MS
5
7
0
12
41.67%
58.33%
0.00%
Total
12
10
5
27

2

Table 8. Effect of Type 2B device (640/875/905nm, 3J/cm , 48h) on IFN-ɣ production by CD4+ T
cells from MS subjects and healthy donors - Patient distribution. P= 0.031929 (Fisher exact test).
Patient
Increase
Reduction
Total
NO CHANGE
20%
20%
(-20% TO 20%)
Healthy

5
35.71%

8
57.14%

1
7.14%

14

MS

6
54.55%

1
9.09%

4
36.36%

11

Total

11

9

5

25

96
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Table 9. Effect of Type 2B device (640/875/905nm, 10J/cm , 120h) on IFN-ɣ production by CD4 +T
cells from MS subjects and healthy donors - Patient Distribution. P= 0.012516 (Fisher exact test).
Patient
Increase
NO CHANGE
Reduction
Total
20%
(-20% TO 20%)
20%
Healthy
MS
Total

2
18.18%
6
75.00%
8

6
54.55%
0
0.00%
6

3
27.27%
2
25.00%
5

11
8
19

2

Table 10. Effect of single pulsed 640nm (3J/cm , 48h) on IFN-ɣ production by PBMC from MS
subjects and healthy donors – Patient distribution. P= 0.021625 (Fisher exact test).
Patient
Increase
NO CHANGE
Reduction
Total
20%
(-20% TO 20%)
20%
Healthy
3
4
8
15
20.00%
26.67%
53.33%
MS
5
9
1
15
33.33%
60.00%
6.67%
Total
8
13
9
30

2

Table 11. Effect of Type 2B device (640/875/905nm, 0.3 J/cm , 120h) on IFN-ɣ production by PBMC
from MS subjects and healthy donors – Patient distribution. P= 0.040956 (Fisher exact test).
Patients
Increase
NO CHANGE
Reduction
Total
20%
(-20% TO 20%)
20%
Healthy
8
4
0
12
66.67%
33.33%
0.00%
MS
2
7
2
11
18.18%
63.64%
18.18%
Total
10
11
2
23

2

Table 12. Effect of 670nm (10 J/cm , 72h) on IL-10 production by CD4+ T cells from MS subjects
and healthy donors – Patient distribution. P= 0.044509 (Fisher exact test).
Patients
Increase
NO CHANGE
Reduction
Total
20%
(-20% TO 20%)
20%
Healthy
MS
Total

0
0.00%
6
28.57%
6

14
82.35%
13
61.90%
27
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3
17.65%
2
9.52%
5

17
21
38

Disease severity affects the response of MS subjects to Photobiomodulation
treatment of PBMC and CD4+ T cells.
Data in other systems suggests that the degree of pathology or severity of
disease may affect the response to PBM treatment. To determine if this held true in MS,
the response of MS subjects to PBM treatment was assessed to determine if it differed
in subjects with no physical deficit (PDDS=0) compared to those with some level of
disability (PDDS ≥1). Due to the variation in the absolute values of cytokine production,
data was analyzed based on a ±20% change in cytokine production over the baseline
(no light treatment). Significant results are summarized in Table 13.

Table 13. Photobiomodulation effect on cytokine production using ±20% cut-off point
Device
830nm
Type 2B
(640/875/905nm)
735nm

Energy
2
Density (J/cm
2
10 J/cm
1 J/cm

2

10 J/cm

2

Treatment
Time-point
48 h

Cells,
cytokines
PBMC-IFNɣ

P value (Fisher
exact test)
0.00979

Outcome
SIGNIFICANT

48 h

CD4-IFNɣ

0.00476

SIGNIFICANT

72 h

CD4-IFNɣ

0.04928

SIGNIFICANT

Patient distributions for PBM treatments that showed significant results are
presented in Tables 14-16. In most cases, cells isolated from subjects with PDDS=0, did
not respond to PBM therapy. On the contrary, although the response was variable, the
cells isolated from majority of subjects with PDDS ≥1 responded to PBM treatment with
changes in cytokine secretion. For instance, PBM with type 2B device (640/875/905nm,
1J/cm2, 48h) 100% of MS subjects with PDDS≥1 showed increase in IFN-ɣ by CD4+ T
cells, whereas 75% of subjects with PDDS=0 did not respond to this device with
changes in IFN-ɣ secretion (Table 15). An exception was noted with treatment with the
735nm (10J/cm2, 72h) device: 67% of subjects with PDDS=0 increased IFN-ɣ secretion
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in response to this device, while 62.5% of MS subjects with PDDS≥1 showed reduction
in IFN-ɣ by CD4+ T cells (Table 16).
2

Table 14. Effect of 830nm (10J/cm , 48h) on IFN-ɣ production by PBMC from MS subjects with
PDDS=0 vs PDDS≥1. Patient distribution. P=0.00979 (Fisher exact test).
PDDS
Increase
NO CHANGE
Reduction
Total
20%
(-20% TO 20%)
20%
0
1
Total

0
0.00%
4
44.44%
4

4
100.00%
1
11.11%
5

0
0.00%
4
44.44%
4

4
9
13

2

Table 15. Effect of Type 2B device (640/875/905nm, 1J/cm , 48h) on IFN-ɣ production by CD4+ T
cells from MS subjects with PDDS=0 vs PDDS≥1. Patient distribution. P= 0.00476 (Fisher exact
test).
PDDS
Increase
NO CHANGE
Reduction
Total
20%
(-20% TO 20%)
20%
0
1
Total

0
0.00%
6
100.00%
6

3
75.00%
0
0.00%
3

1
25.00%
0
0.00%
1

4
6
10

2

Table 16. Effect of 735nm, 10J/cm , 72h) on IFN-ɣ production by CD4+ T cells from MS subjects
with PDDS=0 vs PDDS≥1. Patient distribution. P=0.04928 (Fisher exact test).
PDDS
Increase
NO CHANGE
Reduction
Total
20%
(-20% TO 20%)
20%
0
1
Total

4
66.67%
2
25.00%
6

2
33.33%
1
12.50%
3

0
0.00%
5
62.50%
5

6
8
14

To further investigate the effect of disease severity on cytokine production after
PBM treatment in our MS population, we evaluated the magnitude of cytokine
production for each MS subject based on disease severity (PPDS score=0 vs, PDDS
99

≥1). Unlike the previous section, the ±20% cut-off point was not considered. Significant
differences are summarized in Table 17.
Table 17. Photobiomodulation effect on cytokine production by PBMC and CD4+ T cells from MS
subjects depending on disease severity PDDS=0 vs PDDS≥1.
Cells
Device
Energy
Time
P value (Fisher
Outcome
cytokines
Density
point
exact test)
2
(J/cm )
2
670nm
3 J/cm
48h
0.018163
significant
CD4+ T
IFNɣ

PBMC
IFN-ɣ
CD4+ T
IL-10

Type 2B device
(640/875/905nm)
735nm

1 J/cm

2

10 J/cm

2

48h

0.014214

significant

72h

0.016925

significant

120h

0.008010

significant

735nm

3 J/cm

2

735nm

3 J/cm

2

48h

0.037243

significant

Type 2B device
(640/875/905nm)
Type 2B device
(640/875/905nm)
670nm

1 J/cm

2

120h

0.002856

significant

3 J/cm

2

120h

0.014668

significant

3 J/cm

2

72h

0.039170

significant

Analysis revealed that the nature and magnitude of the response of cells to
particular devices and to particular doses of light differed in subjects with PDDS=0 vs.
PDDS≥ (Figures 7-10). CD4+ T cells isolated from subjects with PDDS≥1 produced
significantly greater IFN-ɣ in response to the 670nm device (3J/cm2, at 48h,
p=0.018163) and type 2b device (640/875/905nm, 1J/cm 2, at 48h, p=0.014214) than did
cells from MS subjects with PDDS=0. Similarly, PBM with the 735nm device (3J/cm2, at
48h, p=0.037243), increased IFN-ɣ production by PBMC in MS subjects with PDDS≥1 in
comparison with cells from MS subjects with PDDS=0 (Figure 7). Conversely, cells from
subjects with PDDS=0 produced a greater response to 735nm light at a higher dose
(10J/cm2, 72h, p=0.016925) and 3J/cm2 (at 120h, p=0.008010) than did cells from
subjects with PDDS≥1 (Figure 8).
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Figure 7. Comparison of PBM treatment effect on IFN-ɣ production by CD4+ T cells and PBMC
2
cells at 48h from MS subjects with PPDS=0 and PDDS≥1. 670nm, (3J/cm , CD4 T cells, p=0.018163),
A) change in pg/mL, B) percentage of change over baseline (no light treatment). Type 2b device
2
(640/875/905nm, 1J/cm , CD4+ T cells, p=0.014214), C) change in pg/mL, D) percentage of change over
2
baseline (no light treatment). 735nm (3J/cm , PBMC, p=0.037243), E) change in pg/mL, F) percentage of
change over baseline (no light treatment). Box represents interquartile range (75%-25%). The bar within
the box is the median. The whiskers are 1.5x the interquartile range. Anything outside these bars is an
outlier.
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Figure 8. PBM treatment with 735nm on IFN-ɣ production by CD4 T cells. Energy density of 10J/cm
at 72h, A) change in pg/mL, B) percentage of change over baseline (no light treatment). Energy density of
2
3J/cm at 120h, C) change in pg/mL, D) percentage of change over baseline (no light treatment). Box
represents interquartile range (75%-25%). The bar within the box is the median. The whiskers are 1.5x
the interquartile range. Anything outside these bars is an outlier.
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A similar difference in the nature of the response was noted by PBMC from
subjects with PDDS=0 vs. PDDS≥1 (Figure 9). Contrary to the response of CD4+ T cells
noted above, increased IFN-ɣ by PBMC from MS subjects with PDDS=0 was noted with
the Type 2B device (640/875/905nm) at 1J/cm2 (72h, p=0.002856) and 3J/cm2 (120h,
p=0.014668) but not MS subjects with PDDS≥1.
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Figure 9. PBM treatment with active device on the production of IFN-ɣ by PBMC. Energy density of
2
1J/cm at 120h, A) change in pg/mL, B) percentage of change over baseline (no light treatment). Energy
2
density of 3J/cm at 120h, C) change in pg/mL, D) percentage of change over baseline (no light
treatment). Box represents interquartile range (75%-25%). The bar within the box is the median. The
whiskers are 1.5x the interquartile range. Anything outside these bars is an outlier.
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Of note, only PBM treatment with 670nm light at 3 J/cm2 (72h, p= 0.039170)
increase the production of anti-inflammatory IL-10 by CD4+ T cells from MS subjects
with PDDS≥1. Furthermore, MS subjects with PDDS=0 responded with minimal change,
or a decrease in IL-10 to this wavelength at this dose (Figure 10).
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Figure 10. PBM treatment with 670nm increased IL-10 production by CD4 T cells from MS subjects
2
with PDDS≥1. Energy density of 3J/cm at 120h, A) change in pg/mL, B) percentage of change over
baseline (no light treatment). Box represents interquartile range (75%-25%). The bar within the box is the
median. The whiskers are 1.5x the interquartile range. Anything outside these bars is an outlier.

Discussion
Multiple Sclerosis (MS) is a CD4+ T autoimmune disease characterized by the
development of plaques in the central nervous system (CNS) [1]. Photobiomodulation
(PBM) is proven to be effective at ameliorating different neurodegenerative conditions
[250, 259-268]. Previously, our lab reported that PBM at 670nm was effective in
ameliorating the clinical severity in mice with EAE [287]. MOG35-55 immunized C57BL/6
mice receiving PBM treatment at 670nm (5J/cm2) for a total of 10 days starting the day
after immunization (suppression protocol) presented with a significant reduction in the
clinical severity of the disease in comparison with controls [287]. In addition, MOG35-55
immunized C57BL/6 mice that received a PBM treatment for 7 days starting with the
day of onset of clinical signs, followed by a period of 7 days without light treatment, with
104

light treatment resuming on days 8 through 14 (double treatment protocol) presented
significant reduction in the severity of disease in comparison with controls. RT-PCR
analysis of spinal cords and lymph nodes collected during the course of experiments
showed that suppression protocol down-regulated IFN-ɣ and TNF-α, and up-regulated
IL-4 and IL-10 during the onset and peak of disease [287]. Interestingly, the doubletreatment protocol resulted in non-statistically significant but reproducible decreases in
IFN-ɣ and TNF-α but significantly up-regulated IL-4 (during the acute stage) and IL-10
(during the chronic stage) [287].
The results presented here demonstrate that PBM is able to modulate cytokine
production by PBMC and CD4+ cells from MS subjects. Contrary to our hypothesis,
PBM also modulated cytokine production by cells isolated from healthy donors. These
results support previous observations by others authors that indicated that PBM is able
to produce an effect in both healthy and compromised systems [248, 249, 307-309].
First, we decided to evaluate if the modulation of cytokines was significantly different
from the baseline (cells without PBM treatment). The absolute expression of cytokines
(IFN-ɣ, IL-10) among subjects were quite different, thus data was analyzed based on a
±20% change in cytokine production over the baseline (no light treatment) to consider a
significant change. The threshold for significance was set at ±20% based on changes
expected in MS subjects over the course of disease and compared to healthy donors.
Studies have indicated that MS subjects present higher levels of pro- and antiinflammatory cytokines compared to matched healthy subjects. The increase in both pro
and anti-inflammatory cytokines among MS subjects is quite variable depending of
disease progression and remission periods [314-317]. CD4+ T cell isolated from healthy
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donors and MS subjects showed increased IFN-ɣ in response to treatment with 670nm
(10J/cm2, 48h) and the type 2b device (640/875/905nm, 3J/cm 2, 48h). In addition, MS
subjects samples also increased IFN-ɣ production by CD4+ T cells in response to the
Type 2B device (640/875/905nm, 10J/cm 2, 120h) and increased IFN-ɣ production by
PBMC in response to single pulsed 640nm (3J/cm 2, 48h), respectively. Healthy subjects
showed increased IFN-ɣ by PBMC with Type 2B device (640/875/905nm, with 0.3
J/cm2 at 120h). Interestingly, 670nm (10J/cm2, 72h) produced increased IL-10
produced by CD4+T cells in MS samples, but there was no significant change in
samples from healthy subjects.
Analysis of data showed that the effect of PBM was different between healthy
and MS subjects. Therefore, we evaluated if the modulation of cytokines significantly
differed from the baseline (cells without PBM treatment) in MS subjects in relation to
disease severity. Data was again analyzed based on a ±20% change in cytokine
production over the baseline to be considered significant. MS subjects were divided in 2
groups—those with PPDS score=0 and those with a PDDS ≥1. The results showed that
the disease severity (PDDS score) affects the response to PBM. 735nm (10J/cm2, 72h)
produced the reduction of IFN-ɣ by CD4+ T cells from MS subjects with PDDS≥1 but not
subjects with PDDS=0. On the other hand, type 2B device (640/875/905nm, 1J/cm 2,
48h) and 735nm (10J/cm2, 72h) increased IFN-ɣ production by CD4 T cells collected
from MS subjects with PDDS≥1 and PDDS=0, respectively. These results suggest that
PBM with 735nm (10J/cm2) might be beneficial on patients with PDDS≥1 because it
reduced

the

production

of

IFN-ɣ.

Conversely,

PBM

with

type

2B

device

(640/875/905nm, 1J/cm2) and 735nm (10J/cm2) would produce a negative effect on MS
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due that they increase the production of IFN-ɣ by CD4 T cells in MS subjects with
PDDS≥1 and PDDS=0, respectively.
The previous results showed that disease severity played a role in the
modulatory effect of PBM on cytokines. Next, we evaluated if the cytokine production
magnitude and regulation after PBM treatment in each MS subject were affected by
disease severity. MS subjects were again divided in 2 groups: MS subjects with
PPDS=0 and MS subjects with PDDS≥1. No cut-off point was considered. The results
showed that disease severity plays a role in the levels of cytokine being produced and
in the modulatory effect of PBM on cytokines. PBM treatment with 735nm (3 J/cm 2 at
120h, and 10J/cm2 at 72h) and Type 2B device (640/875/905nm (1 and 3J/cm2 at 120h)
induced higher production of IFN-ɣ in CD4+ T cells and PBMC, respectively, in MS
subjects with PDDS=0 in comparison with MS subjects with PDDS≥1. Interestingly,
PBM with 670nm (3J/cm2 at 72h) induced a higher production of IL-10 by CD4+ T cells
from MS subjects with PDDS≥1, but not from subjects PDDS=0. These results indicate
that the use of PBM with 670nm (3J/cm 2) on MS subjects with PDDS≥1 might be
beneficial because it induces the production of the anti-inflammatory cytokine IL-10 and
there is no significant increase in the pro-inflammatory cytokine IFN-ɣ. The fact that
PBM treatment with 735nm and type 2b device (640/87/905nm) increased the
production of IFN-ɣ by CD4+ T cells and PBMC in MS subjects with PDDS=0 will
require further investigation in its potential effect on MS subjects. For some time, IFN-ɣ
has been considered detrimental in MS due to its participation in the development and
progression of MS and EAE MS [46-52]. However, several studies indicate that IFN-ɣ
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can play a beneficial role in MS and EAE [53-65]. Thus, the increase of IFN-ɣ due to
PBM treatment in MS subjects with PDDS=0 might be beneficial to ameliorate disease.
Our results agree with previous observations from other authors who indicated
that the effect of PBM on a system depends on its redox status [248, 249, 307-309]. For
instance, Karu group evaluated the changes in the absorption spectra of HeLa cells
before and after PBM. PBM treatment (632.8nm, 103J/m 2) on HeLa cells with oxidized
cytochrome c oxidase resulted in an initial reduction of cytochrome C oxidase, followed
by oxidation (a bell shaped curve). Then, PBM treatment on HeLa cells with reduced
cytochrome c oxidase resulted in an initial oxidation of the cytochrome c oxidase,
followed by its reduction (inverted bell shaped curve). This suggested that the effect of
PBM will depend of the redox status of a system [307]. Similarly, Huang group
evaluated the effects of PBM under oxidative stress conditions. Primary cultured murine
cortical neurons where incubated alone or with one of three oxidative stressors
including hydrogen peroxide, cobalt chloride, and rotenone with or without PBM at
810nm, 3J/cm2 [308]. The oxidative stressors increased ROS and reduced
mitochondrial membrane potential and ATP production. PBM on cells alone (with no
oxidative stressors) increased mitochondrial membrane potential and ATP production
above baseline and a modest increase in ROS levels. Conversely, in conditions of cells
with oxidative stress, PBM treatment increased mitochondrial membrane potential back
to basal levels, increased ATP production, reduced high ROS levels, and reduced cell
death. The results showed that PBM can reduce oxidative stress in compromised
systems (oxidative stress conditions) but in healthy cells can increase ROS levels [308].
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The fact that PBM induced the production of IFN-ɣ by CD4+ T cells in persons
with MS with PDDS=0 and PDDS≥1 will require further investigation in the possible
effect of IFN-ɣ on MS subjects. Due to its pro-inflammatory characteristics, IFN-ɣ is
considered as one of the main players in the development and progression of MS and
EAE. Studies demonstrated the positive correlation between the high levels of IFN-ɣ
and the clinical manifestations, relapses, and disease stages in MS and EAE [46-52].
For instance, in a clinical trial, 18 RRMS subjects received recombinant IFN-ɣ at 3
different doses: low (1mcg); intermediate (30mcg); and high (1000mcg). The results
showed that serum levels of IFN-ɣ were proportional to dose administrated. In addition,
7 out of 18 RRMS subjects presented exacerbation during the treatment [51].
On the contrary, several studies showed that IFN-ɣ can play a disease limiting
role in MS and EAE [53-65]. For instance, several studies showed that IFN-ɣ can play a
protective role in the EAE model using IFN-ɣ-KO mice. The lack of IFN-ɣ led to the
development of EAE even in strains that are normally resistant to EAE [53-55, 63, 64].
In one study, the Billiau group evaluated the effect of anti-IFN-ɣ antibodies on EAE in
mice [56]. Anti-IFN-ɣ antibodies were injected intraperitoneally into C57BL/6J mice on
days -6, 0, 7, and 14 relative to the time of EAE induction. The mice treated with
antibody mice developed EAE with higher, incidence and mortality in comparison with
controls. Histological damage correlated with the clinical severity of the disease. These
results suggested that anti-IFN-ɣ antibodies increased the severity of disease and
therefore IFN-ɣ plays a protective role. Next the authors administrated intraperitoneally
IFN-ɣ (rDNS-IFN-ɣ) to SJL/L mice on days -1, 0, 1, 3, 5, 7, and 9 relative to EAE
induction. These mice presented with EAE with a reduced clinical score and mortality

109

rate in comparison with controls [56]. The authors suggested that IFN-ɣ can produce
different effects based on local or systemic expression. The local IFN-ɣ promotes
inflammation whereas the systemic IFN-ɣ produces an anti-inflammatory effect. The
authors suggested that the anti-IFN-ɣ antibodies neutralized the systemic IFN-ɣ present
in the circulatory and peripheral compartments but they were not able to reach the IFN-ɣ
found in the CNS due to the blocking by the blood brain barrier. The neutralization of the
systemic IFN-ɣ suppressed the protective role (anti-inflammatory) of IFN-ɣ leading a
more severe EAE. Thus, the systemic IFN-ɣ present during EAE induction or
development of EAE can play a disease-limiting role. This also explains how the
administration of IFN-ɣ before the induction of EAE was useful to reduce the severity of
disease [56]. Additional studies by Billiau group investigated the role of IFN-ɣ in a
chronic relapsing remitting model of EAE using SJL/J mice [61]. Intraperitoneal
injections of anti-IFN-ɣ antibody were administrated on days 21 and 27 (disease free
interval) in EAE-induced SJL/J mice. These mice developed higher disease severity and
faster progression of disease than the control group. The results suggested that the
severity of disease was increased due to the administration of anti-IFN-ɣ antibody
during the disease free period. This suggested that the IFN-ɣ produced during the
disease free period participates in the protection against EAE [61]. Therefore, the use of
PBM treatment during disease free periods in order to increase IFN-ɣ in MS subjects
and its protective role in disease should be explored with extreme caution.
Our results showed that 670nmm (3J/cm2, 120h, p=0.039170) increased IL-10
produced by CD4+T cells in MS subjects with PDDS≥1 in comparison with MS subjects
with PDDS=0. This is important given the anti-inflammatory role of IL-10 in MS and
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EAE. Studies demonstrate that IL-10 is an anti-inflammatory cytokine that produces a
protective role in MS and EAE [86-88, 90]. For instance, Samilova et al. showed that IL10 deficient mice, but not IL-4 deficient mice, developed accelerated EAE onset in
comparison with WT mice [86]. Spontaneous recovery was present in WT and IL-4
deficient mice but recovery was not present in IL-10 deficient mice, suggesting that IL10 is fundamental in the amelioration or recovery process [86]. In one study by
Rodriguez et al., the authors quantified the levels of TNF-α, IL-10, and nitric oxide in
serum and cerebrospinal fluid (CSF) from MS subjects before and during an active
relapse. Their results showed that during the active relapse, MS subjects presented
higher levels of TNF-α, IL-10, and nitric oxide in comparison to levels before the relapse
and also in comparison with healthy subjects. The results suggested that Th1 and Th2
cell activations (pro- and anti-inflammatory responses) are present simultaneously
during an active relapse [90].
In conclusion, the results presented here show the potential of PBM in the
modulation of cytokines in MS subjects. The results suggest that PBM treatment on MS
subjects must be applied with extreme caution. Due to the small size of our sample
population and the variety in PDDS scores among MS subjects it was not possible to
establish a definite wavelength or energy dose to modulate cytokine expression.
Therefore, the specific wavelengths, the energy density, the clinical stage (disease
severity) in combination with PPDS scores for each patient are some of the factors that
need to be considered before the application and optimization of PBM treatment. In
addition, the fact that PBM induces the modulation of cytokines (IFN-ɣ, IL-10) is
remarkable. This suggests that in the same way that cytokines and PDDS scores are
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used to monitor MS progression, and drug treatment efficacy, they could be used to
monitor the effect of PBM treatment in MS subjects.

CHAPTER

3.

CHARACTERIZATION

OF

THE

EFFECTS

OF

PHOTOBIOMODULATION (PBM) ON NITROSATIVE STRESS IN MULTIPLE
SCLEROSIS SUBJECTS.

3.1 Abstract
Multiple Sclerosis (MS) is a CD4+ T cell-mediated demyelinating autoimmune
neurodegenerative disease that affects the central nervous system (CNS). Nitrosative
stress and mitochondrial dysfunction are events present even in early stages of disease
even before the myelin destruction. There is no a cure for MS. Current drug treatments
focus on the modulation of the immune response during initial stages of disease in order
to slow down progression but they are not effective in chronic stages where nitrosative
stress takes control of disease progression. Therefore, alternative approaches to
modulate immune response and nitrosative stress in early or chronic stages of disease
are needed. Photobiomodulation (PBM) with light in the visible and near infrared regions
of the spectrum is showing promise as a therapeutic strategy to treat chronic
inflammation and neurological disorders. Previously our lab studied the effect of PBM
with light at 670nm on the Experimental autoimmune encephalopathy (EAE) model of
MS. 670nm light reduced nitrosative in in-vitro and in-vivo experiments using mice with
EAE. The reduction in nitrosative stress correlated with the reduction in clinical severity
of EAE. Here we evaluated the ability of PBM to reduce nitrosative stress in immune
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cells from MS subjects. Peripheral blood mononuclear cells (PBMC) from MS subjects
were activated with Phytohemagglutinin (PHA), and received PBM treatment.
Supernatants were collected and used to measure nitrite (NO2-) levels. 830nm (10J/cm2,
72h, p=0.0153) reduced the levels of nitrate compared to controls (no light treatment).
The reduction in nitrate correlated with the increase in IL-10 by PBMC (p=0.0271) and
reduction in IFN-ɣ by PBMC (not significant p=0.1940). PBM at 830nm has the potential
to participate as a therapeutic tool in the reduction of nitrosative stress and modulation
of immune response in MS.

3.2 Introduction
Multiple Sclerosis (MS) is a CD4+ T cell-mediated demyelinating autoimmune
disease that affects the central nervous system (CNS) [1]. The destruction of the myelin
sheath interrupts the transmission of nerve impulses from the CNS to other parts of the
body causing the symptoms of MS [2]. Previous studies showed that nitrosative stress
is present in early stages even before the myelin destruction [147, 178-184]. Under high
concentration of Nitric oxide (NO), NO competes with oxygen for binding to Cytochrome
c oxidase (CCO or complex IV), the enzyme that catalyzes the transfer of electrons from
cytochrome c to molecular oxygen in mitochondrial electron transport, causing
mitochondrial dysfunction and depletion of ATP [160-162].
There is not a cure for MS. Current drug treatments focus on the modulation of
the immune response during initial stages of disease in order to slow down progression
but they are not effective in chronic stages where nitrosative stress takes control of
disease progression. Therefore, alternative approaches to modulate immune response
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and nitrosative stress at any stage of disease are needed. Photobiomodulation (PBM) is
a therapeutic approach proving effective in the amelioration of neurological disorders
including traumatic brain injury (TBI), Alzheimer disease (AD) and Parkinson disease
(PD) [238, 250, 259-268]. It is proposed that during PBM treatment, VIS/NIR light is
absorbed by cytochrome c oxidase (CCO) improving mitochondrial function and
increasing ATP production [239-242].
Our lab previously reported that PBM treatment with light at 670nm ameliorated
clinical severity and reduced nitrosative stress in the Experimental Autoimmune
Encephalomyelitis (EAE) model of MS [288]. Here, we extend these studies to the
clinical disease, MS. We investigated the effect of PBM treatment on nitrite production
by peripheral blood mononuclear cells (PBMC) from MS subjects as a marker of
nitrosative stress. We hypothesized that PBM would reduce nitrite, indicative of
decreased nitrosative stress. We observed that in vitro PBM therapy of PBMC treated
with 830nm light at 10J/cm2) reduced nitrite production in comparison with cells not
receiving light treatment. This reduction correlated with increased in IL-10 and reduced
IFN-ɣ secretion by PBMC.

3.3 Materials and Methods
Subject population. Recruitment of subjects was carried out following the guidelines of
the Institutional Review Board of the University of Wisconsin Milwaukee (IRB# 18.020)
and Marquette University (IRB# HR-1710020115). All subjects were informed about the
project and consent forms were signed by the patient and the lab personal providing the
information. Inclusion criteria: RRMS subjects (n=23; male=4, female=19) between 18-
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80 years of age with no history of relapse or immunosuppressive therapy in the previous
6 months. Any current disease modifying therapy was recorded. Exclusion criteria:
RRMS subjects with any current infection, any additional neurodegenerative,
autoimmune, or mitochondrial disease. Selection of RRMS was carried out using a
questionnaire in order to evaluate optimal state of health. Measurement of hematocrit
was performed before the collection of blood in order to rule out the presence of
anemia. Hematocrit was obtained by finger stick. Briefly, the fingertip of the index finger
was wiped with an alcohol pad and pricked with a sterile lancet. The first 2-3 drops of
blood were discarded and the hematocrit tube was filled until the two-thirds of capacity.
Two hematocrit tubes were filled to validate results. One side of the tubes was sealed
and spun down in a microhematocrit centrifuge for 5 min at high speed. Hematocrit
values were measured in a hematocrit reader (ruled apparatus). Normal ranges
considered: male 42-54%, female 38-46%.

MS patient classification. MS subjects were classified based on the Patient
Determined disease steps (PDDS) scale. PDDS scale is a patient reported outcome of
disability of multiple sclerosis. PDDS scale is based on motor and ambulatory
dysfunction present in MS subjects. PDDS scale has 7 levels ranging from 0= normal to
6= Confined to wheelchair (Table 4) [304, 305].

Cell isolation and cell culture conditions. Blood (50ml) from RRMS were drawn in
EDTA tubes (BD Vacutainer, NJ US). Peripheral blood mononuclear cells (PBMC) were
isolated by ficoll-paque (MP-Biomedicals, Solon, OH) gradient centrifugation (400g,
30min) and washed with PBS. PBMC were cultured (300,000 cells/ml) and activated
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with phytohemagglutinin (PHA, 10μg/mL, MP-Biomedicals, Solon, OH) in RPMI medium
[supplemented with 10% FCS, penicillin (100U/ml)/streptomycin (100Mg/mL), Lglutamate (2mM), sodium pyruvate (0.1mM), 2-mecarptoethanol (50mM)] with 1% AB
human serum and incubated at 37C, 10% CO2. Cells received PBM treatment every
24h for a total of 120h. Supernatants were collected at 48, 72 and 120h and stored at 80°C until analysis.

Photobiomodulation. Two types of light devices were used (Table 5). Type 1 devices.
Continuous wave devices at: 670, 735, and 830nm (VIS, light emitting diode [LED])
(Quantum Devices, Barneveld, WI). Doses of energy applied: 3 and 10J/cm 2, 300s.
Type 2 devices. Pulsed wave devices (Multiradiance Medical, Solon OH). Type 2
devices were divided in two groups depending on the wavelengths delivered. Type 2A
delivers a single pulsed wavelength at 640nm (VIS, light emitting diode [LED]). Doses of
energy applied: 3 and 10J/cm2. Type 2B delivers 3 pulsed wavelengths at the same
time, these include: 640nm (VIS, light emitting diode [LED]), 875nm (NIR; LED) and
905nm light (NIR; super-pulsed Galium Arsenic laser). Doses of energy applied: 0.3, 1,
3 and 10 J/cm2. All PBM treatments were applied every 24h for a total of 120h starting
2h after initial platting.

Nitrite quantification. Nitric oxide has a short half-life making almost impossible to
quantify directly.

The measurement of its final oxidized products nitrite (NO 2-) and

nitrate (NO3-), the final oxidized products of NO, provide an indirect method to measure
nitric oxide. Supernatants were used to measure nitrite (NO 2-) using the fluorometric
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assay OxiSelect In Vitro Nitric Oxide (Nitrite / Nitrate) Assay Kit (Cell Biolabs, San Diego
CA). The levels of nitrite were calculated according to a standard curve (<0.547 μM
detection limit). Briefly, the nitrate (NO3-) in the sample is converted to nitrite (NO2-) by
the nitrate reductase enzyme, and the amount of nitrite produced is detected with the
fluorescent probe, DAN (2,3-diaminonapthalene). The fluorescence was measured
using a plate reader equipped for excitation in the 360-365nm range and for emission in
the 430-450nm range.

Data analysis. Data were analyzed with GraphPad Prism 7 (La Jolla CA, USA).
Statistical analysis was performed with SAS 9.4 (Cary, NC). Multiple comparisons
performed by Wilcoxon signed rank test, Chi-Square Test for Equal Proportions, and
Fisher exact test were performed as appropriate. P<0.05 was considered significant.
Statistical analysis was carried out by Chi Cho, MS, in the college of Health Sciences,
University of Wisconsin Milwaukee.

3.4 Results
Photobiomodulation by 830nm and 640nm reduces nitrite production in vitro by
PBMC from MS subjects.
To investigate the effect of PBM on nitrosative stress in MS, we determined if
light treatment could reduce nitrite production by PMBC isolated from MS subjects.
PBMC from MS subjects were cultured with phytohemagglutinin (PHA) and received
different PBM treatments every 24h for a total of 120h (Table 5). Nitrite production was
measured in cell culture supernatants using a fluorometric assay. Data showed that at
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72h PBMC that received PBM treatment at 830nm (10J/cm 2, p=0.0153, Wilcoxon
signed rank test) reduced the levels of nitrite in comparison with no light controls (Figure
11). No other PBM light treatments tested significantly reduced nitrite production in the
cultures.

Figure 11. Photobiomodulation reduces nitrite production by PBMC from MS subjects. PBMC from
MS subjects were cultured with phytohemagglutinin (PHA 10μg/mL). Cells received PBM treatment as
2
indicated in materials and methods. At 72h continuous wavelength at 830nm (10J/cm , p=0.0153)
reduced nitrite in comparison with controls (no light treatment). Each box represents interquartile range
(75%-25%). The bar within the box is the median. The whiskers are 1.5x the interquartile range. Each line
represent a MS subject and shows how they changed after PBM treatment. The red line shows the
change in the average of nitrite with no light treatment (control) and after PBM treatment.
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PBM induced reduction on nitrite production by PBMC correlates with the PBMmodulation of pro- and anti- inflammatory cytokines in MS subjects
Results in Chapter 2 showed that PBM treatment resulted in the modulation of
pro-(IFN-ɣ) and anti-(IL-10) inflammatory cytokines produced by PBMC. In order to
further evaluate the effect of PBM treatments on cytokine modulation and nitrite
production, we investigated possible relationships between them. We analyzed nitrite
production versus IL-10 and IFN-ɣ produced by PBMC. Photobiomodulation treatment
with 830nm (10J/cm2, at 72h) produced both a reduction in nitrite and an increase in IL10 produced by PBMC (p=0.0271, Chi-Square Test for Equal Proportions) Figure 12,
Table 18. In addition, 830nm (10J/cm2, at 72h) produced a reduction in both nitrite
levels and IFN-ɣ produced by PBMC, however this reduction was not significant
(p=0.1940) Figure 13, Table 19.
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Figure 12. 830 nm (10J/cm , 72h) reduces nitrite and IL-10 production by PBMC from MS
subjects. Analysis of data showed that there is a correlation between the reduction of nitrite and
reduction of IL-10 by PBMC (p=0.0.0271). DIFNITRITE= difference in nitrite between 830nm and no-light
treatment (control). DIFPBMCIL10= difference in PBMC-IL10 between 830nm and no-light treatment
(control). The red lines are set at 0 for both axes, if the value is positive it means that the production is
higher after 830nm than with no light treatment (control). If the number is negative then the production if
lower after 830nm thank with no light treatment (control).
2

Table 18. Relationship between Nitrite production and IL-10 production by PBMC, 830nm 10/cm ,
72h, n=23, p=0.0271 (Chi-Square Test for Equal Proportions)
Frequency
Percent
Increase Nitrite / Increase PBMC-IL10
4
17.39
Decrease Nitrite / Increase PBMC-IL10
12
52.17
Decrease Nitrite / Decrease PBMC-IL10
4
17.39
Increase Nitrite / Decrease PBMC-IL10
3
13.04
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Figure 13. 830 nm (10J/cm , 72h) reduces nitrite and IFN-ɣ production by PBMC from MS
subjects. Analysis of data showed that there is a correlation between the reduction of nitrite and
reduction of IFN-ɣ by PBMC (p=0.1940). DIFNITRITE= difference in nitrite between 830nm and no-light
treatment (control). DIFPBMCIFNG= difference in PBMC-IFNɣ between 830nm and no-light treatment
(control). The red lines are set at 0 for both axes, if the value is positive it means that the production is
higher after 830nm than with no light treatment (control). If the number is negative then the production if
lower after 830nm thank with no light treatment (control).
Table 19. Relationship between Nitrite production and IFN-ɣ production by PBMC, 830nm
2
10/cm , 72h, n=23, p=0.1940 (Chi-Square Test for Equal Proportions).
Frequency
Percent
Increase Nitrite / Increase PBMC-IFN-ɣ
3
14.29
Decrease Nitrite / Increase PBMC- IFN-ɣ
6
28.57
Decrease Nitrite / Decrease PBMC- IFN-ɣ
9
42.86
Increase Nitrite / Decrease PBMC- IFN-ɣ
3
14.29

121

We carried out analysis of data to determine if the severity of disease (PDDS
score) affected the modulation of nitrite and IL-10 and IFN-ɣ. MS subjects were divided
in 2 groups depending of PDDS score, MS subjects with PDDS=0 and MS subjects with
PDDS≥1. Severity of disease showed not significant effect in the modulation of nitrite,
IL-10 and IFN-ɣ by PBMC receiving 830nm (10J/cm2) (Tables 20, 21).

Table 20. Production of Nitrite and IL10 in PBMC grouped by PDDS
PDDS

0
1
Total

INCREASE NO /
INCREASE
PBMC-IL10

DECREASE NO /
INCREASE
PBMC-IL10

DECREASE NO /
DECREASE
PBMC-IL10

INCREASE NO /
DECREASE
PBMC-IL10

0
0.00%
2
18.18%
2

5
71.43%
5
45.45%
10

1
14.29%
2
18.18%
3

1
14.29%
2
18.18%
3

Total
7
11
18

Fisher's Exact Test
Probability (P) 0.0713
Pr ≤ P 0.8812
Table 21. Production of Nitrite and IFN-ɣ in PBMC grouped by PDDS
PDDS

INCREASE NO /
INCREASE PBMCIFNG

DECREASE NO /
INCREASE PBMCIFNG

DECREASE NO /
DECREASE PBMCIFNG

0

0
0.00%
2
20.00%
2

2
33.33%
4
40.00%
6

4
66.67%
2
20.00%
6

1
Total

Fisher's Exact Test
Probability (P) 0.0281
Pr ≤ P 0.4181
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INCREASE NO /
DECREASE PBMCIFNG
Total
0
0.00%
2
20.00%
2

6
10
16

3.5 Discussion
Multiple Sclerosis (MS) is a CD4+ T autoimmune demyelinating disease
characterized by the development of plaques in the central nervous system (CNS) [1].
MS studies demonstrated that nitrosative stress is present during acute and chronic
stages of MS and EAE [147, 178-184]. Current MS treatments focus in the modulation
of immune response during the initial stages of disease but they are not effective during
chronic stages of disease where nitrosative stress takes control of disease over the
immune response. Photobiomodulation (PBM) is proven to be effective at ameliorating
different neurodegenerative conditions [250, 259-268].
Our group previously reported the effect of PBM at 670nm light to reduce clinical
severity of disease and reduce nitrosative stress in the EAE model [288]. In-vitro studies
using isolated lymphocytes from mice with EAE cultured with MOG 35-55 receiving PBM
with 670nm light (0.028 W/cm2, 90s, 2.5J/cm2) demonstrated reduction in the nitrite
(NO2-) production in cell culture supernatants [288]. In in-vivo experiments, PBM
treatment 670nm light decreased iNOS expression in spinal cord tissue isolated during
the chronic stage of disease from mice with EAE [288]. In support of a role for NO in the
amelioration of EAE by PBM, PBM therapy did not affect the severity of EAE induced in
iNOS knockout (iNOS-/-) mice. These results suggested that the presence of NO
produced by iNOS (NO-iNOS) was necessary in the beneficial effects of PBM [288].
In order to extrapolate our previous findings of the effect of PBM at 670nm on the
reduction of nitrosative stress in the EAE model, we evaluated additional wavelengths
(Table 5). 670nm and 830nm wavelengths have been reported by others as useful
wavelengths on different systems during PBM treatment, in addition 670 and 830nm
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correlate with the absorption spectra of CCO [243]. We also evaluated devices able to
deliver pulsed wavelengths. One device delivered a single pulsed 640nm wavelength
and other device delivers 3 wavelengths simultaneously including 640, 875, and 905nm.
We hypothesized that for the 3-wavelentgh device it could be possible to need a lower
energy density in order to observe an effect. For this device a wider range of energy
densities were tested including 0.3, 1, 3, and 10J/cm 2 in order to anticipate a possible
biphasic dose effect.
A biphasic dose response effect is commonly observed in PBM treatments. At
low energy doses, there is not enough energy to produce an effect (below threshold).
When the energy dose is increased a biologic effect is observed and a threshold is
achieved. If more energy continues to be administered, a threshold is crossed and the
biologic effect is inhibited [244]. The effect of a biphasic dose response curve due to
different wavelengths and doses of energy during PBM treatments have been studied in
different systems [244, 248-252]. Based on previous data from our lab on PBM
optimization, we tested 3 and 10J/cm2 on cell cultures in order to anticipate the effect of
a biphasic dose curve. The results presented here support previous findings reported by
our lab where PBM at 670nm on mice with EAE reduced pro-inflammatory cytokines
(IFN-ɣ, TNF-α), increased anti-inflammatory cytokines (IL-4, IL-10) and reduced
nitrosative stress [287, 288]. The results showed that PBM at 830nm (10J/cm 2, 72h) on
PBMC reduced the production of nitrite as marker of oxidative stress. Nitrite reduction
correlated with the increase IL-10 (p=0.0271) and the reduction of IFN-ɣ (p=0.1940),
however this last one was not statistically significant likely due to our small size sample.
The fact that 3J/cm2 did not produce an effect on PBMC on nitrite, IL-10, and IFN-ɣ
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regulation as 10J/cm2 did, suggest that a low dose of energy was not enough to
produce a therapeutic effect. These results correlate with the biphasic dose response
curve principle. Our lab previously showed that 670nm participate in the regulation of
nitrite and cytokines using C57BL/6 mouse cells with EAE, here we showed that 830nm
produced a regulation using human cells from MS subjects. This would suggest that
670nm is more effective in mice and 830nm in humans, however, the literature shows
that both wavelengths can produce an effect in mice or humans. Therefore,
wavelengths and doses of energy have to be studied together when they are applied to
a particular system.
Data presented in chapter 2 showed that severity of disease (PDDS score) plays
a role in the regulatory effect of PBM on cytokines. Interestingly, the analysis of data of
nitrite regulation by PBM based on severity of disease (PDDS score) showed that the
severity of disease does not play a role in the modulatory effect of PBM at 830nm
(10J/cm2) on nitrate and IL-10 production by PBMC. Therefore, this suggests that PBM
at 830nm (10J/cm2) can be used to reduce nitrite levels (nitrosative stress) and increase
IL-10 at any point of disease. This is particularly important because as it has been
mentioned, MS studies demonstrated that nitrosative stress is present during acute and
chronic stages of MS and EAE [147, 178-184]. Future studies with bigger sample size
and MS subjects on different stages of disease are needed to verify these results.
The fact that PBM at 830nm reduced nitrite levels is in agreement with other studies
that indicate that PBM can modulate nitrosative stress on different systems [308, 310313]. For instance, Huang group investigated the effects of PBM treatment (810nm,
20mW/cm2, 3J/cm2) on cultured murine cortical neurons cultured with oxidative
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stressors including H2O2, cobalt chloride and rotenone [308]. PBM reduced ROS
generation, increased mitochondrial membrane potential, and reduced cell death. These
results suggested that PBM can produce a positive effect when oxidative stress is
elevated [308]. Zhang group investigated the effects of 630nm to reduce brain H2O2
levels (reactive oxygen specie) in the senescence-accelerated prone 8 mouse (SAMP8)
model of age-related dementia [311]. Age-associated H2O2 inhibits the formaldehyde
dehydrogenase enzyme producing the accumulation of formaldehyde which inhibits
choline acetyltransferase causing acetylcholine deficiency. The application of 630nm
produced the activation of catalase and formaldehyde dehydrogenase in the brain and
cell cultures producing a reduction in H2O2, reduction in formaldehyde, and restoring the
levels of acetylcholine. These results correlated with the improvement in memory
presented in SAMP8 mice [311].
PBM at 830nm (10J/cm2, 72h) on PBMC reduced the production of nitrite which
correlated with the increase in IL-10 (p=0.0271) and the reduction of IFN-ɣ (p=0.1940,
no significant). The increase in IL-10 can be explained by the participation of both drug
treatment and PBM treatment in the regulation of immune response. Most of the MS
subjects were under MS drug treatment. MS drugs as well as PBM treatment shift the
immune response from Th1 to Th2 responses increasing the production of antiinflammatory cytokines. The reduction of both nitrite and IFN-ɣ by PBMC can be
explained by recognized overlapping regulatory pathways for NO and IFN-ɣ [104]. In
immune cells, the regulation of NO produced by iNOS is regulated TLR-4 and as well as
IFN-ɣ-receptor. The binding of pathogens or lipopolysaccharides TLR-4 leads to the
activation of the NfkB pathway, leading to the activation of iNOS and subsequently the
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generation of NO [104]. Similarly, the binding of IFN-ɣ to IFNɣ-receptor on immune cells
leads to the activation of STAT1 which activates the gene expression of iNOS [104].
Th1 cells play a fundamental role in the development and pathogenesis of inflammatory
diseases, including MS and EAE. The IFN-ɣ produced by Th1 cells activates
macrophages to induce the expression of iNOS, leading to production of high amounts
of NO. Studies showed that high amounts of NO produced by iNOS can inhibit the
expansion of Th1 cells by negative feedback mechanism whereby activated
macrophages inhibit IL-12 which is necessary for Th1 differentiation and subsequent
production of IFN-ɣ [112, 121]. The Chen group reported the anti-inflammatory effect of
PBM with 810nm on murine bone marrow derived dendritic cells [309]. Dendritic cells
were activated with lipopolysaccharide (TLR4 agonist) or CpG oligodeoxynucleotide
(TLR9 agonist), then PBM treatment at 810nm at 0.3, 3 or 30 J/cm 2 was applied. PBM
810nm treatment with any of the 3 energy densities reduced dendritic cell activation as
evidenced by reducing all measured the cell surface markers (MHC-II, CD86, CD11c),
secretion of IL-12 in cells stimulated with LPS or CpG, and reduced the activation of
NFkβ in cells activated with CpG. The results suggested PBM treatment at 810nm had
an anti-inflammatory effect on dendritic cells by reducing IL-12 and NFkb signal
pathway [309].
Studies demonstrated that mitochondrial dysfunction and nitrosative stress play a
fundamental role in MS pathogenesis during acute and chronic stages [147, 178-184].
For instance, chronic active plaques obtained from MS subjects present oxidative
damage to mitochondrial DNA which correlates with a reduction in the activity of
complex I (NADH dehydrogenase) and increased activity of complex IV (cytochrome c
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oxidase, CCO) [178]. Microarray analysis showed that postmortem motor cortex
samples from MS subjects presented down regulation of mitochondrial genes, as well
as the activities of the complexes I and III of the respiratory chain, suggesting that
mitochondrial dysfunction in demyelinated axons leads to ATP reduction, which
participates in the progression to permanent disability in MS [179]. Cerebrospinal fluid
analysis from MS subjects showed increased iNOS activity, nitrite, peroxynitrites, Snitrosothiols, and reduction in the levels of glutathione [184]. Therefore, the reduction of
nitrosative stress and subsequent mitochondrial dysfunction are fundamental to delay
the progression of MS.
The results presented here support our previous findings of the potential of PBM
treatment in the modulation of cytokines and reduction of nitrosative stress in the EAE
model [287, 288]. 830nm (10J/cm2) led to reduced nitrite production by PBMC. In
addition, the reduction in nitrite production by PBMC at 830nm at 10J/cm 2 correlated the
increase IL-10 (p=0.0271). PBM treatment produced a reduction of nitrite levels
regardless of the PDDS score (severity of disease) among MS subjects. These results
further support the potential of PBM as an additional therapeutic tool to reduce
nitrosative stress in MS to affect disease progression.
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CHAPTER 4. CHARACTERIZATION OF THE EFFECTS OF PHOTOBIOMODUATION
ON INFLAMMATORY CYTOKINES IN SERUM SAMPLES OBTAINED FROM MS
SUBJECTS.

4.1 Abstract
Multiple Sclerosis (MS) is a CD4+ T cell-mediated autoimmune demyelinating
disease characterized by the development of plaques (lesions) in the central nervous
system (CNS). Some of the symptoms of MS include motor dysfunctions, tremor, pain,
numbness, weakness, and muscle fatigue. Currently there is no cure for MS. The drug
treatments available focus on the modulation of the immune response during the acute
phases of disease but they are not effective during chronic stages. The development of
new therapeutic approaches to regulate the immune system and reduce the symptoms
of disease at any stage is needed. Photobiomodulation (PBM) is a therapeutic approach
showing effective results in the amelioration of neurological disorders as well as
reduction of skeletal muscle fatigue, strength loss, and enhanced muscle rehabilitation.
It is proposed that the therapeutic effects of PBM are by the improvement of
mitochondrial function. Previously our lab studied the effect PBM at 670nm on the
Experimental autoimmune encephalopathy (EAE) model, the animal model of MS.
670nm modulated pro-(IFN-ɣ, TNF-α) and anti-(IL-4, IL-10) inflammatory cytokines
which correlated with the reduction in severity of EAE.
In this study we evaluated the effects of PBM treatment on muscle fatigue and
pro- and anti-inflammatory cytokines in relapsing-remitting MS subjects. The effect of
PBM treatment with either an ―active device‖, emitting simultaneously 640, 875, and
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905nm at 40, 80, 120J, or a ―placebo device‖ emitting only 640nm light at 3, 6, and 9 J,
on muscle recovery was evaluated in MS subjects over 4 visits. Muscle strength was
evaluated pre- and post- PMB treatment by maximal voluntary contractions (MVCs) of
the tibialis anterior (TA) muscle. The results showed each patient demonstrated
improvement in muscle recovery with the active device at 80J and 120J. An extended
PBM treatment protocol showed improvement in muscle recovery in some MS subjects,
however statistical significance was not achieved. Most of the levels of IFN-ɣ, IL-6 and
IL-10 among MS subjects were below the limit of detection, which correlates with no
active disease. TGF-β levels were lower in MS subjects with higher disability status
(PDDS≥1) than MS subjects with PDDS=0. The extended PBM treatment with the active
device increased TGF-β in MS subjects with PDDS≥1, however, the increase was not
significant. The results showed the potential of PBM to improve muscle recovery,
reduce muscle fatigue and modulate the immune response in persons with MS.

4.2 Introduction
Multiple sclerosis (MS) is a neurodegenerative CD4+ T mediated autoimmune
disease that affects the central nervous system (CNS). MS is characterized by the
destruction of the myelin sheath disrupting the nerve impulse transmissions from the
CNS to other parts of the body causing the development of symptoms [2]. Some
symptoms include motor dysfunctions, walking problems, tremor, pain, numbness,
weakness, and fatigue [2]. Approximately 80% of MS subjects present muscle
weakness and fatigue due to the combination of compromise function of the central
motor drive and intramuscular function [223, 289-294]. Fatigue is additionally related to
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alterations in skeletal muscle, such as reduction in the size of muscle fibers and
reduction in the activity of mitochondrial enzymes involved in the production of energy
[294].
CD4+ T cells play an important role in the pathogenesis of MS. CD4+ T cells can
differentiate into pro-inflammatory Th1 and Th17 cell subtypes, which are considered
pathogenic in MS. Th1 cells produce TNF-α, IFN-γ and IL-2. Th17 cells produce IL-17,
IL-6, IL-21, IL-22, and TNF-α [23, 38]. CD4+ T cells can also differentiate into Th2 and
regulatory T cells (Tregs) which are considered protective against the disease due to
their production of anti-inflammatory cytokines [23, 38]. Th2 cells produce IL-4, IL-5, IL6, and IL-10. Treg cells produce TGF-β and IL-10 [23, 38].
PBM is proving to be effective at ameliorating pathology and clinical severity for
various neurodegenerative diseases [250, 259-268]. In addition, PBM on healthy
subjects showed to reduce skeletal muscle fatigue, strength loss, exercise-induced
oxidative stress, and improve muscle rehabilitation after exercise [295-303]. The
mechanism of action of PBM is not fully elucidated, however, it is proposed that that
during PBM treatment, the light is absorbed by cytochrome c oxidase (CCO) improving
mitochondrial function and ATP production[239-242]. Our lab previously focused on the
study of PBM for the treatment of MS using the experimental autoimmune
encephalomyelitis model (EAE). PBM (670nm, 5J/cm2) regulated the production of proand anti-inflammatory cytokines, reduced nitrosative stress, and ameliorated disease
severity in the EAE model [287, 288]. Our next goal was to study the potential effect of
PBM on immune regulation and muscle fatigue in MS subjects. We hypothesized that
PBM treatment would reduce muscle fatigue and reduce pro-inflammatory cytokines
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(IFN-ɣ, IL-6) and increase anti-inflammatory cytokines (IL-10, TGF-β) in serum samples
collected from MS subjects after PBM treatment.

4.3 Materials and methods
Subject population. Recruitment of subjects was carried out following the guidelines of
the Institutional Review Board of the University of Wisconsin Milwaukee (IRB# 18.020)
and Marquette University (IRB# HR-1710020115). Inclusion criteria: RRMS male and
female subjects between 20-60 years of age with no history of relapse or
immunosuppressive therapy in the previous 6 months. Any current disease-modifying
drug treatment was recorded. Exclusion criteria: RRMS subjects with any current
infection, any additional neurodegenerative, autoimmune, or mitochondrial disease.

MS patient classification. MS subjects were classified based on the Patient
Determined disease steps (PDDS) scale. PDDS scale is a patient reported outcome of
disability of multiple sclerosis. PDDS scale is based on motor and ambulatory
dysfunction present in MS subjects. PDDS scale has 7 levels ranging from 0= normal to
6= Confined to wheelchair (Table 4) [304, 305].
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Photobiomodulation (PBM). PBM treatment was applied using customized ―Painaway
Post-Op Laser‖ devices (Multiradiance Medical, Solon, OH). Two different devices were
used. The ―Placebo‖ device delivered a single pulsed wavelength at 640nm (VIS, light
emitting diode [LED] at 25mW/cm2). The ―Active‖ device delivered 3 pulsed wavelengths
simultaneously, including: 640nm (VIS, light emitting diode [LED]); 875nm (NIR;LED);
and 905nm light (NIR; super-pulsed Galium Arsenic laser, at a total power density of
33mW/cm2). Devices and energies used are summarized in Table 22.

Wavelength

Type 2A
640 nm
Type 2B
640 nm
875 nm
905 nm

Table 22. Photobiomodulation parameters
Power
Time
Energy
Surface
2
2
Density
(sec)
Density (J/cm ) area (4 cm )
2
(W/cm )
2
2
300 sec
0.75 J/cm
4 cm
2
2
Pulsed LED
0.0025
600 sec
1.5 J/cm
4 cm
2
(MRM)
W/cm
2
2
900 sec
2.25 J/cm
4 cm
2
2
300 sec
10 J/cm
4 cm
2
2
LED
600 sec
20 J/cm
4 cm
2
LED
0.033 W/cm
2
2
900 sec
30 J/cm
4 cm
Superpulsed
laser
(MRM)
Device

Total
Energy (J)
3
6
9
40
80
120

Study Design. Phase 1: Energy dose optimization. We first sought to determine the
best dose of energy able to produce an improvement in muscle function in MS subjects.
Using a randomized double blinded repeated measured design, MS subjects were
scheduled for 4 appointments. In 3 out of the 4 appointments, each patient received a
different dose of energy using the active device (Type 2B device) including 40, 80,
and 120 J. During the fourth appointment, each patient received a low dose of energy
using the placebo device (Type 2A device) including 3, 6 and 9 J. PBM treatment was
applied in the tibialis anterior of the right leg. Muscle function was measured before and
20 minutes after PBM treatment by Dr. Alexander Ng’s lab at Marquette University using
techniques standard in his lab. Phase #2. Extended PBM treatment (crossover
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study). The objective of this phase was to determine the effects of sustained PBM
treatment on the reduction of muscle fatigue and immune regulation in MS subjects. For
each patient, the best dose of energy that showed an improvement in muscle function
during phase 1, it was used in phase 2. Patients were scheduled for 5 appointments. In
the first and third appointment, each patient received a PBM device (therapeutic or
placebo) to apply the light treatment at home for 2 consecutive weeks. Patients were
instructed to apply PBM treatment to the gastrocnemius of both legs every morning, and
the tibialis anterior of both legs every night. Patients came back to evaluate the effects
of PBM treatment on muscle fatigue (appointments 2 and 4). Then the patients went
sent home for a period of two weeks without PBM treatment and then they came back
to evaluate the lasting effect of PBM treatment (appointments 3 and 5). In each
appointment subjects were evaluated for the effect of PBM treatment on muscle fatigue
Figure 14.

Visit 1
Blood sample
Muscle
fatigue assay
PBM at home
for 2 weeks

Visit 2
Blood sample
Muscle
fatigue assay
No PBM for
2weeks

Visit 3
Blood sample
Muscle
fatigue assay
PBM at home
for 2weeks

Visit 4
Blood sample
Muscle
fatigue assay
No PBM for
2weeks

Visit 5
Blood sample
Muscle
fatigue assay

Figure 14. Phase 2 study design.

Blood sample collection. Blood (10ml) was collected at each of the 5 appointments.
Blood collected in the absence of anticoagulant and were allowed to clot. Samples were
centrifuged (1500g, 10min) and serums were aliquoted and stored at -80C until ELISA
quantification.
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Cytokine quantification by ELISA. Serum collected from MS subjects were used for
quantification of IFN-ɣ (<15.6pg/mL detection limit, Duoset ELISA R&D systems, MN),
IL-6 (<9.3pg/mL detection limit, Duoset ELISA R&D systems, MN), IL-10 (<7.8pg/mL
detection limit, Quantikine ELISA R&D systems, MN), TGF-β (<31.3pg/mL detection
limit, Quantikine ELISA R&D systems, MN) by ELISA following manufacturer
instructions. Absorbance was measured using a plate reader (Bio-Tek, model KC4,
Winooski, VT) at 450nm. Levels of cytokines were calculated according to a standard
curve.

Data analysis. Statistical analysis was performed with SAS 9.4 (Cary, NC). For muscle
recovery, McNemar’s test was used to test for each light dose compared to placebo and
Spearman’s correlations were compared with Fisher’s r to z transformation. For serum
cytokine data, multiple comparisons performed by Wilcoxon Two-Sample Test were
performed as appropriate. P<0.05 was considered significant. Statistical analysis was
carried out by Chi Cho, MS, in the college of Health Sciences, University of Wisconsin
Milwaukee.

4.4 Results
Phase 1. Energy dose optimization. Acute PBM treatment improves muscle
strength recovery in MS subjects
To determine an optimal dose for subsequent study, we evaluated the acute
effect of PBM treatment on muscle recovery following a fatiguing task on persons with
RRMS (―Phase 1‖). Using a randomized double blinded repeated measured design, pre-

135

and post- PBM treatment effect on muscle recovery was evaluated in MS subjects
(n=17, males=3, females=14) over the course of 4 visits over a 4-week period.
Evaluation of muscle strength consisted in 3 maximal voluntary contractions (MVCs) of
tibialis anterior muscle followed by 2min of intermittent isometric contraction at 45% of
MVC. Then, PBM treatment was applied to the tibialis anterior muscle using 1 of 3
energy doses with the ―active device‖: 40, 80, 120J or 1 dose with the ―placebo device‖:
3, 6, 9 J. Once PBM treatment was applied, a recovery period of 20min was allowed,
after which recovery MVCs were evaluated. Muscle fatigue was evaluated by the
degree of recovery in the MVC before PBM treatment. Twelve out of 17 subjects
recruited finished the 4 visits.
All subjects who completed 4 visits were able to recover strength within 12% of
their initial strength after PBM treatment with the active device using a total energy dose
of 120J. This difference in force recovery between 120J energy dose and placebo was
significant (p=0.03). In addition, the results showed that there was not an optimal dose
of energy to improve muscle recovery rather each patient showed improvement in
muscle recovery at a specific dose (Table 23). Doses of energy at 80J (5 patients) and
120J (6 patients) showed the best results to improve muscle recovery.
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Table 23. Optimal Energy Dose for Subjects.
Patient
PDDS
#
Gender Age score
Dose of energy
1
Male
59
0
High, 120J, 15min
2
Female 53
0
High, 120J, 15min
3
Female 59
0
High, 120J, 15min
4
5
6
7
8
9

Female
Female
Female
Female
Female
Female

56
46
54
46
41
23

0
4
1
3
0
1

High, 120J, 15min
High, 120J, 15min
Medium, 80J, 10min
Medium, 80J, 10min
Medium, 80J, 10min
Medium, 80J, 10min

10
11
12

Female
Female
Female

47
55
47

No info
1
2

Low, 40J, 5 min
Low, 40J, 5 min
Low, 40J, 5 min

The effect of Extended PBM treatment on muscle fatigue in persons with
MS.

Following dose optimization, we investigated the effects of an extended PBM

treatment on the reduction of muscle fatigue and immune regulation in MS subjects
using an extended, 2-week treatment protocol (―Phase 2‖). PBM doses used in Phase 2
were individually assigned based on the optimal dose determined in Phase 1(Table 23).
MS subjects (n=12; male=1, females=11) were scheduled for 5 appointments. In the
first and third appointment, each patient received a PBM device (therapeutic or placebo)
to apply the light treatment at home for 2 consecutive weeks. Patients were instructed to
apply PBM treatment every morning to the gastrocnemius of both legs. At night,
treatment was applied to the tibialis anterior of both legs. Patients came back to
evaluate the effects of PBM treatment on muscle fatigue (appointments 2 and 4).
Following a 2-week washout period without PBM treatment, subjects returned to the lab
to evaluate the lasting effect of PBM treatment (appointments 3 and 5). In each
appointment subjects were evaluated for the effect of PBM treatment on muscle fatigue
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and a blood sample was collected. The collection of data is completed. However, the
analysis of data for the muscle fatigue studies is ongoing.

Effect of extended PBM treatment on serum cytokines
Serum cytokine analysis was performed using blood samples collected during
Phase 2. Pro-(IFN-ɣ, IL-6) and anti- (IL-10, TGF-β) inflammatory cytokines were
measured by ELISA to investigate the systemic effect of PBM treatment on the immune
response. For IFN-ɣ, IL-6, and IL-10 most of the patients showed results below the
limits of detection during the 5 appointments. A summary of the results is shown in
Appendix Table 24. For IFN-ɣ, 2 out of 12 patients presented detectable values
between 10-20 pg/mL. For IL-6, 4 out of 12 patients presented detectable values
between 20-80pg/mL. For IL-10, 1 out of 12 patients reported detectable values
between 10-15 pg/mL. Analysis of data showed that PBM treatment did not produce a
significant change on the production IFN-ɣ, IL-6 and IL-10 among MS subjects.
Contrary to other cytokines measured, all MS subjects presented with
measurable TGF-β values between 10,000 and 25,000pg/mL. TGF-β results were
plotted against the PDDS scores. Subjects were divided into two groups based on their
PDDS score: Group 1 included subjects with PDDS=0 (n=6); Group 2 included subjects
with PPDS ≥1 (n=6). The results showed that in MS subjects with PDDS≥1, the mean
values of TGF-β were lower compared to MS subjects with PDDS=0. Furthermore, PBM
treatment with the active device was associated with an increase in TGF-β with in
subjects with PDDS≥1 compared to subjects with PDDS=0. However, the increase was
not statistically significant (p=0.2403, Wilcoxon Two-Sample Test) (Figure 15).
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PDDS≥1

TGF-β average (pg/mL)

PDDS=0

Figure 15. TGF-β values in serum collected from MS subjects during phase 2. MS subjects with
PDD≥1 presented lower values of TGF-β in comparison with MS subjects with PDDS=0. During PBM with
the active devise, MS subjects with PDDS≥1 showed an increase in TGF-β, however the increase was
not statistically significant (p=0.2403, Wilcoxon Two-Sample Test) Box represents interquartile range
(75%-25%). The bar within the box is the median. The whiskers are 1.5x the interquartile range. Anything
outside these bars is an outlier. The red lines connect the median score at each time point. The circles
represent subjects at each visit
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4.5 Discussion
The destruction of the myelin sheath in MS interrupts the transmission of nerve
impulses from the brain to other parts of the body causing the symptoms of MS [2].
Muscle weakness and fatigue are commonly present in MS subjects due to alterations
in both the central motor drive and intramuscular function [223, 289-294]. Fatigue is
additionally related to alterations in skeletal muscle, reduction in the size of muscle
fibers, and reduction in energy by mitochondria [294]. Currently, there is no cure for MS.
Current treatments focus on the suppression of the immune system to slow down
disease progression but they are not effective in chronic stages of disease.
Photobiomodulation (PBM) is proving to be effective to ameliorate different neurological
disorders [250, 259-268]. In addition, in healthy subjects, PBM is effective to reduce
muscle fatigue, improve exercise performance, reduce strength loss, and improve
muscle rehabilitation after injury or exercise [295-303]. Previously, our laboratory
studied the effects of PBM in the experimental autoimmune encephalomyelitis (EAE)
[287, 288]. PBM at 670nm on mice with EAE reduced pro-inflammatory cytokines (IFNɣ, TNF-α), increased anti-inflammatory cytokines (IL-4, IL-10), and reduced nitrosative
stress, which correlated with the reduction in disease severity [287, 288]. Here, we
investigated the effect of PBM on immune regulation and muscle fatigue in MS subjects.
The first step in the study (Phase 1) was to evaluate the acute effect of PBM on
muscle fatigue in RRMS. RRMS subjects (n=17) where scheduled for 4 visits to the
laboratory in a period of 4 weeks. Muscle fatigue pre- and post- PBM treatment was
evaluated maximal voluntary contractions (MVCs) of tibialis anterior (TA) muscle in the
right leg or dominant leg. Muscle fatigue was evaluated by the degree of recovery in the
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MVC before PBM treatment. The results showed that all patients were able to recover
strength within 12% of their initial strength after PBM treatment with the active device
using a total energy dose of 120J. In addition, the results showed that there was not an
optimal energy dose to improve muscle fatigue rather each patient showed
improvement in muscle recovery at a unique dose. This differences in energy
requirement can be explained due to the fact that MS is a very variable disease, each
MS subject is in a different stage of disease and each of them develop different motor
problems at a different levels. Therefore the energy requirements to improve muscle
function could be different. Energy doses of 80 and 120J showed to best results in
muscle recovery. Analysis of data is ongoing. Preliminary analysis suggests that MS
subjects with motor dysfunction problems (i.e. walking problems), higher depression,
and lower quality of life showed a better response to PBM treatment (data not shown).
Phase 2 employed a cross-over study design to investigate the effect of an
extended PBM treatment protocol on muscle fatigue in MS subjects. MS subjects were
scheduled for 5 appointments. Patients received a PBM device (therapeutic or placebo)
and were instructed to apply the PBM treatment at home using the energy dose from
Phase 1 that improved muscle recovery. The PBM treatment was applied for 2
consecutive weeks every morning in the gastrocnemius of both legs and every night in
the tibialis anterior of both legs with washout periods (2 weeks) between the extended
PBM treatments.
At each appointment, muscle fatigue was evaluated using the maximal voluntary
contractions (MVCs) of tibialis anterior (TA), as performed in Phase 1, and a blood
sample was collected for serum cytokines quantification. Collection of data is complete
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but the analysis of data is still pending. Preliminary analysis of data showed that
patients with motor problems (walking problems) or higher disability showed a more
noticeable muscle fatigue improvement. The low improvement in muscle fatigue among
patients after PBM treatment can be explained due to the low sensitivity of the muscle
fatigue task and the short period of time of PBM treatment. In future studies a more
sensitive assay and longer PBM treatment will be necessary to evaluate muscle
recovery.
Published studies analyzed the cytokine profile of MS subjects with the main goal
of identify biomarkers for the diagnosis, identification of disease stages, identification of
the correct MS subtype, and monitoring of the drug treatment [314-317]. Our serum
cytokine data presented here correlate with these published results. Martins et al.
quantified pro-inflammatory Th1 (IFN-ɣ, IL-2, IL-12) and anti-inflammatory Th2 (IL-4, IL5, IL-10, IL-13) cytokines in serum samples from 833 MS subjects and 117 healthy
controls in order to investigate cytokine differences among disease stages [314]. MS
subjects included primary progressive (n=27), relapsing remitting (n=656), and
secondary progressive (n=150), receiving IFN-β, Glatiramer acetate, other diseasemodifying therapy (not specified), or no drug treatment, with no active disease present.
When the results of the 3 MS groups were compared individually (pairwise) with each
other, no significant differences were found comparing cytokine expression, indicating
that the results obtained were not directly related to the subtype of the disease.
Significant increases in MS samples in comparison with healthy controls were found for
IFN-ɣ (mean 7.5 vs 0.4pg/mL, p=0.0002), IL-2 (mean 5.7 vs 1.0pg/mL, p=0.0002), TNFα (mean 4.1 vs 1.2pg/mL, p=0.01) IL-4 (mean1.4 vs 0.1pg/ml, p≤0.0001), IL-10 (mean
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16.8 vs 7.5pg/mL, p=0.03). The increase in both pro- and anti- inflammatory cytokines
correlates with the progression of the disease due to the increase in pro-inflammatory
cytokines, and the simultaneous restorative process by anti-inflammatory cytokines
[314].
Kallaur et al. also evaluated the serum cytokine profile from RRMS patient with
the progression and activity of the disease [315]. Serum cytokines levels in RRMS
(n=169) and healthy donors (n=132) were measured by ELISA. All RRMS subjects were
in remission period and were prescribed IFN-β1a, IFN-β1b, Glatiramer acetate,
Natalizumab, or corticosteroid treatment with no presence of relapse for at least 3
months before the study. Serum cytokine results were analyzed based on the disability
and activity of the disease using the expanded disability status scale (EDSS) and
Magnetic resonance imaging lesions. IFN-ɣ, IL-6, IL-12, IL-4, and IL-10 were higher in
RRMS patient compared to healthy donors. Interestingly, IL-4 levels were higher in
RRMS subjects with mild disability compared with those with moderate and severe
disability. TNF-α and IL-10 levels were higher in RRMS subjects with inactive disease in
comparison with active disease. The results suggested that the production of antiinflammatory cytokines is to counteract the presence of pro-inflammatory cytokines
present during the progression of MS [315].
Nicoletti et al. used ELISA to measure serum levels of TGF-β in RRMS subjects,
and SPMS subjects with no MS drug treatment [316]. The control group consisted of
age matched healthy subjects (n=29). RRMS subjects (n=65) were divided in 2 groups
depending on if they were on remission (n=41), or relapse (n=24). RRMS subjects in
remission presented TGF-β values of approximately 70ng/mL. Relapsing patients
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showed values of approximately 90pg/mL. The control group presented values of
approximately 20ng/ml. In addition, 10 RRMS subjects were monitored for 4-6 months
before and during a relapse period. The longitudinal analysis showed that the mean
value for TGF-β before the attack was 50ng/mL, and the mean value during the attack
was 82ng/mL. The data indicated that the increase in TGF-β during the attack period
was due to the activation of immunomodulatory mechanisms in a feedback fashion by
the pro-inflammatory events present during the relapse period [316].
In our study, the low levels of pro-(IFN-ɣ, IL-6) or anti-(IL-10, TGF-β)
inflammatory cytokines obtained from RRMS subjects through the 5 visits in phase 2
correlate with the lack active disease (i.e., all subjects were in a remission period). In
addition, the low serum cytokine levels obtained indicate that the drug treatment used
by patients is efficiently modulating the immune response. Our results showed that PBM
treatment did not produce significant change on low serum levels of IFN-ɣ, IL6, and IL10 detected in our study population. On the other hand, PBM treatment resulted in an
increase in TGF-β levels in MS subjects with PDDS≥1 during the extended PBM
treatment with the active device, however, this increase was not significant. The
observation that PBM treatment produced an effect on patients with higher disability
(PDDS≥1) but not in patients with normal motor functions or no limitations on activity
(PDDS=0) suggests that PBM treatment might be more effective in chronic stages of
disease or with higher disability (i.e. motor dysfunctions). Therefore, the lack of
significant in the increment of TGF-β after PBM treatment could be explained due to the
low number of subjects in our study, the low number of patients with higher disability
status, as well the fact that none of our subjects presented with active disease, which
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suggest that anti-inflammatory cytokines (IL-10, TGF-β) would not be elevated. The
presence of TGF-β and the lack of IL-6 are particularly important because these
conditions induce CD4+ T cells to differentiate into Tregs, which are protective in MS.
On the other hand, TGF-β and the presence of IL-6 induce CD4+ T cells to differentiate
to Th17, which are pathogenic in MS [23, 38].
In conclusion, the results presented here suggest that PBM treatment has the
potential to be used as an additional therapeutic tool to modulate immune response and
reduce muscle fatigue in MS subjects. Our data suggest that PBM therapy might be
effective in MS subjects in chronic stages or with higher disability status. In addition, the
serum cytokine data indicate that biomarkers such as IL-10 and TGF-β in combination
with PDDS scale can be used to monitor the efficacy of PBM treatment on MS subjects.
Future studies are needed to investigate the effect of PBM treatment for extended
periods of time on serum cytokines (pro- and anti-inflammatory cytokines), evaluate
motor function with more sensitive assays and possibly different muscles in the body
(i.e. legs, biceps, triceps, back, muscle fatigue in general) as well as recruit MS subjects
in more advanced stages of disease or with higher disability status.
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CHAPTER 5.
GENERAL DISCUSSION
In MS, the destruction of myelin blocks the transmission of nerve impulses or
messages from the CNS to other parts of the body causing the symptoms of MS such
as anxiety, depression, motor dysfunctions, walking problems, pain, muscle fatigue,
fatigue in general, etcetera [2]. There is no cure for MS. Currently therapeutic agents
impact disease through modulation of the immune response in order to slow down the
progression of disease. Importantly, these agents are only approved relapsing-remitting
disease and are not effective against progressive stages where nitrosative stress is
largely responsible for disease pathogenesis. However, studies demonstrated that
nitrosative stress events are in fact present during the acute stages of disease, even
before the cellular infiltration in the central nervous system, and play role in
pathogenesis [147, 178-184]. Thus, the development of therapeutic approaches that
target the generation of nitrosative stress are needed.
Photobiomodulation (PBM) is a therapeutic approach demonstrating potential
toward ameliorating pathology and clinical severity for various neurodegenerative
conditions, including traumatic brain injury (TBI), acute ischemic stroke (AIS), familial
amyotrophic lateral sclerosis (FALS), spinal cord injury (SCI), Alzheimer disease (AD)
and Parkinson disease (PD) [250, 259-268]. It is proposed that the biological effects of
PBM are elicited through improvement of mitochondrial function. Previous studies
demonstrated that during PBM treatment, VIS/NIR light (600-1100nm wavelength
range) is absorbed by cytochrome c oxidase (CCO, complex IV), the mitochondrial
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enzyme responsible for catalyzing the transfer of electrons from cytochrome c to
molecular oxygen in the generation of ATP [239-242].
Our lab previously studied the effect PBM at 670nm on the EAE model of MS.
670nm light reduced pro-inflammatory cytokines (IFN-ɣ, TNF-α), increase antiinflammatory cytokines (IL-4, IL-10) and reduce nitrosative stress, correlating with a
reduction in disease severity [287, 288]. The main goal of the current study was to
investigate the effect of PBM in the modulation of pro- and anti-inflammatory cytokines
and nitrosative stress in peripheral blood mononuclear cells (PBMC) and CD4+ T cells
obtained from MS subjects. Based on our previous work, we evaluated the effect of
PBM with 670nm light [287, 288]. In addition, we investigated the effects of different
wavelengths with proven effectiveness in other different systems [239, 240, 243, 245,
246, 248].
First, we compared the effect of PBM treatment on the modulation of cytokines
between MS subjects and healthy subjects (control group). The threshold for
significance was set at ±20% based on changes expected in MS subjects over the
course of disease and compared to healthy donors. MS subjects did not present active
disease or other inflammatory condition, each of them is on a different stage of disease,
and most of them are receiving drug treatment to modulate disease. Our data revealed
unique PBM wavelengths and doses effective at modulating cytokine secretion in MS
subjects and healthy donors (Chapter 2, Table 6). Importantly, the results showed both
MS subjects and healthy donors responded to PBM treatment with the modulation of
cytokine production by PBMC and CD4+ T cells under unique conditions. This was
unexpected, as the current paradigm in the PBM community supports the notion that
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healthy individuals should not respond to PBM treatment. Our results demonstrate that
at least some individuals considered ―healthy‖ do in fact respond to PBM therapy. One
explanation for this is that many healthy patient present some degree of inflammation
that allows to PBM affects the production of cytokines.
Next we analyzed the effect of PBM treatment on cytokine production in MS
subjects based on disease severity (Table 13). MS subjects were divided in 2 groups
based on the Patient Determined Disease Steps (PDDS) scale, a self-reported measure
of disease severity. MS subjects with PDDS=0 showed no change in the production of
IFN-ɣ by PBMC. Meanwhile, most MS subjects with PDDS≥1 responded with changes
in IFN-ɣ production with these parameters, albeit with mixed results, with equal
percentages of subjects responding with increased versus decreased cytokine
production. In response to the Type 2b device (640/875/905nm, 1J/cm2 at 48h), CD4+ T
cells from the majority (75%) of subjects with PDDS=0 did not change IFN-ɣ production,
while 25% of subjects reduced cytokine secretion under the conditions. On the other
hand, 100% of MS subjects with PDDS≥1 showed an increase in IFN-ɣ in response to
this same device. Unexpectedly, 735nm light (10J/cm 2) affected cytokine production in
MS subjects with PDDS=0, with 66.67% of CD4+ T cell cultures showing increased IFNɣ production in response to these conditions. Cells from MS subjects with PDDS≥1 also
responded to these conditions, with 25% of cultures presented an increase and 62.5% a
reduction in IFN-ɣ.
The results showed that disease severity played a role in the modulatory effect of
PBM on cytokines. Then, we evaluated if the magnitude in cytokine production in each
patient was different between MS subjects with PDDS=0 compared to MS subjects with
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PDDS≥1 after PBM treatment (Table 17). The results showed that MS subjects with
PDDS=0, in comparison with MS subjects with PDDS≥1, presented higher levels of IFNɣ produced by CD4+ T cells after PBM treatment with 735nm (3J/cm 2 at 120h and
10J/cm2 at 72h) and higher levels of IFN-ɣ produced by PBMC after treatment with type
2b device (640/875/905nm, with 1 and 3J/cm 2 at 120h). The fact that PBM treatment
with 735nm and type 2b device (640/87/905nm) increased the production of IFN-ɣ by
CD4+ T cells and PBMC from patients with PDDS=0 will require further investigation in
its potential effect on MS subjects. For some time IFN-ɣ has been considered
detrimental in MS due to its participation in the development and progression of MS and
EAE [46-52]. However, several studies indicate that IFN-ɣ can play a beneficial role in
MS and EAE [53-65]. Thus, the increase of IFN-ɣ due to PBM treatment in MS subjects
with PDDS=0 might be beneficial to ameliorate disease. Conversely, our results showed
that 670nm (3J/cm2 at 72h) produced a reduction or no change in IFN-ɣ production by
PBMC and CD4+ T cells but increased IL-10 by CD4+ T cells from MS subjects with
PDDS≥1 compared to MS subjects with PDDS=0, which showed increase in IFN-ɣ and
no change in IL-10. These results are very important because they show that the
production of cytokine and its regulation among MS subjects with PPDS=0 and PDDS≥1
is different after PBM treatment. In addition, MS subjects with higher severity in disease
(PDDS≥1) presented an anti-inflammatory effect after PBM with 670nm (3J/cm 2 at 72h),
and patients with normal functions (PDDS=0) presented no effect or a low proinflammatory response. Thus, optimization of PBM treatment parameters to support
efficacy and prevent unwanted responses will be necessary if PBM therapy is to used
successfully in the clinical setting.
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Initially, we considered 735nm as a negative control in our experimental design,
due to our previous studies that showed that wavelengths around 700nm did not
provide significant effect during PBM, correlating with the absorption spectrum of CCO
[243]. On the contrary, our results showed that CD4+ T cells from MS subjects with
PDDS=0, but not MS subjects with PDDS≥1, expressed higher levels of IFN-ɣ produced
by CD4 T cells after PBM treatment with 735nm (3J/cm 2 at 120h and 10J/cm2 at 72h).
This result is important because it indicates that wavelengths in the 700nm range are
able to produce a significant effect in at least some circumstances. Therefore, in
addition to wavelength, energy densities (J/cm2), cell type, severity of disease are some
of the factors that also need to be considered when optimizing PBM treatment.
Our results correlate with previous observations from other authors that indicate
that the effect of PBM treatment is affected by the redox status of the system [248, 249,
307-309]. Karu et al. evaluated the changes in the absorption spectra of HeLa cells
before and after PBM [307]. 632.8nm (103J/m2) on HeLa cells with oxidized cytochrome
c oxidase resulted in the reduction of the cytochrome C oxidase, followed by its
subsequent oxidation, producing a bell-shaped dose-response curve. Conversely, the
application of PBM treatment to HeLa cells with reduced cytochrome c oxidase first led
to the oxidation, followed by the reduction, of the cytochrome c oxidase, resulting in an
inverted bell-shaped curve dose-response curve. These results indicated that PBM can
produce reduction or oxidation of CCO depending on the redox status of the enzyme,
and the maximum in the bell-shape dose-dependent curve or minimum in the inverted
bell-shape dose-dependent curve is the dose threshold or inflection point between the
changes in redox state [307]. These results correlate with the observations by others
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characterizing the effect of PBM on healthy cells in comparison with cells under
oxidative stress. For instance, Chen et al. reported that 830nm (3J/cm 2) on healthy
embryonic fibroblasts increased CCO activity, mitochondrial membrane potential above
normal baseline, and increased ROS production significant enough to activate NFb
[249]. Using primary cultured murine cortical neurons, Huang et al. demonstrated that,
under conditions of experimentally-induced oxidative stress, 810nm at 3J/cm 2 returned
mitochondrial membrane potential back to basal levels, increase ATP production,
reduced high ROS levels, and reduced cell death [308]. Conversely, cells exposed to
the same PBM condition in the absence of oxidative stressors showed a similar
increase in mitochondrial membrane potential and ATP production but a modest
increase in ROS levels. The results showed that PBM can reduce oxidative stress in
compromised systems (oxidative stress conditions) but in healthy cells can increase
ROS levels [308].
The reduction of IFN-ɣ after PBM treatment in MS subjects with PDDS≥1
correlates with the observations by Karu and others that indicate that PBM effect will
depend of the redox state of the system [248, 249, 307-309]. Our results showed that
that PBM treatment on PBMC and CD4+ T cells reduced IFN-ɣ secretion by cells
isolated from MS subjects with PDDS≥1 (presence of disability) and increased IFN-ɣ
secretion

by cells from MS subjects with PDDS=0 (normal patients, no disability

present). High levels of IFN-ɣ were previously correlated with the progression of MS and
EAE [46-52]. For instance, in a clinical study, RRMS (n=18) patients received
recombinant IFN-ɣ over a range of doses [low (1mcg); intermediate (30mcg); and high
(1000mcg)]. In a dose-dependent manner, disease was exacerbated in 39% of subjects
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receiving exogenous IFN-ɣ, suggesting that IFN-ɣ administration activated the immune
response, leading to disease activity clinical relapse. [51]. Conversely, studies
demonstrated a protective role of IFN-ɣ in EAE and MS [53-65]. The Billiau group
showed that the intraperitoneal administration of anti-IFN-ɣ antibodies into EAE-induced
C57BL/6J mice on days -6, 0, 7, and 14 relative to EAE induction increased the
incidence, disease severity and mortality [56]. Conversely, the intraperitoneal injections
of recombinant-DNA-derived IFN-ɣ into EAE-induced SJL/J mice on days -1, 0, 1, 3, 5,
7, and 9 relative to EAE induction reduced disease severity and mortality [56]. The
authors proposed that it is important to differentiate between the local and systemic
effects of IFN-ɣ. Local IFN-ɣ promotes inflammation whereas the systemic IFN-ɣ
produced an anti-inflammatory effect. Anti-IFN-ɣ antibodies neutralized the IFN-ɣ
present in the circulation and peripheral body compartments but not that produced
locally in the CNS, which is difficult to reach due to the presence of the blood brain
barrier. The blocking of the systemic IFN-ɣ suppresses the anti-inflammatory properties
of IFN-ɣ, leading to increase of EAE severity. The endogenous IFN-ɣ formed during the
induction or development of EAE, as well as the administration of IFN-ɣ before EAE
induction, can play a disease-limiting role therefore it should not be blocked during the
inflammation of CNS. [56]. Similarly, the Furlan group showed that the localized over
expression of IFN-ɣ in the CNS reduced the severity of disease in EAE-induced mice
[65]. Overexpression of IFN-ɣ was carried out by using an IFN-ɣ gene-containing vector
inserted in Herpes simplex virus type 1 (HSV-1) which was injected intracisternally in
C57BL/6 mice. These mice developed EAE with earlier disease onset, milder disease
course, reduction in apoptotic T cells, inflammatory infiltrates, demyelination, axonal

152

loss, and 83% of mice recovered from disease compared to mice with no IFN-ɣ genecontaining vector (control group) [65]. The results challenge the general idea that the
presence of IFN-ɣ in EAE and MS leads to the worsening of disease. Depending on
disease stage and site of production (systemic or local), IFN-ɣ can play a dual role in
EAE and MS: 1) a protective role to reduce disease severity or 2) a pathogenic role
which participates in the progression and development of disease [65]. Thus, the
modulation of IFN-ɣ at any stage of MS or EAE (before, during or after relapse) could be
potentially useful to reduce the clinical symptoms during the progression of the disease.
Our results showed that PBM at 670nm (3J/cm 2) on cells isolated from MS
subjects with PDDS≥1 lead to increased IL-10 production by CD4+ T cells in
comparison with MS subjects with PDDS=0. These results are very important because
they show that MS subjects with higher severity in disease present an anti-inflammatory
effect after PBM treatment. Studies demonstrated the protective role of IL-10 in the
amelioration of MS and EAE [86, 87]. For instance IL-10 deficient mice, but not IL-4
deficient mice, developed accelerated EAE onset in comparison with WT mice [86].
Spontaneous recovery was present in WT and IL-4 deficient mice but recovery was not
present in IL-10 deficient mice suggesting that IL-10 is fundamental in the amelioration
or recovery process [86]. In one study, quantification of IFN-ɣ, TNF-α, IL-4, and IL-10 in
serum isolated from MS subjects during relapse (n=42) showed higher levels of these
cytokines in comparison with healthy controls (n=12). In addition, the quantification of
TNF-α, IL-10, and nitric oxide (NO) in 17 MS subjects during active relapse showed
higher levels in comparison with healthy subjects [90]. Together, these studies
suggested that the simultaneous activation of Th1 and Th2 cells is present during the
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acute stages of the disease [89, 90]. Thus, the increased IL-10 production, especially in
patients with higher disability can participate in the amelioration of disease.
Nitrosative stress is linked to disease progression in EAE and MS. NO also plays
an important role in the modulation of cellular respiration and mitochondrial function.
Under either hypoxic conditions or high concentration of NO, NO competes with oxygen
and binds reversibly to Cytochrome c oxidase (CCO or complex IV). This leads to
inhibition of CCO and subsequent reduction of ATP production [160-162]. In addition,
ROS and RNS inhibit the activity of complexes I, II, IV and V of the respiratory chain
leading to mitochondria dysfunction and reduction in ATP production [167-169]. MS and
EAE studies showed that nitrosative stress and mitochondrial dysfunction are events
present in early and chronic stages of disease [147, 178-184]. For instance, Lu et al.,
showed that chronic active plaques from MS subjects presented high oxidative damage
of mitochondrial DNA (mtDNA) which correlated with a reduction in the activity of
complex I of the respiratory chain and a possible compensatory increase in the activity
of complex IV (CCO) [178]. Qi et al. reported that mitochondrial dysfunction due to
oxidative stress was present in the CNS of immunized mice before the infiltration of
immune cells the CNS [180]. Mice immunized for the induction of EAE were euthanized
3 days after EAE induction, prior to the appearance of clinical signs, and the optic
nerves, retinas, brains, and spinal cords were analyzed for signs of disease pathology
[180]. None of the mice showed clinical signs of EAE or cellular infiltration in the CNS,
but nitrated proteins, apoptosis of oligondendrocytes, and reduced ATP levels were
present in all of the samples [180]. Histological analysis of spinal cords showed positive
iNOS immunofluorescence, mitochondrial vacuolization and dissolution of cristae which
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correlate with the presence of nitrosative stress and the degeneration of axons at an
early stage of EAE [180]. Quantification of nitrosative stress parameters in
cerebrospinal fluid and plasma samples collected from MS subjects revealed increased
iNOS activity, nitrotyrosine, nitrite, peroxynitrites, and S-nitrosothiols in comparison with
controls [184].
Previous work from our lab showed that treatment of MOG 35-55-induced EAE in
mice with 670nm light reduced nitrosative stress which correlated with the reduction in
the severity of disease [288]. In cell culture experiments using lymphocytes isolated
from peripheral lymph nodes from mice with EAE incubated with MOG 35-55, PBM
treatment with 670nm light resulted in a reduction in nitrite (NO2-) levels in comparison
with control (no light treatment). Similarly, in vivo experiments showed that mice with
EAE receiving double light treatment protocol (light treatment for 7 days starting with the
day of onset of clinical signs, followed by a period of 7 days without light treatment, with
light treatment resuming on days 8 through 14) presented with a reduction the clinical
severity of disease [288]. Spinal cords collected during the course of the experiment
were used to quantify iNOS expression. INOS expression was not reduced during the
acute phase of the disease. However, there was a significant down-regulation iNOS
expression in the chronic phase of the disease. In addition, the double treatment
protocol was applied on iNOS knockout (iNOS-/-) mice and WT C57BL/6 mice
immunized with MOG35-55. The double light treatment protocol resulted in amelioration
of clinical severity in WT mice but did not produce amelioration in iNOS -/- mice,
suggesting that NO produced by iNOS is necessary in the beneficial effects of PBM
[288].
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Peripheral blood mononuclear cells are a heterogeneous population of cells
representing the circulating immune response. In addition to CD4 + T cells, the
population contains other lymphocytes and monocytes/macrophages. Important to
these studies, monocytes and differentiated macrophages are the principal source of
NO produced by iNOS. To investigate the effect of PBM on the generation of
NO/nitrosative stress, PBMC were isolated from MS subjects, activated with
Phytohemagglutinin (PHA) and received PBM treatment as indicated in materials and
methods (Table 5). Supernatants collected at 72h were used to measure nitrite (NO 2-)
levels by fluorescence. PBM treatment at 830nm (10J/cm 2, 72h, p=0.0153) produced a
statistically significant reduction in the levels of nitrite in comparison with controls (no
light treatment). Some of the other PBM treatments produced mixed results that were
not statistically significant.
Further analysis of data showed that 830nm (10J/cm2) was also capable of
cytokine modulation. Analysis demonstrated that 830nm (10J/cm 2, at 72h) produced
both a reduction in nitrite and increase in IL-10 produced by PBMC (p=0.0271). These
results are important because they show that PBM can participate in the reduction of
nitrosative stress and also provide an anti-inflammatory effect due to the increase in IL10. In addition, 830nm (10J/cm2, at 72h) produced a reduction in both nitrite levels and
IFN-ɣ produced from PBMC in the majority of our subjects. However, this reduction did
not reach statistical not significance (p=0.1940) in this study. The lack of significance in
the reduction of IFN-ɣ can be explained based by: 1) the small size of our sample; 2) all
MS subjects included in the study are not on relapse and therefore the levels of IFN-ɣ
were to be low; 3) most of the patients were prescribed MS disease-modifying therapy
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to control their disease. One mechanism by which these therapies control MS is through
the shift from Th1 to Th2 responses which leads to low levels of pro-inflammatory
cytokines such as IFN-ɣ, as was observed in our subject population. Interestingly, unlike
what was noted above with respect to immune modulation by PBM, we did not observe
significant difference with respect to nitrite, IL-10 and IFN-ɣ correlation and disease
severity (PDDS=0 vs PDDS≥1). This is particularly important because it suggests that
PBM can be useful to reduce nitrosative stress in MS subjects in early stages of disease
with no motor dysfunctions as well as patients in a more advanced stage with motor
dysfunction present.
Together with the pro-inflammatory immune response, nitrosative stress plays a
central role in MS pathogenesis. Therefore, the reduction of nitrosative stress is
fundamental to the development of effective therapies for MS. Furthermore, the
expression of pro-inflammatory cytokines such as IFN-ɣ and NO are coordinately
regulated. The IFN-ɣ produced by Th1 cells activates macrophages leading to the
expression of iNOS and production of high amounts of NO. Similarly, high amounts of
NO produced by iNOS inhibit the expansion of Th1 cells and IFN-ɣ by a negative
feedback mechanism whereby activated macrophages inhibit IL-12 production which is
necessary for Th1 differentiation [121]. Fenyk-Melody, J.E., et al. showed that EAE
induction in iNOS-deficient mice result in more severe clinical disease in comparison
with disease induced in WT mice, suggesting that the NO produced by iNOS in WT
mice-EAE immunized prevents CD4+ T cells differentiation to Th1 cells [122, 123].
Thus, therapeutic targeting on NO will directly target pathogenic mechanisms
responsible for disease progression and immune modulation leading to a decrease in
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the pro-inflammatory immune response. Together, these actions would be predicted to
ameliorate MS disease severity and perhaps prevent disease progression.
In our project we also carried out a pilot clinical study to investigate the effect of
PBM treatment on muscle fatigue as well cytokine modulation in serum in MS subjects.
PBM studies showed a positive effect on the reduction of skeletal muscle fatigue,
exercise performance, reduction of strength loss, reduction in exercise-induced
oxidative stress, and enhancement of muscle rehabilitation [295-303]. Phase 1 of the
study evaluated the acute effect of PBM in muscle recovery to determine an optimal
dose for follow-up studies. The effect of pre and post PBM treatment on muscle
recovery in MS subjects was evaluated in 4 different visits by maximal voluntary
contractions (MVCs) of tibialis anterior muscle. The results showed that there was not
an optimal energy dose for muscle recovery, rather each patient showed improvement
in muscle recovery at a specific dose: 5 patients with 120J, 4 patients with 80J and 3
patients with 40J.
In phase 2, we evaluated the effect of an extended (2-week) PBM treatment on
the reduction of muscle fatigue and immune regulation in MS subjects. Each MS subject
applied their optimal dose of energy determined in Phase 1. Phase 2 consisted in 5
appointments. In the first and third appointment, each subject received a PBM device
(therapeutic or placebo) to apply the light treatment at home for 2 weeks every morning
in the gastrocnemius of both legs, and every night in the tibialis anterior of both legs.
Muscle strength was evaluated by MVCs of tibialis anterior muscle and a blood sample
was collected at follow-up appointments (visits 2 and 4). Analysis Visits 3 and 5 assess
for a continued effect of PBM treatment after 2 weeks of discontinued treatment.
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Analysis of muscle recovery data has not been completed. However, preliminary
analysis showed that there was not significant improvement in muscle strength after the
extended PBM treatment. The lack of significance in the results can be explained based
to the short period of time (2 weeks) of PBM treatment, the small sample size of our
patient population, and the low sensitivity of the muscle fatigue task. Therefore, in future
studies it will be necessary to increase our sample size, and include more sensitive
assays to evaluate muscle recovery, as well as include other muscles to evaluate
muscle recovery (i.e. biceps, triceps).
The analysis of blood samples collected during phase 2 showed that the values
of IFN-ɣ, IL-6, and IL-10 in most of the MS subjects were below the limits of detection
during the 5 appointments. The low values of these cytokines can be explained because
the all subjects that were included in the study presented no active disease and most of
them were under drug treatment. The main goal of the MS drug is to modulate he
immune response MS drug shift Th1 to Th2 responses, thus low values of IFN-ɣ and IL6 correlate with the use of the drug treatment. These results correlate with the results
presented by others where MS subjects in a remission period presented low values of
cytokines, and increased values during active periods [314-317]. Those studies showed
that the increase in both pro- and anti- inflammatory cytokines correlates with the
progression of the disease due to the increase in pro-inflammatory cytokines, and the
simultaneous restorative process by anti-inflammatory cytokines [314-317].
Unlike other cytokines measured, TGF-β expression was measurable in all
subjects prior to light treatment and showed changes during the PBM treatment in a
disease severity dependent manner in phase 2. MS subjects with PDDS=0 presented

159

higher levels of TGF-β compared to PDDS≥1, however this difference was not
significant. Interestingly, MS subjects with PDDS≥1 responded to PBM treatment with
the active device with increased levels of TGF-β compared to the placebo treatment,
however, this increase was not significant (p=0.2403). This increase was not observed in
MS subjects with PDDS=0 (Figure 15). The fact that the levels of IL-6 were below of
limit of detection while amounts of TGF-β present were significant is particularly
important in MS. The presence of TGF-β and the lack of IL-6 induce CD4+ T cells to
differentiate in Tregs which are considered protective in MS due to the production of
production of anti-inflammatory cytokines (TGF-β, IL-10). Conversely, conditions were
TGF-β and IL-6 are present lead to CD4+ T cells to differentiate into Th17, which are
pathogenic in MS due to their production of pro inflammatory cytokines (IL-17, IL-6, IL21, IL-22,TNF-α) [23, 38]. In addition, even though the increase in TGF-β was not
significant, it is important in future studies to evaluate the effect of PBM on TGF-β in cell
culture and in vivo experiments due to its role in MS and EAE. TGF-β is an antiinflammatory cytokine that plays an important role in cell development differentiation
and immune regulation [91]. TGF-β inhibits Th1 cell activation by the inhibition of both
Jak-2 and Tyk-2 kinases and subsequently the phosphorylation of STAT 3 and STAT4.
This inhibition leads to reduced T cell proliferation and IFN-ɣ production and increased
apoptosis [93]. Several studies evaluated the role of TGFβ1 in the EAE mice [95-99].
Kuruvilla group reported that a daily intraperitoneal injection of TGF-β on SJL/J mice for
2 weeks starting the day of EAE induction delayed the onset of symptoms, reduced the
severity of the second episode, and reduced the development of spontaneous relapses
[95]. The Racke group showed that the addition of TGF-β to cell cultures inhibited the
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activation and proliferation of myelin basic protein-specific lymph nodes cells. When
these cells were transferred to naive mice, the EAE induction was reduced [96]. In in
vivo experiments, the administration of TGF-β to mice with EAE reduced the severity of
the disease, cellular infiltration in CNS, the expression of cell adhesion surface molecule
lymphocyte function-associated Ag-1 (LFA-1), and the expression of MHC-II on antigen
presenting cells in comparison with EAE mice without TGF-β1 treatment [96].
In conclusion, the results presented here show the potential effect of PBM to
modulate immune response and nitrosative stress in MS subjects. The results showed
that there was not a specific wavelength and dose of energy (J/cm 2) to modulate the
immune response and reduce oxidative stress. The clinical severity of the disease
seems to be an important factor during PBM treatment. We observed that MS subjects
with higher severity of disease (PDDS≥1) responded better to PBM than those with low
disease severity (PDDS=0). One of the most significant results obtained was with
830nm light treatment of PBMC. PBM with 830nm light (10J/cm 2, at 72h) produced both
a reduction in nitrite and increase in IL-10 produced by PBMC (p=0.0271) as well as
reduced IFN-ɣ produced by PBMC. The direct application of PBM treatment on MS
subjects seems to be safe. The results suggest that it is necessary to recruit MS
subjects with higher disability status (PDDS≥1) in order to observe more dramatic effect
of PBM. However, the direct application of PBM on MS patient with higher disability
must be monitored with extreme caution in order to avoid any imbalance in the immune
response that could affect the health of MS subjects.
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MODEL OF THE EFFECT OF PBM ON MS
Our results show that PBM has the potential to modulate cytokine production and
nitrosative stress in MS subjects which correlate with our previous data collected using
the EAE model. Data presented by others showed that PBM is absorbed by CCO in
order to improve mitochondrial function and increase ATP production [239-242]. The
improvement of mitochondrial function leads to a reduction of nitrosative stress which is
a fundamental player in MS and EAE. Our data from the EAE model [287, 288] in
combination with the data collected from MS subjects here show that PBM leads to a
reduction of iNOS which induces the reduction of nitric oxide, which was indirectly
measured by the quantification of nitrite. In the EAE model, the reduction of nitrite
correlated with the reduction in the severity of disease, reduction in apoptosis, and
reduction in cellular infiltration in the CNS [288]. Future studies are needed to evaluate
the effect of PBM treatment in mitochondrial function (i.e. seahorse assay) in mice with
EAE as well as in MS subjects.
Our data suggest that the reduction in nitric oxide as well as PBM treatment are
involved in the shifting of Th1 responses to Th2 responses leading to an reduction of
pro-inflammatory cytokines (IFN-g, IL-6) and an increase in anti-inflammatory cytokines
(IL-10, TGF-β). Our data showed that PBM treatment is affected by the severity of
disease presented by MS subjects. Therefore, patients with higher severity of disease
showed more dramatic results. Future studies need to evaluate the role of MS diseasemodifying drugs during PBM treatment. Most of our patients were receiving MS diseasemodifying drugs, which mainly function to produce a shift of Th1 to Th2 responses in
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order to prevent relapses. PBM in combination with the MS disease-modifying drugs
could participate in improving the shift from Th1to Th2 responses.

FUTURE DIRECTIONS
The data collected here suggest that PBM has the potential to regulate immune
response, nitrosative stress, and muscle fatigue in MS subjects. Previous work from our
lab showed that 670nm (5J/cm2) on C57BL/6 mice with EAE reduced IFN-ɣ and TNF-α,
increased IL-10, and IL-4, and reduced nitrosative stress (NO2 and iNOS) which
correlated with a reduction in disease severity [287, 288]. C57BL/6 mice with EAE are
characterized by the development of a chronic disease and only 20-30% of mice
present relapses. Here we showed that 830nm was one of the best wavelengths to
modulate cytokines and reduce nitrosative stress in MS subjects. Administration of
830nm light (10J/cm2, at 72h) on PBMC resulted in reduced nitrite and IFN-ɣ (p=0.1940)
and increased IL-10 (p=0.0271). Our results showed that the clinical severity of the
disease plays a role during PBM treatment. MS subjects with higher severity of disease
(PDDS≥1) showed better results to PBM than patients with low disease severity
(PDDS=0). This, to some extent, correlates with the results observed in mice with EAE.
Mice with chronic disease showed an improvement after PBM treatment [287, 288]. The
fact that 670nm and 830nm regulated cytokines and nitrosative stress in EAE and MS
respectively correlate with the observations made by Wong-Riley group where 670nm
and 830nm increased CCO activity and ATP production [243]. In addition, they showed
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that there was a positive correlation between the action spectra of CCO activity and the
ATP content (at 670nm and 830nm) with the absorption spectrum of CCO [243].
MS is an autoimmune disease, however mitochondrial dysfunction and
nitrosative stress are also present during acute and chronic stages of disease [147,
178-184]. Our experiments from mice with EAE and MS subjects showed that PBM can
regulate the immune response and reduce nitrosative stress. However, the effect of
PBM on mitochondrial function MS subjects has not been studied. Future experiments
are needed in order to produce a sustained effect by PBM on the regulation of
cytokines, reduction of nitrosative stress, and investigate the effect on mitochondrial
function. Being able to determine the correct wavelengths and energy doses to improve
mitochondrial function and understand how mitochondrial function evolves during PBM
treatment can provide pivotal information to improve PBM treatments on MS subjects.
Seahorse assay allows the use cells to evaluate mitochondrial function and production
of ATP. Therefore, seahorse assay can be used to monitor how mitochondrial function
behaves under specific wavelengths and doses of energies in order to find the best
conditions to improve mitochondrial function. Furthermore, the seahorse assay can
determine the initial state of mitochondria and then monitor their progression throughout
PBM treatment. It could be possible that the energy doses needed to improve
mitochondrial function would be different depending of disease severity. Therefore, the
use of different doses of energy (energy dose curve assays) and the use of the
seashore assay to monitor mitochondrial function will help to determine the optimal
doses of energy during PBM for MS subjects with specific disease severity. We
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hypothesized that the improvement of mitochondrial function will correlate with a
reduction in nitrosative stress and regulation of cytokines.
The study of PBM on muscle fatigue in MS subjects needs also to be expanded.
Our data showed that PBM reduced muscle fatigue in MS subjects with higher disease
severity. However, data did not achieved statistical significance due to the small size of
population, low number of patients with higher disease severity, and short period of
PBM treatment (2 weeks). Therefore, to address these drawbacks in future experiments
it will be necessary to increase our population size, increase the number of MS subjects
with higher disease severity (PPDS≥1), apply PBM for longer period of time (i.e. 1
month), include more sensitive assays to evaluate muscle performance (i.e. walking
tests, number of repetitions), evaluate serum enzymes related to muscle performance
(CK, CKMB, LDH, PCR), evaluate serum cytokines during the course of the study. At
different stages of disease, MS subjects develop motor problems, muscle fatigue in
different parts of the body (i.e. arms, legs, back) or chronic fatigue en general
Therefore, evaluating different muscle groups (i.e. biceps, triceps) could show the
potential of PBM to treat different parts of the body to improve muscle activity in MS
subjects.
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APPENDIX A
Table 24. Phase 2. Serum cytokines
IFN-ɣ
IL-6
TGF-β

PBMS #1 No on drug
Visit
1
2
3
4
5

IL-10

0
0
0
0
0

mean
0
0
0
0
0

mean
12718.7263
10477.8341
9974.07215
8812.58763
11628.64

mean
0
0
1.74552055
1.83589912
2.41773911

IFN-ɣ

IL-6

TGF-β

IL-10

0
0
0
0

0
0
0
0

22459.3002
23433.9321
22400.5556
16932.3233

5.97012211
0
2.46357524
1.1266452

0

0

19745.4444

1.39736355

IFN-ɣ

IL-6

TGF-β

IL-10

0
0
0

0
0
0

12592.4592
16600.5296
10566.3162

4.76855078
4.95307585
4.76831511

0
0

0
0

9921.95786
9063.48748

4.30605042
3.61280463

IFN-ɣ

IL-6

TGF-β

IL-10

2.94898637
1.29298628

51.5240978
41.775989

11674.5572
14890.0912

12.7005531
10.0080058

3
4
5
PBMS #17 GILENYA
Visit
1

1.39546597
0
0

48.3109143
41.6851965
48.4530275

12049.5792
11949.0826
11590.4679

8.66000166
9.5165494
8.70220676

IFN-ɣ

IL-6

TGF-β

IL-10

6.87711101

61.71561

17773.48

0

2
3
4
5

7.32600608
7.26926837
10.0519821
8.44337528
0

74.7527985
73.2116544
73.2728667
71.831385
0

16709.0213
15441.0018
19349.032
19812.133
0

1.44014512
1.70154463
2.05789447
0
0

IFN-ɣ

IL-6

TGF-β

IL-10

0
0

0
0

19591.9203
18429.1715

12.7449621
10.3602818

PBMC #6, COPAXONE
Visit
1
2
3
4
5
PBMS#14 OCREVUS
Visit
1
2
3
4
5
PBMS #10 REBIF
Visit
1
2

PBMS #18, betaseron
Visit
1
2
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3
4

0
0

0
0

17862.7382
18092.6441

3.98179006
5.41620128

5
PBMS #7 GILENYA
Visit
1
2
3

0

0

19085.225

4.25935237

IFN-ɣ

IL-6

TGF-β

IL-10

0
0
0

0
0
0

11238.6134
16267.1026
20355.9881

3.15010852
0
4.53726978

4
5
PBMS #13 GILENYA
Visit
1
2
3

0
1.9693794

0
0

22211.4102
11875.9331

2.31312066
1.74646812

IFN-ɣ

IL-6

TGF-β

IL-10

0
0
0

2.68914523
5.82705739
3.56073298

20832.5446
20040.0433
18876.5231

0
0
1.3266452

4
5
PBMS #4 No on Drug
Visit
1
2

0
0

2.88724344
3.75471019

20103.6391
24918.0458

1.70912442
1.72013461

IFN-ɣ

IL-6

TGF-β

IL-10

0
0

0
0

20200.9095
17722.9096

0
0

0
0
0

0
0
0

18837.1404
14624.451
15173.4319

0
1.77013461
0

3
4
5
PBMS #3 COPAXONE
Visit
1

IFN-ɣ

IL-6

TGF-β

IL-10

19.5442543

82.606487

16528.7463

1.61385166

2
3
4
5
PBMS #11 Tecfidera
Visit

17.1022064
16.0330914
15.4429519
12.793903

77.3337887
80.2054393
71.948152
70.8422623

14460.5177
11505.2837
16927.6269
11816.7011

5.41633814
3.65913273
1.75756871
2.39160364

IFN-ɣ

IL-6

TGF-β

IL-10

1
2
3
4
5
PBMS #21 No on Drug

9.88521891
12.9502414
12.901799
11.6999615
10.9333311

31.1689317
31.5987165
31.7221459
31.762209
27.2321192

14483.1586
10762.9151
12770.5176
15257.403
16042.0072

2.12770151
1.18464977
2.19402789
3.30141138
1.72280162

Visit
1
2
3

IFN-ɣ

IL-6

TGF-β

IL-10

0
0
0

0
0
0

16355.8775
20887.8034
16957.2835

2.51488913
1.1266452
3.7054598

167

4
5

0
No sample

0
No sample

21169.8565
No sample

3.42687064
No sample
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catalysts. Palladium catalysts provide an alternative pathway for cross-coupling reaction
of cyclic compounds.
-Assist with academic research.
-Analyze data.
-Prepare reagents and materials for current research projects in the lab.
-Organize, maintain and update lab books, inventory and data bases.
-Supervise undergraduate students working on assignment research projects.
-Attend to lab discussions, meetings and seminars.
Full-Time Research Assistant, Chemistry Department, U. of Guanajuato, Mexico.
Assignments:
-Work in the synthesis of organic molecules i.e. bi-aryl compounds with biological
activities using boronic acids. The use of boronic acids allows the production of poly-aryl
molecules which are present in different kind of compounds with biological activity such
as antibiotics and antivirals.
-Assist with academic research.
-Analyze data.
-Prepare reagents and materials for current research projects in the lab.
-Organize, maintain and update lab books, inventory and data bases.
-Supervise undergraduate students working on assignment research projects.
-Attend to lab discussions, meetings and seminars.

Knowledge/skills in laboratory techniques and equipment
-Knowledge in tissue culture techniques, ELISA, western blot, PCR, Nuclear Magnetic Resonance
spectrophotometry (NMRS), High Performance Liquid Chromatography (HPLC), electrophoresis,
clinical lab equipment, flow-cytometry, data analysis software.
-Knowledge in methodologies related to neuroscience, neuroimmunology, multiple sclerosis, and
prostate cancer.
-Ability to develop and follow research methodology and protocols.
-Ability to design, organize, and coordinate scientific research projects.
-Self-motivated, capable to design and conduct experiments.
-Knowledge of lab bio-hazards, safety practices, as well as care and use of laboratory equipment.

Grants obtained in the College of Health Sciences
2019
Student Research Grant Award (SRGA). Fall 2019-Spring 2020. College of Health
Sciences. University of Wisconsin Milwaukee. Project title: Evaluation of the potential
effect of Photobiomodulation Therapy (PBMT) on nitrosative stress and mitochondrial
function in Multiple Sclerosis (MS) patients. Grant: $2000.00 USD.
2018
Student Research Grant Award (SRGA). Fall 2018-Spring 2019. College of Health
Sciences. University of Wisconsin Milwaukee. Project title: Study to evaluate
Photobiomodulation at 670, 830, and 735 nm on both immune and mitochondrial
functions of human lymphoid cells. Grant: $2000.00 USD.
2015
Student Research Grant Award (SRGA). Fall 2015-Spring 2016. College of Health
Sciences. University of Wisconsin Milwaukee. Project title: Characterization of the
186

2013

Effect of Photobiomodulation at 670, 830, and 735nm on human activated CD4+ T
cells. Grant: $2000.00 USD.
Student Research Grant Award (SRGA). Fall2013-Spring 2014. College of Health
Sciences. University of Wisconsin. Project title: Investigation of the Effect of 670nm
light-mediated Photomodulation on Human Lymphoid Cells. Grant: $2000.00 USD.

Publications
2018-2019 Book chapter. Book title: “Photobiomodulation and the Brain” subtitle "Low-level
Laser (Light) Therapy in Neurology and Neuroscience” edited by Michael R Hamblin
and Yingying Huang. Published by Elsevier. Chapter 21: PBM for MS in animal
models, Photobiomodulation in the Brain. Miguel A. Tolentino and Jeri-Anne Lyons
2014
Book chapter. Low-Level Laser Therapy: A Treatment Modality for Multiple Sclerosis
Targeting Autoimmunity and Oxidative Stress. Zenas George, Miguel A. Tolentino,
and Jeri-Anne Lyons. Handbook of Low-Level Laser Therapy. Edited by y Michael
Hamblin, Tanupriya Agrawal, Marcelo de Sousa. Pan Stanford Publishing.

Conference Presentations
2019
Poster and podium presentation. Photobiomodulation therapy (PBMT) regulates
the production of IL-10 and IFN-ɣ by peripheral blood mononuclear cells (PBMC)
and CD4+ T cells isolated from subjects with Multiple Sclerosis (MS). The American
Association of Immunologists. May 9-13. Abstract selected accepted for podium
2019
and poster presentation.
Poster presentation. Photobiomodulation therapy (PBMT) regulates the production
of IL-10 and IFN-ɣ by peripheral blood mononuclear cells (PBMC) and CD4+ T cells
2018
isolated from subjects with Multiple Sclerosis (MS). May 3. University of Milwaukee
Health Research Symposium.
Poster and podium presentation. Poster title: “Photobiomodulation therapy (PBMT)
regulates production of inflammatory cytokines IL-10 and IFN-ɣ involved in multiple
sclerosis”. Autumn Immunology Conference, Chicago Illinois, November 16-19.
Abstract selected among the top five abstracts related to multiple sclerosis or
general autoimmunity.
2016
Speaker. The Role of the Clinical Lab in the Control of Diabetes Mellitus. June 26.
General Hospital Juventino Rosas. Guanajuato Health Department, Mexico.
2015
Poster title: Potential Antioxidant Function of PEDF in Prostate Tissue and Prostate
Cancer. Crump, L, M Tolentino, SM Wcislak, and JA Doll. Medical College of
Wisconsin Cancer Center.
2015
Speaker: Updates on Pulmonary Tuberculosis. August 7. General Hospital Juventino
Rosas. Guanajuato Health Department, Mexico.
2014
Speaker. Course/training: Medic Microbiology. July 2-4. General Hospital Juventino
Rosas. Guanajuato Health Department, Mexico.
2013
Speaker. Blood Transfusion and Blood Bank Updates. July 29-31. General Hospital
Juventino Rosas. Guanajuato Health Department, Mexico.
2012
Poster title: “Metformin-induced PEDF expression regulates cell proliferation and
lipid metabolism in prostate cancer cells”. Miguel Tolentino, Susan M. Wcislak,
Ayesha T. Chawla, Betsy Abroe, Akash Patnaik, Massa Mafi, Lewis C. Cantley and
Jennifer A. Doll. Fall Research Symposium, U. of Wisconsin Milwaukee.
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2012

2011
2010

Poster title: “Metformin’s anti-prostate cancer effect may be via increased PEDF
levels and lipolytic activity”. Miguel Tolentino, Massa Mafi, Akash Patnaik, Susan M.
Wcislak, Betsy Abroe, Ayesha T. Chawla, Lewis C. Cantley and Jennifer A. Doll.
Spring Research Symposium. U. of Wisconsin Milwaukee.
Speaker. Training: updates on Tuberculosis. March 24. Guanajuato Health
Department. General Hospital Juventino Rosas. Mexico.
Speaker. Training on blood transfusion services. August 31. Guanajuato Health
Department. General Hospital Juventino Rosas. Mexico.

Training and Conferences Attended
2018
Training: Biosafety Course on Bloodborne Pathogens. December 29. Occupational
Safety and Health Administration (OSHA). University of Wisconsin Milwaukee.
2018
Autumn Immunology Conference. November 16-19. Poster and oral presentation.
Chicago IL.
2017
College of Health Sciences Research Symposium. Fall. University of Wisconsin
Milwaukee.
2017
Training: Bloodborne Pathogens. October 3. University Safety and Assurances.
University of Wisconsin Milwaukee.
2017
Training: Satellite Hazardous Waste Accumulation. September 6. University Safety
and Assurances. University of Wisconsin Milwaukee.
2017
Course: Checkpoint, Data Security and Privacy. October 2. EVERFI. University of
Wisconsin- Milwaukee.
2017
Training: Biological Safety. September 8. University of Wisconsin Milwaukee.
2017
2017
2016
2016
2015
2014
2014
2013
2013
2012
2012
2011
2009

Course: Intersections preventing Harassment and Sexual Violence. February 19.
EVERFI. University of Wisconsin- Milwaukee.
Course/Training: Medical Parasitology. January 6. General Hospital Juventino Rosas.
Guanajuato Health Department, Mexico.
College of Health Sciences Research Symposium. Fall. University of Wisconsin
Milwaukee.
Autumn Immunology Conference. Chicago IL.
College of Health Sciences Research Symposium. Fall. University of Wisconsin
Milwaukee.
Autumn Immunology Conference. Chicago IL.
College of Health Sciences Research Symposium. Fall. University of Wisconsin
Milwaukee.
Fulbright seminar: “From Lab to Market”. Boston, MA.
College of Health Sciences Spring Research Symposium. Poster presentation. May 3.
University of Wisconsin Milwaukee.
College of Health Sciences Spring Research Symposium. Poster presentation. May 4.
University of Wisconsin Milwaukee.
Training: Chemical hygiene plan and laboratory safety. February 2. University Safety
and Assurances. University of Wisconsin Milwaukee.
Academic English Program. August 1-26. University of California San Diego.
Seminar: “Reduction of Stigma and Discrimination of Personnel who Live with HIV
AIDS”. July 7. Institute of Public Health, Guanajuato, Mexico.
188

2009
2008
2008
2008
2007
2007
2007

2007
2007
2006
2006
2006
2004
2004

Course-workshop: “Tuberculosis and Bacilloscopy”. April 27-29. State Laboratory Of
Public Health, Guanajuato, Mexico.
Congress: “The Process for Standardization of Bacteriological Studies in the Clinical
Area”. October 10-12. University of Guanajuato, Mexico.
XIV Congress of Chemists of the State of Guanajuato. July 25-27. University of
Guanajuato. Mexico.
Course: “Clinical Mycology”. February 29-March 1. The Mexican Association of
Medical Clinical Mycology, Guanajuato, Mexico.
Training on: “Procedures in the Area of Blood Donation and Transfusion Service”.
December 3-7. General Hospital of Dolores Hidalgo, Mexico.
Course: “Liquids and electrolytes”. August 7. Medical College of Guanajuato,
Mexico.
Congress: “2nd International Cycle of Conferences on Quality”. June 30.
International Federation of Clinical Chemistry and Laboratory Medicine (IFCC),
Mexico.
Course: “Use and Handling of Blood and its Derivatives”. May 16 and 23. General
Hospital Dolores Hidalgo, Mexico.
Course: “Updating in Clinical Analysis”. General Hospital of Dolores Hidalgo. Mexico.
Congress: “16th International Conference on Organic Synthesis”. June 11-15, IUPAC,
Mexico.
Course: “Asymmetric Synthesis”. February 20-22. Mexican Academy of Organic
Chemistry. University of Guanajuato, Mexico.
Course: “Design of Pharmaceuticals”. February 20-22. Mexican Academy of Organic
Chemistry. University of Guanajuato, Mexico.
Workshop: “Formulation of Medicines and Cosmetics”. October 7-8. University of
Guanajuato, Mexico.
Biomedical Sciences Conference. October 7-8. University of Guanajuato, Mexico.
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